<SEC-DOCUMENT>0001171843-16-011964.txt : 20160826
<SEC-HEADER>0001171843-16-011964.hdr.sgml : 20160826
<ACCEPTANCE-DATETIME>20160826171714
ACCESSION NUMBER:		0001171843-16-011964
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20160825
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160826
DATE AS OF CHANGE:		20160826

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Capstone Therapeutics Corp.
		CENTRAL INDEX KEY:			0000887151
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				860585310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21214
		FILM NUMBER:		161855534

	BUSINESS ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		6022865520

	MAIL ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOLOGIC CORP
		DATE OF NAME CHANGE:	19940211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_082616.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">UNITED STATES</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549<BR>
______________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">FORM 8-K<BR>
CURRENT REPORT</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Pursuant to Section 13 or 15(d)<BR>
of the Securities Exchange Act of 1934</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">_______________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Date of Report: August 25, 2016 (Date of earliest event reported)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;<BR>
<B>CAPSTONE THERAPEUTICS CORP.</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in">Delaware</TD>
    <TD STYLE="width: 2%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 36%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in">000-21214</TD>
    <TD STYLE="width: 2%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 29%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in">86-0585310</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">(Commission File Number)</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">(I.R.S. Employer</P>
        <P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; width: 45%">1275 West Washington Street, Suite 104, Tempe, Arizona</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; width: 45%">85281</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0"><BR> </P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Registrant&rsquo;s telephone number, including area code:<BR>
(602) 286-5520</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 1in">[&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 1in">[ &nbsp;]&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 1in">[ &nbsp;]&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 1in">[&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Section 1 &ndash; Registrant&rsquo;s Business and Operations</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On August 25, 2016, Capstone Therapeutics Corp. (OTCQB: CAPS)
(&ldquo;the Company&rdquo;) and LipimetiX Development, Inc<B>., </B>the Company&rsquo;s drug development joint venture
(&ldquo;<B>JV</B>&rdquo;), issued a press release announcing that the JV&rsquo;s Series B-1 preferred stock offering totaling
$1,012,000 closed on August 25, 2016. Individual accredited investors and management participated in the financing. The
Series B Preferred Stock and Warrant Purchase Agreement is furnished as Exhibits 10.1 to 10.5 to this Current report on Form
8-K and is incorporated by reference. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on form
8-K and is incorporated by reference.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">This initial closing of the Series B-1 preferred stock offering resulted
in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV&rsquo;s common stock at the election
of the holders, and warrants to purchase an additional 33,088 shares of JV preferred stock, at an exercise price of $10.70, with
a ten-year term. The preferred stock represents 7.8% of the post-closing common stock of the JV, on an as-converted basis and suggests
an approximate $13.7 million post-money valuation. Following this initial Series B-1 closing, the Company owns 59.3% of the JV.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In connection with the Series B-1 financing, the JV entered into
the Series B Preferred Stock and Warrant Purchase Agreement, furnished as Exhibit 10.1 to this Current report on Form 8-K. The
Series B Preferred Stock and Warrant Purchase Agreement allows for issuance of up to an additional 45,640 Series B-1 preferred
stock and 15,975 preferred stock warrants at the same terms as the current Series B-1 preferred stock and warrants, and up to 1,200,000
additional Series B-2 preferred stock, at terms yet to be determined. Series B preferred stock is a participating preferred stock.
As a participating preferred, the preferred stock will earn a 5% cumulative dividend, payable only upon the election by the JV
or in liquidation. Prior to the JV common stock holders receiving distributions, the participating preferred stockholders will
receive their earned dividends and payback of their original investment. Subsequently, the participating preferred will participate
in future distributions on an equal &ldquo;as converted&rdquo; share basis with common stock holders. The Series B preferred stock
has &ldquo;as converted&rdquo; voting rights and other terms standard to a security of this nature.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Raising additional funds in the JV may or may not occur, and additional
funds raised, if any, may not be sufficient for the JV to reach its development goals or create shareholder value, and may also
contain terms or conditions that could significantly impact the Company&rsquo;s investment value or ownership position.</P>

<P STYLE="font-size: 10pt; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>Section 9 &ndash; Financial Statements and
Exhibits</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>Item 9.01</B></TD>
    <TD COLSPAN="2"><B>Financial Statements and Exhibits.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 58%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>(d)</TD>
    <TD>Exhibits</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B><U>Exhibit No.</U></B></TD>
    <TD COLSPAN="2"><B><U>Description</U></B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>10.1</TD>
    <TD COLSPAN="2">LipimetiX Development, Inc. Series B Preferred Stock and Warrant Purchase Agreement effective August 25, 2016.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>10.2</TD>
    <TD COLSPAN="2">Series B Preferred Stock and Warrant Purchase Agreement - Exhibit
B &ndash; Form of Warrants</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>10.3</TD>
    <TD COLSPAN="2">Series B Preferred Stock and Warrant Purchase Agreement - Exhibit
C &ndash; Form of Amended and Restated Certificate of Incorporation of LipimetiX Development, Inc.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>10.4</TD>
    <TD COLSPAN="2">Series B Preferred Stock and Warrant Purchase Agreement
- Exhibit F &ndash; Form of Registration Rights Agreement</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>10.5</TD>
    <TD COLSPAN="2">Series B Preferred Stock and Warrant Purchase
Agreement - Exhibit G - Form of Amended and Restated Stockholders Agreement among LipimetiX Development, Inc. and The
Stockholders Named Herein</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.1</TD>
    <TD COLSPAN="2">Press release dated August 25, 2016</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Dated: August 26, 2016</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">CAPSTONE THERAPEUTICS CORP.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ John M. Holliman, III</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>John M. Holliman, III</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Executive Chairman and CEO</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><BR>
<BR></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0 0 12pt; background-color: transparent"><B>Exhibit 10.1</B></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>LIPIMETIX DEVELOPMENT, INC.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>SERIES B PREFERRED STOCK</B><BR>
<B>AND WARRANT PURCHASE AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B><I><U>TABLE OF CONTENTS</U></I></B></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left; width: 3%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 87%">&nbsp;</td>
    <TD STYLE="text-decoration: underline; text-align: right; width: 5%">Page</td></tr>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">1</td>
    <td colspan="2" style="text-align: left">Purchase and Sale of Preferred Stock and Warrants.</td>
    <TD STYLE="text-align: right">1</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">1.1</td>
    <TD STYLE="text-align: left">Sale and Issuance of Series&nbsp;B Preferred Stock and Warrants.</td>
    <TD STYLE="text-align: right">1</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">1.2</td>
    <TD STYLE="text-align: left">Closing; Delivery.</td>
    <TD STYLE="text-align: right">1</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">2</td>
    <TD COLSPAN="2">Representations and Warranties of the Company</td>
    <TD STYLE="text-align: right">4</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">4</td>
    <td colspan="2" style="text-align: left">Conditions to the Purchasers&rsquo; Obligations at Closing</td>
    <TD STYLE="text-align: right">11</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.1</td>
    <TD STYLE="text-align: left">Representations and Warranties</td>
    <TD STYLE="text-align: right">11</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.2</td>
    <TD STYLE="text-align: left">Performance</td>
    <TD STYLE="text-align: right">11</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.3</td>
    <TD STYLE="text-align: left">Compliance Certificate</td>
    <TD STYLE="text-align: right">11</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.4</td>
    <TD STYLE="text-align: left">Qualifications</td>
    <TD STYLE="text-align: right">11</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.5</td>
    <TD STYLE="text-align: left">Registration Rights Agreement</td>
    <TD STYLE="text-align: right">11</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.6</td>
    <TD STYLE="text-align: left">Amended and Restated Stockholders Agreement</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.7</td>
    <TD STYLE="text-align: left">Amended and Restated Certificate</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.8</td>
    <TD STYLE="text-align: left">Secretary&rsquo;s Certificate</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.9</td>
    <TD STYLE="text-align: left">Proceedings and Documents</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">4.10</td>
    <TD STYLE="text-align: left">Preemptive Rights</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">5</td>
    <td colspan="2" style="text-align: left">Conditions of the Company&rsquo;s Obligations at Closing</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">5.1</td>
    <TD STYLE="text-align: left">Representations and Warranties</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">5.2</td>
    <TD STYLE="text-align: left">Performance</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">5.3</td>
    <TD STYLE="text-align: left">Qualifications</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">5.4</td>
    <TD STYLE="text-align: left">Registration Rights Agreement</td>
    <TD STYLE="text-align: right">12</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">5.5</td>
    <TD STYLE="text-align: left">Amended and Restated Stockholders Agreement</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">6</td>
    <td colspan="2" style="text-align: left">Miscellaneous.</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.1</td>
    <TD STYLE="text-align: left">Survival of Warranties</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.2</td>
    <TD STYLE="text-align: left">Successors and Assigns</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.3</td>
    <TD STYLE="text-align: left">Governing Law</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.4</td>
    <TD STYLE="text-align: left">Counterparts</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.5</td>
    <TD STYLE="text-align: left">Titles and Subtitles</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.6</td>
    <TD STYLE="text-align: left">Notices</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.7</td>
    <TD STYLE="text-align: left">No Finder&rsquo;s Fees</td>
    <TD STYLE="text-align: right">13</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.8</td>
    <TD STYLE="text-align: left">Intentionally Omitted</td>
    <TD STYLE="text-align: right">14</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.9</td>
    <TD STYLE="text-align: left">Attorneys&rsquo; Fees</td>
    <TD STYLE="text-align: right">14</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.10</td>
    <TD STYLE="text-align: left">Amendments and Waivers</td>
    <TD STYLE="text-align: right">14</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.11</td>
    <TD STYLE="text-align: left">Severability</td>
    <TD STYLE="text-align: right">14</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.12</td>
    <TD STYLE="text-align: left">Delays or Omissions</td>
    <TD STYLE="text-align: right">14</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.13</td>
    <TD STYLE="text-align: left">Entire Agreement</td>
    <TD STYLE="text-align: right">14</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.14</td>
    <TD STYLE="text-align: left">Corporate Securities Law</td>
    <TD STYLE="text-align: right">15</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left">&nbsp;</td>
    <TD STYLE="text-align: left">6.15</td>
    <TD STYLE="text-align: left">Dispute Resolution</td>
    <TD STYLE="text-align: right">15</td></tr>
</table>


<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent"></P>

<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 12pt; background-color: transparent"><B><U>TABLE
OF CONTENTS</U></B><BR>
<B>(continued)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 12pt; background-color: transparent"><B>&nbsp;</B></P>



<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent"></P>

<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent">&#9;<U>Exhibit A</U> -&#9;SCHEDULE
OF PURCHASERS</P>

<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent">&#9;<U>Exhibit B</U> -&#9;FORM
OF WARRANT</P>

<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent">&#9;<U>Exhibit C</U> -&#9;FORM
OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</P>

<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent">&#9;<U>Exhibit D</U> -&#9;DISCLOSURE
SCHEDULE</P>

<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent">&#9;<U>Exhibit E</U> -&#9;RISK
FACTORS</P>

<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent">&#9;<U>Exhibit F</U> -&#9;FORM
OF REGISTRATION RIGHTS AGREEMENT</P>

<P STYLE="font-size: 10pt; text-indent: -126pt; margin: 0 0 12pt 126pt; background-color: transparent">&#9;<U>Exhibit G</U> -&#9;FORM
OF AMENDED AND RESTATED STOCKHOLDERS AGREEMENT</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt 36pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 24pt; background-color: transparent"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 24pt; background-color: transparent"><B>SERIES B PREFERRED STOCK PURCHASE
AGREEMENT</B></P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent"><FONT STYLE="font-weight: normal; font-style: normal; text-transform: uppercase">This
Series B Preferred Stock AND WARRANT Purchase Agreement</FONT> <FONT STYLE="font-weight: normal; font-style: normal">(this &ldquo;Agreement&rdquo;)
is made and entered into as of August 25, 2016, by and among LipimetiX Development, Inc., a Delaware corporation (the &ldquo;Company&rdquo;),
and the investors set forth on <U>Exhibit A</U> attached to this Agreement (each, a &ldquo;Purchaser&rdquo; and collectively, the
&ldquo;Purchasers&rdquo;).</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 12pt; background-color: transparent"><B>RECITALS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">The Company
desires to sell to the Purchasers, and the Purchasers desire to purchase from the Company, shares of the Company&rsquo;s <B>Series
B-1</B> Preferred Stock, par value $0.00001 per share (the &ldquo;<B>Series B-1 Preferred Stock</B>&rdquo;) or Series B-2 Preferred
Stock, par value $0.00001 per share (the &ldquo;<B>Series B-2 Preferred Stock</B>,&rdquo; and collectively with the Series B-1
Preferred Stock, the &ldquo;<B>Series B Preferred Stock</B>&rdquo;), on the terms and subject to the conditions set forth in this
Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">The Purchasers
who purchase shares of Series B-1 Preferred Stock shall also acquire, without additional consideration, warrants to purchase up
to an aggregate of 49,100 shares of Series B-1 Preferred Stock in the form of <U>Exhibit B</U> attached hereto (the &ldquo;<B>Warrants</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 12pt; background-color: transparent"><B>AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">The parties
hereby agree as follows:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt; background-color: transparent">1.<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Purchase and Sale of Preferred Stock and Warrants.</U></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale and Issuance of Series&nbsp;B Preferred Stock and Warrants</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt; background-color: white">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall adopt and file with the Secretary of State of the State of Delaware on or before the Initial Closing (as
defined below) the Amended and Restated Certificate of Incorporation in the form of <U>Exhibit C</U> attached to this Agreement
(the &ldquo;<B>Restated Certificate</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt; background-color: white">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the terms and conditions of this Agreement, each Purchaser agrees to purchase at the Closing and the Company
agrees to sell and issue to each Purchaser at the Closing that number of shares of Series&nbsp;B-1 Preferred Stock and Warrants
or Series B-2 Preferred Stock set forth opposite each Purchaser&rsquo;s name on <U>Exhibit A</U>, at the purchase price set forth
on <U>Exhibit A</U>. The shares of Series&nbsp;B-1 Preferred Stock and Series B-2 Preferred Stock issued to the Purchasers pursuant
to this Agreement (including any shares issued at the Initial Closing and any Additional Shares, as defined below) shall be referred
to in this Agreement as the &ldquo;<B>Shares</B>.&rdquo; The shares of Series B-1 Preferred Stock issuable upon exercise of the
Warrants shall be referred to in this Agreement as the &ldquo;<B>Warrant Shares</B>.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing; Delivery</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt; background-color: transparent">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The<B> </B>initial purchase and sale of the Shares and Warrants shall take place remotely via the exchange of documents
and signatures, on August 25, 2016, or at such other time and place as the Company and the Purchasers mutually agree upon, orally
or in writing (which time and place are designated as the &ldquo;<B>Initial Closing</B>&rdquo;). In the event there is more than
one closing, the term &ldquo;<B>Closing</B>&rdquo; shall apply to each such closing unless otherwise specified.</P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt; background-color: transparent">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At each Closing, the Company shall deliver to each Purchaser a certificate representing the Shares being purchased by such
Purchaser at such Closing against payment of the purchase price therefor by check payable to the Company or by wire transfer to
a bank account designated by the Company. In addition, the Company will issue to each Purchaser of Series B-1 Preferred Stock a
Warrant to purchase the number of Warrant Shares set forth opposite such Purchaser&rsquo;s name on <U>Exhibit A</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt; background-color: transparent">1.3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Sale of Additional Shares of Preferred Stock</U>. After the Initial Closing, the Company may sell, on similar terms and
conditions as those contained in this Agreement as determined by the Company, up to 45,640 additional shares of Series B-1 Preferred
Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or similar recapitalization
affecting such shares) and additional Warrants to purchase up to 15,975 shares of Series B-1 Preferred Stock, and up to 1,200,000
shares of Series B-2 Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or similar recapitalization affecting such shares) (the additional shares of Series B-1 Preferred Stock and Series B-2 Preferred
Stock are referred to herein collectively as the &ldquo;<B>Additional Shares</B>&rdquo;), to one or more purchasers (the &ldquo;<B>Additional
Purchasers</B>&rdquo;), provided that (i) such subsequent sale is consummated prior to December 31, 2016; and (ii) each Additional
Purchaser shall become a party to the Transaction Agreements (as defined below), by executing and delivering a counterpart signature
page to each of the Transaction Agreements. <U>Exhibit A</U> to this Agreement shall be updated to reflect the number of Additional
Shares, and Warrants if applicable, purchased at each such Closing, the parties purchasing such Additional Shares, and Warrants
if applicable, and the purchase price per share.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt; background-color: transparent">1.4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Use of Proceeds</U>. In accordance with the directions of the Company&rsquo;s Board of Directors, the Company will use
the proceeds from the sale of the Shares to provide working capital for the development and commercialization of AEM-28-14 and
analogs, for other general corporate purposes, and to repay a revolving line of credit to Capstone Therapeutics Corp.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt; background-color: transparent">1.5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Defined Terms Used in this Agreement</U>. In addition to the terms defined above, the following terms used in this Agreement
shall be construed to have the meanings set forth or referenced below.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Accounting Services Agreement</B>&rdquo; means that certain Accounting Services Agreement, effective as of August
3, 2012, as amended from time to time, by and between the Company and Capstone Therapeutics Corp.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Affiliate</B>&rdquo; means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing
member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or
more general partners or managing members of, or shares the same management company with, such Person.</P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Amended and Restated Stockholders Agreement</B>&rdquo; means that certain Amended and Restated Stockholders Agreement,
dated as of the date hereof, by and among the Company and the stockholders party thereto.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Code</B>&rdquo; means the Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Company Covered Person</B>&rdquo; means, with respect to the Company as an &ldquo;issuer&rdquo; for purposes of
Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Company Intellectual Property</B>&rdquo; means all patents, patent applications, trademarks, trademark applications,
service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, mask works, information and proprietary
rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments
of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases that are owned or used by the
Company in the conduct of the Company&rsquo;s business as now conducted and as presently proposed to be conducted.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Key Consultants</B>&rdquo; means any executive-level employee of Benu BioPharma, Inc., as well as any employee
or consultant of Benu BioPharma, Inc. who either alone or in concert with others develops, invents, programs or designs any Company
Intellectual Property pursuant to the Management Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Knowledge</B>&rdquo; including the phrase &ldquo;<B>to the Company&rsquo;s knowledge</B>&rdquo; shall mean the
actual knowledge of the Company&rsquo;s executive officers.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(i)<FONT STYLE="font-size: 10pt"> <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp; </B></FONT>&ldquo;<B>Management Agreement</B>&rdquo; means that certain Management Agreement, dated as of
August 3, 2012, by and among the Company, Benu BioPharma, Inc. and certain affiliates of Benu BioPharma, Inc., as amended
from time to time.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(j)<FONT STYLE="font-size: 10pt">
</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Material Adverse Effect</B>&rdquo; means a material adverse effect on the business, assets (including intangible
assets), liabilities, financial condition, property, or results of operations of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Person</B>&rdquo; means any individual, corporation, partnership, trust, limited liability company, association
or other entity.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(l)<FONT STYLE="font-size: 10pt">
</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Purchaser</B>&rdquo; means each of the Purchasers who is initially a party to this Agreement and any Additional
Purchaser who becomes a party to this Agreement at a subsequent Closing under <U>Subsection 1.2</U>(b).</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(m)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>&ldquo;<B>Registration Rights Agreement</B>&rdquo;<B> </B>means that
certain Registration Rights Agreement, dated as of the date hereof, by and among the Company and the stockholders party
thereto.</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(n)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Securities</B>&rdquo; means the Shares, the Warrants, the Warrant Shares, and the Common Stock issuable upon the
conversion of the Shares.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(o)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Securities Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(p)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Shares</B>&rdquo; means the shares of Series B-1 Preferred Stock and Series B-2 Preferred Stock issued at the
Initial Closing and any Additional Shares issued at a subsequent Closing under <U>Subsection 1.2</U>(b).</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(q)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B>Transaction Agreements</B>&rdquo; means this Agreement, the Warrants, the Amended and Restated Stockholders Agreement,
and the Registration Rights Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt; background-color: transparent">2.<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Representations and Warranties of the Company</U>. The Company hereby represents and warrants to each Purchaser that,
except as set forth on the Disclosure Schedule attached as <U>Exhibit D</U> to this Agreement, which exceptions shall be deemed
to be part of the representations and warranties made hereunder, the following representations are true and complete as of the
date of the Initial Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding
to the numbered and lettered sections and subsections contained in this <U>Section 2</U>, and the disclosures in any section or
subsection of the Disclosure Schedule shall qualify other sections and subsections in this <U>Section 2</U> only to the extent
it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt; background-color: transparent">2.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Organization, Good Standing, Corporate Power and Qualification</U>. The Company is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry
on its business as presently conducted and as proposed to be conducted. The Company is duly qualified to transact business and
is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt; background-color: transparent">2.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Capitalization</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The authorized capital of the Company consists, immediately prior to the Initial Closing, of:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt; background-color: transparent">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>3,000,000 shares of Class A-1 and Class A-2 common stock, $.00001 par value per share (the &ldquo;<B>Common Stock</B>&rdquo;),
1,120,000 shares of which are issued and outstanding immediately prior to the Initial Closing. All of the outstanding shares of
Common Stock have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal
and state securities laws.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt; background-color: transparent">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>5,000,000 shares of Series A Preferred Stock, $.00001 par value per share (the <B>&ldquo;Series A Preferred Stock&rdquo;</B>)
of which 3,500,000 shares are issued and outstanding immediately prior to the Initial Closing. The rights, privileges and preferences
of the Preferred Stock are as stated in the Restated Certificate and as provided by the Delaware General Corporation Law.</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt; background-color: transparent">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>350,000 shares of Series B-1 Preferred Stock, $.00001 par value per share, none of which are issued and outstanding immediately
prior to the Initial Closing, and 1,200,000 shares of Series B- 2 Preferred Stock, $.00001 par value per share, none of which are
issued and outstanding immediately prior to the Initial Closing. The rights, privileges and preferences of the Preferred Stock
are as stated in the Restated Certificate and as provided by the Delaware General Corporation Law.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has adopted an equity incentive plan (the &ldquo;<B>Stock Plan</B>&rdquo;) and has reserved 71,500 shares of
Class A-1 Common Stock, which represents six percent (6%) of the total outstanding shares of Common Stock on a fully diluted basis
(prior to issuance of the Series B Preferred Shares pursuant hereto), for issuance to officers, directors, employees and consultants
of the Company pursuant to the Stock Plan.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsection 2.2(b)</U> of the Disclosure Schedule sets forth the capitalization of the Company immediately following the
Initial Closing including the number of shares of the following: (i)&nbsp;issued and outstanding Class A-1 Common Stock and Class
A-2 Common Stock; (ii)&nbsp;granted stock options, including vesting schedule and exercise price; (iii)&nbsp;shares of Common Stock
reserved for future award grants under the Stock Plan; (iv)&nbsp;each series of Preferred Stock; and (v)&nbsp;warrants or stock
purchase rights, if any. Except for (A) the conversion privileges of the Shares to be issued under this Agreement, (B) the Warrants,
(C) the rights provided in the Stockholders Agreement, and (D) the securities and rights described in<U> Subsection 2.2(a)(iii)</U>
of this Agreement and<U> Subsection 2.2(b)</U> of the Disclosure Schedule, there are no outstanding options, warrants, rights (including
conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase
or acquire from the Company any shares of Common Stock or Preferred Stock, or any securities convertible into or exchangeable for
shares of Common Stock or Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Subsidiaries</U>. The Company currently owns all of the outstanding equity of LipimetiX Australia Pty Ltd (<B>&ldquo;LipimetiX
Australia&rdquo;</B>). The Company formed LipimetiX Australia in order to allow the Company to perform clinical trials in Australia
and to participate in a program sponsored by the Australian government which may provide reimbursement to the Company of forty-five
percent (45%) of allowable expenses incurred by the Company in Australia to perform such clinical trials. Except for LipimetiX
Australia, the Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership,
trust, joint venture, limited liability company, association, or other business entity.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Authorization</U>. All corporate action required to be taken by the Company&rsquo;s Board of Directors and stockholders
in order to authorize the Company to enter into the Transaction Agreements, and to issue the Shares and Warrants, as applicable,
at the Closing, and to issue the Warrant Shares and the Common Stock issuable upon conversion of the Shares, has been taken or
will be taken prior to the Closing. All action on the part of the officers of the Company necessary for the execution and delivery
of the Transaction Agreements, the performance of all obligations of the Company under the Transaction Agreements to be performed
as of the Closing, and the issuance and delivery of the Shares and Warrants has been taken or will be taken prior to the Closing.
The Transaction Agreements, when executed and delivered by the Company, shall constitute valid and legally binding obligations
of the Company, enforceable against the Company in accordance with their respective terms except (i)&nbsp;as limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or
affecting the enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies, or (iii)&nbsp;to the extent indemnification provisions contained
in the Transaction Agreements may be limited by applicable federal or state securities laws.</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Valid Issuance of Shares</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement
will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under
the Transaction Agreements, applicable state and federal securities laws and liens or encumbrances created by or imposed by a Purchaser.
Assuming the accuracy of the representations of the Purchasers in <U>Section 3</U> of this Agreement and subject to the filings
described in <U>Subsection&nbsp;2.5</U>(b) below, the Shares will be issued in compliance with all applicable federal and state
securities laws. The Warrant Shares and the Common Stock issuable upon conversion of the Shares have been duly reserved for issuance,
and upon issuance in accordance with the terms of the Restated Certificate, will be validly issued, fully paid and nonassessable
and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable federal and
state securities laws and liens or encumbrances created by or imposed by a Purchaser.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No &ldquo;bad actor&rdquo; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a &ldquo;<B>Disqualification
Event</B>&rdquo;) is applicable to the Company or, to the Company&rsquo;s knowledge, any Company Covered Person, except for a Disqualification
Event as to which Rule 506(d)(2)(ii&ndash;iv) or (d)(3), is applicable.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Governmental Consents and Filings</U>. Assuming the accuracy of the representations made by the Purchasers in <U>Section
3</U> of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration
or filing with, any federal, state or local governmental authority is required on the part of the Company in connection with the
consummation of the transactions contemplated by this Agreement, except for (i) the filing of the Restated Certificate, which will
have been filed as of the Initial Closing, and (ii) filings pursuant to Regulation&nbsp;D of the Securities Act, and applicable
state securities laws, which have been made or will be made in a timely manner.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>. There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending
or to the Company&rsquo;s knowledge, currently threatened in writing (i) against the Company; or (ii) to the Company&rsquo;s knowledge,
that questions the validity of the Transaction Agreements or the right of the Company to enter into them, or to consummate the
transactions contemplated by the Transaction Agreements; or (iii) to the Company&rsquo;s knowledge, that would reasonably be expected
to have, either individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. The Company possesses certain intellectual rights pursuant to the Exclusive License Agreement,
dated August 26, 2011, between The UAB Research Foundation and LipimetiX Development, LLC, as amended and assigned to the Company,
governing the license and exploitation of the Licensed Patents, as defined therein, relating to Apolipoprotein E mimetic peptides.
The Company has also filed one formulation patent application with the United States Patent and Trademark Office.</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Other Instruments</U>. The Company is not in violation or default (i) of any provisions of its Restated
Certificate or Bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or
(iv) under any lease, agreement, contract or purchase order to which it is a party or by which it is bound that is required to
be listed on the Disclosure Schedule,<I> </I>or (v) to its knowledge, of any provision of federal or state statute, rule or regulation
applicable to the Company, the violation of which would have a Material Adverse Effect. The execution, delivery and performance
of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements will not result
in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either (i)
a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement, or (ii) an event which results
in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or
nonrenewal of any material permit or license applicable to the Company.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Agreements; Actions</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except for the Transaction Agreements, the Exclusive License Agreement, the Management Agreement and the Accounting Services
Agreement, there are no agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party
or by which it is bound that involve (i)&nbsp;obligations (contingent or otherwise) of, or payments to, the Company in excess of
$1,000,000, (ii) the license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company,
(iii)&nbsp;the grant of rights to manufacture, produce, assemble, license, market, or sell its products to any other Person that
limit the Company&rsquo;s exclusive right to develop, manufacture, assemble, distribute, market or sell its products, or (iv) indemnification
by the Company with respect to infringements of proprietary rights.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has not (i)&nbsp;declared or paid any dividends, or authorized or made any distribution upon or with respect
to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed other than indebtedness in the aggregate
principal amount of approximately $1,500,000 owed to Capstone Therapeutics Corp., or indebtedness incurred in the ordinary course
of business, (iii)&nbsp;made any loans or advances to any Person, other than ordinary advances for travel expenses, or (iv)&nbsp;sold,
exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of
business. For the purposes of (a) and (b) of this <U>Subsection 2.9</U>, all indebtedness, liabilities, agreements, understandings,
instruments, contracts and proposed transactions involving the same Person (including Persons the Company has reason to believe
are affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsection.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt; background-color: transparent">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is not a guarantor or indemnitor of any indebtedness of any other Person.</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Transactions</U>. The Company is not indebted, directly or indirectly, to any of its directors, officers or employees
or to their respective spouses or children or to any Affiliate of any of the foregoing, other than in connection with expenses
or advances of expenses incurred in the ordinary course of business or employee relocation expenses and for other customary employee
benefits made generally available to all employees. None of the Company&rsquo;s directors, officers or employees, or any members
of their immediate families, or any Affiliate of the foregoing are, directly or indirectly, indebted to the Company.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.12.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Returns and Payments</U>. There are no federal, state, county, local or foreign taxes due and payable by the Company
which have not been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Company
which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by
any applicable federal, state, local or foreign governmental agency. The Company has duly and timely filed all federal, state,
county, local and foreign tax returns required to have been filed by it and there are in effect no waivers of applicable statutes
of limitations with respect to taxes for any year.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.13.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Permits</U>. The Company has all franchises, permits, licenses and any similar authority necessary for the conduct of
its business, the lack of which could reasonably be expected to have a Material Adverse Effect. The Company is not in default in
any material respect under any of such franchises, permits, licenses or other similar authority.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">2.14.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure</U>. The Company has made available to the Purchasers all the information reasonably available to the Company
that the Purchasers have requested for deciding whether to acquire the Shares, including a PowerPoint presentation regarding proposed
pharmaceutical development operations (the &ldquo;<B>Operating Plan</B>&rdquo;). No representation or warranty of the Company contained
in this Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or to be furnished to Purchasers at the
Closing contains any untrue statement of a material fact or, to the Company&rsquo;s knowledge, omits to state a material fact necessary
in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were
made. The Operating Plan was prepared in good faith; however, the Company does not warrant that it will achieve any results projected
in the Operating Plan. It is understood that this representation is qualified by the fact that the Company has not delivered to
the Purchasers, and has not been requested to deliver, a private placement or similar memorandum or any written disclosure of the
types of information customarily furnished to purchasers of securities.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt; background-color: transparent">3.<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Representations, Warranties and Covenants of the Purchasers</U>. Each Purchaser hereby represents and warrants to the
Company, severally and not jointly, that:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Authorization</U>. The Purchaser has full power and authority to enter into the Transaction Agreements. The Transaction
Agreements to which the Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally
binding obligations of the Purchaser, enforceable in accordance with their terms, except (a)&nbsp;as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement
of creditors&rsquo; rights generally, and as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies, or (b)&nbsp;to the extent the indemnification provisions contained in the Transaction Agreements
may be limited by applicable federal or state securities laws.</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Purchase Entirely for Own Account</U>. This Agreement is made with the Purchaser in reliance upon the Purchaser&rsquo;s
representation to the Company, which by the Purchaser&rsquo;s execution of this Agreement, the Purchaser hereby confirms, that
the Shares, Warrants, and Warrant Shares, as applicable, to be acquired by the Purchaser will be acquired for investment for the
Purchaser&rsquo;s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof,
and that the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same.
By executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking,
agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with
respect to any of the Shares, Warrants or Warrant Shares. The Purchaser has not been formed for the specific purpose of acquiring
the Shares, Warrants or Warrant Shares.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Information</U>. The Purchaser has had an opportunity to discuss the Company&rsquo;s business, management,
financial affairs and the terms and conditions of the offering of the Shares with the Company&rsquo;s management and has had an
opportunity to review the Company&rsquo;s facilities. The foregoing, however, does not limit or modify the representations and
warranties of the Company in Section 2 of this Agreement or the right of the Purchasers to rely thereon.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Restricted Securities; No Public Market</U>. The Purchaser understands that the Securities have not been, and will not
be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act
which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser&rsquo;s
representations as expressed herein. The Purchaser understands that the Shares and Warrants are, and the Warrant Shares and Common
Stock issuable upon conversion of the Shares will be, &ldquo;restricted securities&rdquo; under applicable U.S. federal and state
securities laws and that, pursuant to these laws, the Purchaser must hold the<B> </B>Securities indefinitely unless they are registered
with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification
requirements is available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Securities
for resale except as set forth in the Registration Rights Agreement. The Purchaser further acknowledges that if an exemption from
registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time
and manner of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the
Purchaser&rsquo;s control, and which the Company is under no obligation<I> </I>and may not be able to satisfy. The Purchaser understands
that no public market now exists for the Securities, and that the Company has made no assurances that a public market will ever
exist for the Securities.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>High Degree of Risk; Reliance on Own Advisors</U>. The Purchaser acknowledges that an investment in the Securities involves
a high degree of risk and there can be no assurance regarding the current or future economic value of the Securities or the performance
of the Company or its business operations. <B>The Purchaser has carefully read the Risk Factors attached to this Agreement as <U>Exhibit
E</U> and incorporated into this Agreement by this reference (&ldquo;Risk Factors&rdquo;), has had an opportunity to review the
Risk Factors with the officers of the Company and their representatives, and to ask questions and receive answers from them regarding
such matters. The Purchaser further acknowledges that the Purchaser has relied on his, her or its own analysis and evaluation of
the merits of acquiring the Shares and Warrants, as applicable, and has reviewed with his, her or its own tax advisors the U.S.
federal, state, local and any applicable foreign tax consequences of acquiring the Shares and Warrants, as applicable. With respect
to such matters, the Purchaser relies solely on such advisors and not on any statements or representations of the Company or any
of its officers or agents, written or oral.</B></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Legends</U>. The Purchaser understands that the Shares and the Warrant Shares and any securities issued in respect of
or exchange for the Shares or the Warrant Shares, may be notated with one or all of the following legends:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt; background-color: transparent">&ldquo;THE SHARES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO,
OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE
SECURITIES ACT OF 1933.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt; background-color: white">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any legend set forth in, or required by, the other Transaction Agreements.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt; background-color: white">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares or Warrant
Shares represented by the certificate, instrument, or book entry so legended.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Accredited Investor</U>. The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Foreign Investors</U>. If the Purchaser is not a United States person (as defined by Section&nbsp;7701(a)(30) of the
Code), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in
connection with any invitation to subscribe for the Shares or any use of this Agreement, including (i)&nbsp;the legal requirements
within its jurisdiction for the purchase of the Shares, (ii)&nbsp;any foreign exchange restrictions applicable to such purchase,
(iii)&nbsp;any governmental or other consents that may need to be obtained, and (iv)&nbsp;the income tax and other tax consequences,
if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. The Purchaser&rsquo;s subscription
and payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of the
Purchaser&rsquo;s jurisdiction.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>No General Solicitation</U>. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders
or partners has either directly or indirectly, including, through a broker or finder (a)&nbsp;engaged in any general solicitation,
or (b)&nbsp;published any advertisement in connection with the offer and sale of the Shares or Warrants.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exculpation Among Purchasers</U>. The Purchaser acknowledges that it is not relying upon any Person, other than the Company
and its officers and directors, in making its investment or decision to invest in the Company.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Residence</U>. If the Purchaser is an individual, then the Purchaser resides in the state or province identified in the
address of the Purchaser set forth on <U>Exhibit A</U>; if the Purchaser is a partnership, corporation, limited liability company
or other entity, then the office or offices of the Purchaser in which its principal place of business is identified in the address
or addresses of the Purchaser set forth on <U>Exhibit A</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">3.12.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgment Regarding Contracts and Plan</U>. The Purchaser hereby acknowledges that (i) the Company is party to the
Management Agreement, pursuant to which Benu Biopharma, Inc., an Affiliate of certain of the stockholders of the Company, is contracted
to manage all aspects of AEM-28 and analogs development, which Management Agreement provides for a monthly fee to Benu Biopharma
for such services, as referenced in the Disclosure Schedule, and (ii) the Company is party to the Accounting Services Agreement,
pursuant to which Capstone Therapeutics Corp., on a monthly fee basis, provides all cash management, accounting and contract administration
to the Company, and management of LipimetiX Australia, as referenced in the Disclosure Schedule. The Purchaser also acknowledges
that the Company may increase the number of shares available under the Stock Plan, and does hereby consent to and approve any amendment
to increase such number of shares subject to the Stock Plan, and agrees to vote in favor thereof if presented to the stockholders
of the Company for approval.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt; background-color: transparent">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT><U>Conditions
to the Purchasers&rsquo; Obligations at Closing</U>. The obligations of each Purchaser to purchase Shares and Warrants at the
Initial Closing or any subsequent Closing are subject to the fulfillment, on or before such Closing, of each of the following
conditions, unless otherwise waived:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The representations and warranties of the Company contained in Section&nbsp;2 shall
be true and correct in all respects as of such Closing.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance</U>. The Company shall have performed and complied with all covenants, agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by the Company on or before such Closing.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance Certificate</U>. The President of the Company shall deliver to the Purchasers at such Closing a certificate
certifying that the conditions specified in Subsections 4.1 and 4.2 have been fulfilled.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Qualifications</U>. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body
of the United States or of any state that are required in connection with the lawful issuance and sale of the Shares and the Warrants
pursuant to this Agreement shall be obtained and effective as of such Closing.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights Agreement</U>. The Company and<B> </B>each Purchaser (other than the Purchaser relying upon this
condition to excuse such Purchaser&rsquo;s performance hereunder) and the other stockholders of the Company named as parties thereto
shall have executed and delivered the Registration Rights Agreement, substantially in the form of <U>Exhibit F</U> hereto.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amended and Restated Stockholders Agreement</U>. The Company, each Purchaser (other than the Purchaser relying upon
this condition to excuse such Purchaser&rsquo;s performance hereunder), and the other stockholders of the Company named as parties
thereto shall have executed and delivered the Amended and Restated Stockholders Agreement, substantially in the form of <U>Exhibit
G</U> hereto.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amended and Restated Certificate</U>.<U> </U>The Company shall have filed the Restated Certificate with the Secretary
of State of Delaware on or prior to the Closing, which shall continue to be in full force and effect as of the Closing<U>.</U></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Secretary&rsquo;s Certificate</U>. The Secretary of the Company shall have delivered to the Purchasers at the Closing
a certificate certifying (i) the Bylaws of the Company, (ii) resolutions of the Board of Directors of the Company approving the
Transaction Agreements and the transactions contemplated under the Transaction Agreements, and (iii) resolutions of the stockholders
of the Company approving the Restated Certificate.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Proceedings and Documents</U>. All corporate and other proceedings in connection with the transactions contemplated
at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to each Purchaser, and
each Purchaser (or its counsel) shall have received all such counterpart original and certified or other copies of such documents
as reasonably requested. Such documents may include good standing certificates.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">4.10<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Preemptive Rights</U>. The Company shall have fully satisfied (including with respect to rights of timely notification)
or obtained enforceable waivers in respect of any preemptive or similar rights directly or indirectly affecting any of its securities.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt; background-color: transparent">5.<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Conditions of the Company&rsquo;s Obligations at Closing</U>. The obligations of the Company to sell Shares and Warrants
to the Purchasers at the Initial Closing or any subsequent Closing are subject to the fulfillment, on or before the Closing, of
each of the following conditions, unless otherwise waived:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The representations and warranties of each Purchaser contained in Section 3 shall
be true and correct in all respects as of such Closing.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">5.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance</U>. The Purchasers shall have performed and complied with all covenants, agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by them on or before such Closing.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">5.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Qualifications</U>. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body
of the United States or of any state that are required in connection with the lawful issuance and sale of the Shares and Warrants,
as applicable, pursuant to this Agreement shall be obtained and effective as of the Closing.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">5.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights Agreement</U>. Each Purchaser shall have executed and delivered the Registration Rights Agreement,
substantially in the form of <U>Exhibit E</U> hereto.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">5.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amended and Restated Stockholders Agreement</U>. Each Purchaser and the other stockholders of the Company named as parties
thereto shall have executed and delivered the Amended and Restated Stockholders Agreement, substantially in the form of <U>Exhibit
F</U> hereto.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt; background-color: transparent">6.<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Miscellaneous</U>.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival of Warranties</U>. Unless otherwise set forth in this Agreement, the representations and warranties of the Company
and the Purchasers contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and
the Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf
of the Purchasers or the Company.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon
the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or&nbsp;liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement shall be governed by the internal law of the State of Delaware.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic
mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are used for convenience only and are not to
be considered in construing or interpreting this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall
be deemed effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when
sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business
hours, then on the recipient&rsquo;s next business day, (c) five (5) days after having been sent by registered or certified mail,
return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier,
freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent
to the respective parties at their address as set forth on the signature page or <U>Exhibit A</U>, or to such e-mail address, facsimile
number or address as subsequently modified by written notice given in accordance with this <U>Subsection 6.6</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Finder&rsquo;s Fees</U>. Each party represents that it neither is nor will be obligated for any finder&rsquo;s fee
or commission in connection with the Initial Closing of the sale of the Series B Preferred Stock to the initial Purchasers listed
on <U>Exhibit A</U> hereto. Each Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission
or compensation in the nature of a finder&rsquo;s or broker&rsquo;s fee arising out of this transaction (and&nbsp;the costs and
expenses of defending against such liability or asserted liability) for which each Purchaser or any of its officers, employees
or representatives is responsible. The Company agrees to indemnify and hold harmless each Purchaser from any liability for any
commission or compensation in&nbsp;the nature of a finder&rsquo;s or broker&rsquo;s fee arising out of this transaction (and the
costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees
or representatives is&nbsp;responsible.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intentionally Omitted</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Attorneys&rsquo; Fees</U>. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret
the terms of any of the Transaction Agreements or the Warrants, the prevailing party shall be entitled to reasonable attorneys&rsquo;
fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.10<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Amendments and Waivers</U>. Except as set forth in <U>Subsection 1.2</U>(b) of this Agreement, any term of this Agreement
may be amended, terminated or waived only with the written consent of the Company and the holders of at least fifty percent (50%)
of the outstanding shares of Common Stock (assuming conversion of all outstanding Series B Preferred Stock). Any amendment or waiver
effected in accordance with this <U>Subsection 6.10</U> shall be binding upon the Purchasers and each transferee of the Securities,
each future holder of all such Securities, and the Company.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.11<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Severability</U>. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability
of any other provision.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.12<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Delays or Omissions</U>. No delay or omission to exercise any right, power or remedy accruing to any party under this
Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of
such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be
deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of
any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any
party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically
set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.13<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Entire Agreement</U>. This Agreement (including the Exhibits hereto), the Restated Certificate, the Warrants, and the
other Transaction Agreements constitute the full and entire understanding and agreement between the parties with respect to the
subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties
are expressly canceled.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.14<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Corporate Securities Law</U>. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED
WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR THE PAYMENT OR RECEIPT OF
ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM&nbsp;THE
QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT
ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING OBTAINED UNLESS THE SALE IS SO EXEMPT.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt; background-color: transparent">6.15<FONT STYLE="font-size: 10pt">&nbsp;
</FONT><U>Dispute Resolution</U>. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state
courts of Arizona and to the jurisdiction of the United States District Court for the District of Arizona for the purpose of any
suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other
proceeding arising out of or based upon this Agreement except in the state courts of Arizona<I> </I>or the United States District
Court for the District of Arizona, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise,
in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts,
that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient
forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not
be enforced in or by such court.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt; background-color: transparent"><FONT STYLE="text-transform: uppercase">Waiver
of Jury Trial</FONT>:<B> </B>EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE
OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE
SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH
OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO
AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH
PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS
FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0cm; margin: 0 0 12pt; background-color: transparent"><I>[Signature
Pages Follow.]</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">IN WITNESS
WHEREOF, the parties have executed this Series&nbsp;B Preferred Stock and Warrant Purchase Agreement as of the date first written
above.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0pt 12pt; background-color: Transparent"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: left">COMPANY:</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: left">LIPIMETIX DEVELOPMENT, INC.</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-decoration: none; text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD COLSPAN="2" STYLE="text-decoration: none; text-align: left">By: <U>/s/: Dennis I. Goldberg</U><FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal"><U></U></FONT></td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: left">Name: Dennis I. Goldberg, Ph.D.</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <td colspan="2" style="text-align: left">Title: President</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD STYLE="width: 50%">&nbsp;</td>
    <TD STYLE="width: 8%">Address:</td>
    <TD STYLE="width: 42%">5 Commonwealth Rd., Suite 2A</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Natick, Massachusetts 01760</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Attn: Dennis I. Goldberg, Ph.D.</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Email: dgoldberg@lipimetix.com</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><U>with a copy to<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">:</FONT></U></td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Leslie M. Taeger</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Senior Vice President &amp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-indent: 10pt">Chief Financial Officer</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Capstone Therapeutics Corp.</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>1275 W. Washington St., Suite 104</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Tempe, AZ 85281</td></tr>
</table>


<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0pt 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0pt 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0pt 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 12pt; background-color: transparent"><I>[Signature
Page to Stock Purchase Agreement]</I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 24pt; background-color: Transparent"><BR></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD STYLE="width: 50%">&nbsp;</td>
    <TD STYLE="width: 25%">PURCHASERS:</td>
    <TD STYLE="width: 25%">&nbsp;</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>(Name of Purchaser - See Exhibit A)</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>By: (See Exhibit A)</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>Name: (See Exhibit A)</td>
    <TD>(print)</td></tr>
</table>


<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 24pt; background-color: transparent"></P>

<P STYLE="font-size: 10pt; margin: 0 0 24pt 234pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 24pt; background-color: transparent"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>[Signature Page to Stock Purchase Agreement]</I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I></I></P>



<P STYLE="font-size: 10pt; margin: 0 0 24pt; background-color: transparent"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U>EXHIBIT A</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>SCHEDULE OF PURCHASERS</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD COLSPAN="4" STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 12pt">INITIAL CLOSING</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="width: 49%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><B>Name and Address</B><BR>
<B>of Purchaser</B></TD>
    <TD STYLE="width: 21%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">The Purchasers are accredited investors as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: Transparent">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U>EXHIBIT B</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>FORM OF WARRANT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U></U></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U>EXHIBIT C</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>FORM OF AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U></U></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U>EXHIBIT D</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>DISCLOSURE SCHEDULE</B></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent"><B><U>Capstone Revolving Line of Credit</U></B></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent">At June 30, 2016, the outstanding balance of the Revolving
Line of Credit &ldquo;(Line&rdquo;) extended to LipimetiX Development, Inc. (&ldquo;JV&rdquo; or &ldquo;LipimetiX&rdquo;) by Capstone
Therapeutics Corp. was $1,553,000. The Line bears interest at 5% and is due December 31, 2016.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent"><B><U>Benu BioPharma Management Services Agreement</U></B></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent">The JV entered into a Management Services Agreement
with Benu BioPharma, Inc. (&ldquo;Benu&rdquo;) to manage JV development activities. Benu is composed of Dennis I. Goldberg, Ph.D.,
Phillip M. Friden, Ph.D., and Eric M. Morrel, Ph.D. &nbsp;&nbsp;The current monthly management fee is $80,000. However, no Management
fees are due or payable except to the extent funding is available, as unanimously approved by members of the JV Board of Directors
and as reflected in the approved operating budget in effect at that time.&nbsp; Following the Series B-1 closing, Benu will be
paid $50,000 per month for six months as a stated use of Series B-1 proceeds.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent"><B><U>Capstone Accounting Services Agreement</U></B></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent">The JV entered into an Accounting Services Agreement
with Capstone Therapeutics Corp. to manage JV accounting and administrative functions. The current monthly accounting services
fee is $10,000. However, no Accounting Services fees are due or payable except to the extent funding is available, as unanimously
approved by members of the JV Board of Directors and as reflected in the approved operating budget in effect at that time.&nbsp;
Following the Series B-1 closing, Capstone Therapeutics Corp. will be paid $10,000 per month for six months as a stated use of
Series B-1 proceeds.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent"><B><U>LipimetiX Stock Plan</U></B></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent">The LipimetiX Stock Plan was approved by the LipimetiX
board and a majority of shareholders on June 10, 2016 for the purpose of incentivizing key management, board and consultants who
contribute to the success of LipimetiX. On that date, the board authorized a pool of 71,500 common shares (6% of fully-diluted
shares outstanding prior to the Series B-1 financing) for potential grant.&nbsp; At the same meeting, the board granted a total
of 67,026 options to Dr. Goldberg, Dr. Friden, Dr. Morell, Dr. Anantharamaiah, Dr. Steer, Dr. Garber, Mr. Taeger and Mr. Holliman,
recognizing past and future service to LipimetiX.&nbsp; The options are priced at 10% of the price per share of the Series B-1
or $1.07 per share and are 50% vested as of grant with remaining vesting on a monthly linear basis over 24 months.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U></U></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U>EXHIBIT E</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>RISK FACTORS</B></P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0 0 12pt; background-color: transparent">An investment
in the Shares should be considered highly speculative and involves a number of risks regarding our business, including without
limitation those described below, as well as risks regarding the terms of the investment as set forth in this Agreement, the Certificate
and the other Transaction Agreements. You should conduct your own due diligence prior to investing, and should also make such inquiries
of the Company as you deem appropriate. You should also consult with your own legal, tax and financial advisors. If any of the
following risks actually occur, the Company&rsquo;s business, financial condition, results of operation, or even its continued
existence could be harmed. Additional risks and uncertainties not presently known to the Company, or that it currently thinks are
immaterial, may also impair the Company&rsquo;s business operations. Among the risk components that you should consider and discuss
with your advisors are the following:</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">1. <B><U>We are a biopharmaceutical
company with no revenue generating operations and high investment costs. Therefore, we will require additional funding to realize
revenue from any of our product candidates, and we may never realize any revenue if our product candidates cannot be commercialized.</U></B><U>
</U></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Our current level of funds is not
sufficient to support continued research to develop our product candidates, and the proceeds of this offering will not be sufficient
to fund all the research expenses necessary to achieve commercialization of any of our product candidates. We will require substantial
additional capital, and/or a development partner, to complete the clinical trials and supporting research and production efforts
necessary to obtain FDA or comparable foreign agencies&rsquo; approval, if any, for our product candidates. We may not receive
any revenue from our product candidates until we receive regulatory approval and begin commercialization of our product candidates.
We cannot predict whether, or when, that might occur. We can give no assurances regarding how much further development of our product
candidates the proceeds will fund before more funding is necessary. There is no assurance that we can obtain needed funding from
third parties on terms acceptable to us, or at all. New sources of funds, including raising capital through the sales of our debt
or equity securities, joint venture or other forms of joint development arrangements, sales of development rights, or licensing
agreements, may not be available or may only be available on terms that would have a material adverse impact on our existing stockholders&rsquo;
interests.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Our future cash expenditure levels
are difficult to forecast because the forecast is based on assumptions about the level of future operations, including the number
of research projects we pursue, the pace at which we pursue them, the quality of the data collected and the requests of the FDA
or comparable foreign agencies to expand, narrow or conduct additional clinical trials and analyze data. Changes in any of these
assumptions can change significantly our estimated cash expenditure levels.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">2. <B><U>Our business is subject
to stringent regulation, and if we do not obtain regulatory approval for our product candidates, we will not be able to generate
revenue.</U></B></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Our research, development, pre-clinical
and clinical trial activities and the manufacture and marketing of any products that we may successfully develop are subject to
an extensive regulatory approval process by the FDA and other regulatory agencies in the United States and abroad. The process
of obtaining required regulatory approvals for pharmaceutical products is lengthy, expensive and uncertain, and any such regulatory
approvals may entail limitations on the indicated usage of a product, which may reduce the product&rsquo;s market potential. None
of our product candidates has been approved for sale.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">If we experience delays in our clinical
trials, we will incur additional costs and our opportunities to monetize product candidates will be deferred. Delays could occur
for many reasons, including the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the FDA or other health regulatory authorities, or institutional review boards, do not approve a clinical study protocol or
place a clinical study on hold;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>suitable patients do not enroll in a clinical study in sufficient numbers or at the expected rate, or data is adversely affected
by trial conduct or patient drop out;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patients experience serious adverse events, including adverse side effects of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patients in the placebo or untreated control group exhibit greater than expected improvements or fewer than expected adverse
events;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>third-party clinical investigators do not perform the clinical studies on the anticipated schedule or consistent with the clinical
study protocol and good clinical practices, or other third-party organizations do not perform data collection and analysis in a
timely or accurate manner;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>service providers, collaborators or co-sponsors do not adequately perform their obligations in relation to the clinical study
or cause the study to be delayed or terminated;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we experience difficulties in obtaining sufficient quantities of the particular product candidate or any other components needed
for pre-clinical testing or clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory inspections of manufacturing facilities, which may, among other things, require us or a co-sponsor to undertake
corrective action or suspend the clinical studies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the interim results of the clinical study are inconclusive or negative;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the clinical study, although approved and completed, generates data that is not considered by the FDA or others to be sufficient
to demonstrate safety and efficacy;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in governmental regulations or administrative actions affect the conduct of the clinical trial or the interpretation
of its result;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>there is a change in the focus of our development efforts or a re-evaluation of our clinical development strategy; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">we lack of sufficient funds to pay for development costs.</FONT><BR>
<BR>
</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Consequently, we cannot assure that
we will make submissions to the FDA or comparable foreign agencies in the timeframe that we have planned, or at all, or that our
submissions will be approved by the FDA or comparable foreign agencies. Even if regulatory clearance is obtained, post-market evaluation
of our future products, if required, could result in restrictions on a product&rsquo;s marketing or withdrawal of a product from
the market as well as possible civil and criminal sanctions.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">3. <B><U>If our product candidates
do not gain market acceptance or our competitors develop and market products that are more effective than our product candidates,
our commercial opportunities will be reduced or eliminated.</U></B></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Even if we bring one or more products
to market, there is no assurance that we will be able to successfully manufacture or market the products or that potential customers
will buy them. Market acceptance will depend on our ability to demonstrate to physicians and patients the benefits of the future
products in terms of safety, efficacy, and convenience, ease of administration and cost effectiveness, as well as on our ability
to continue to develop product candidates to respond to competitive and technological changes. In addition, we believe that market
acceptance depends on the effectiveness of our marketing strategy, the pricing of our future products and the reimbursement policies
of government and third-party payors. Physicians may not prescribe our future products, and patients may determine, for any reason,
that our product is not useful to them. Insurance companies and other third party payors may determine not to reimburse for the
cost of the product.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Competition in the pharmaceutical
and biotechnology industries is intense and is expected to increase. Several biotechnology and pharmaceutical companies, as well
as academic laboratories, universities and other research institutions, are involved in research and/or product development for
indications targeted for use by our Apo E mimetic peptide molecule, AEM-28 (&ldquo;AEM-28&rdquo;), and its analogs. Most of our
competitors have significantly greater research and development capabilities, experience in obtaining regulatory approvals and
manufacturing, marketing, financial and managerial resources than we have.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Our competitors may succeed in developing
products that are more effective than the ones we have under development or that render our proposed products or technologies noncompetitive
or obsolete. In addition, certain of our competitors may achieve product commercialization before we do. If any of our competitors
develops a product that is more effective than one that we are developing or plans to develop, or is able to obtain FDA or comparable
foreign agencies&rsquo; approval for commercialization before we do, we may not be able to achieve significant market acceptance
for certain of our products, which would have a material adverse effect on our business.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">4. <B><U>If we cannot protect our
AEM-28 and other patents, or our intellectual property generally, our ability to develop and commercialize our future products
will be severely limited.</U></B><U> </U></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Our success will depend in part
on our ability to maintain and enforce patent protection for AEM-28 and its analogs and each resulting product. Without patent
protection, other companies could offer substantially identical products for sale without incurring the sizable discovery, development
and licensing costs that we have incurred. Our ability to recover these expenditures and realize profits upon the sale of products
would then be diminished.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">AEM-28 is patented and patent applications
for the AEM-28 analogs have be filed. There have been no successful challenges to the patents. However, if there were to be a challenge
to these patents or any of the patents for product candidates, a court may determine that the patents are invalid or unenforceable.
Even if the validity or enforceability of a patent is upheld by a court, a court may not prevent alleged infringement on the grounds
that such activity is not covered by the patent claims. Any litigation to enforce our rights to use our or our licensors&rsquo;
patents will be costly, time consuming and may distract management from other important tasks.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">As is commonplace in the biotechnology
and pharmaceutical industries, we employ, or engage as consultants, individuals who were previously employed at other biotechnology
or pharmaceutical companies, including our competitors or potential competitors. To the extent our employees are involved in research
areas which are similar to those areas in which they were involved at their former employers, we may be subject to claims that
such employees and/or we have inadvertently or otherwise used or disclosed the alleged trade secrets or other proprietary information
of the former employers. Litigation may be necessary to defend against such claims, which could result in substantial costs and
be a distraction to management and which may have a material adverse effect on us, even if we are successful in defending such
claims.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">We also rely on trade secrets, know-how
and other proprietary information. We seek to protect this information, in part, through the use of confidentiality agreements
with employees, consultants, advisors and others. Nonetheless, we cannot assure that those agreements will provide adequate protection
for our trade secrets, know-how or other proprietary information and prevent their unauthorized use or disclosure. The risk that
other parties may breach confidentiality agreements or that our trade secrets become known or independently discovered by competitors,
could adversely affect us by enabling our competitors, who may have greater experience and financial resources, to copy or use
our trade secrets and other proprietary information in the advancement of their products, methods or technologies.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">5. <U> <B>Our success also depends
on our ability to operate and commercialize products without infringing on the patents or proprietary rights of others.</B></U></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">Third parties may claim that we
or our licensors or suppliers are infringing their patents or are misappropriating their proprietary information. In the event
of a successful claim against us or our licensors or suppliers for infringement of the patents or proprietary rights of others,
we may be required to, among other things:</P>

<P STYLE="font-size: 10pt; text-indent: 18pt; margin: 0; background-color: transparent"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>pay substantial damages;</P>

<P STYLE="font-size: 10pt; text-indent: 18pt; margin: 0; background-color: transparent"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>stop using our technologies;</P>

<P STYLE="font-size: 10pt; text-indent: 18pt; margin: 0; background-color: transparent"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>stop certain research and development efforts;</P>

<P STYLE="font-size: 10pt; text-indent: 18pt; margin: 0; background-color: transparent"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>develop non-infringing products or methods; and</P>

<P STYLE="font-size: 10pt; text-indent: 18pt; margin: 0; background-color: transparent"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>obtain one or more licenses from third parties.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; background-color: transparent">A license required under any such patents or proprietary
rights may not be available to us, or may not be available on acceptable terms. If we or our licensors or suppliers are sued for
infringement, we could encounter substantial delays in, or be prohibited from, developing, manufacturing and commercializing our
product candidates.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">6. <B><U>Our reliance on third party
clinical research organizations and other consultants could have a material effect on our ability to conduct clinical trials and
perform research and development. Product development costs to us and our potential collaborators will increase, and our business
may be negatively impacted, if we experience delays in testing or approvals or if we need to perform more or larger clinical trials
than planned</U><I>.</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">To obtain regulatory approvals for
new products, we must, among other things, initiate and successfully complete multiple clinical trials demonstrating to the satisfaction
of the FDA or other regulatory authority that our product candidates are sufficiently safe and effective for a particular indication.
We currently rely on third party clinical research organizations and other consultants to assist us in designing, administering
and assessing the results of those trials and to perform research and development with respect to product candidates. In relying
on those third parties, we are dependent upon them to timely and accurately perform their services. If third party organizations
do not accurately collect and assess the trial data, we may discontinue development of viable product candidates or continue allocating
resources to the development and marketing of product candidates that are not efficacious. ither outcome could result in significant
financial harm to us.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">7. <B><U>The loss of key management
and scientific personnel may hinder our ability to execute our business plan</U></B><U>.</U></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">As a small company our success depends
on the continuing contributions of our management team and scientific consultants, and maintaining relationships with the network
of medical and academic centers in the United States and centers that conduct our clinical trials. If we are not successful in
retaining the services of these individuals, it could materially adversely affect our business prospects, including our ability
to explore partnering or development activities.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">We are managed under contract by
Benu BioPharma Inc., which is comprised of three individuals (Dennis I. Goldberg, Ph.D., Phillip M. Friden, Ph.D., and Eric M.
Morrel, Ph.D.) who are our minority stockholders. Although there is a services contract with Benu BioPharma Inc., there is no direct
agreement with these individuals for continued services, and they are under no legal obligation to remain with Benu BioPharma Inc.
We can give no assurance that all or any of these individuals will continue to provide services to us. Should any of these individuals
not continue to provide services to us, it could have a material adverse effect on our ability or cost to develop AEM-28 and its
analogs.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">8. <B><U>Possible side effects of
our product candidates may be serious and life threatening. If one of our product candidates reveals safety or fundamental efficacy
issues in clinical trials, it could adversely impact the development path for our other current product candidates for that peptide.
We face an inherent risk of liability in the event that the use or misuse of our future products results in personal injury or
death.</U></B></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt; background-color: transparent">The occurrence of any unacceptable
side effects during or after pre-clinical and clinical testing of our product candidates, or the perception or possibility that
our product candidates cause or could cause such side effects, could delay or prevent approval of our products and negatively
impact our business.<B><I> </I></B>The use of our product candidates in clinical trials may expose us to product liability claims,
which could result in financial losses. Our clinical liability insurance coverage<B> </B>may not be sufficient to cover claims
that may be made against us. In addition, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient
amounts or scope to protect us against losses. Any claims against us, regardless of their merit, could severely harm our financial
condition, strain our management and other resources and adversely impact or eliminate the prospects for commercialization of
the product which is the subject of any such claim.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U>EXHIBIT F</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>FORM OF REGISTRATION RIGHTS
AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; background-color: transparent"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0; background-color: transparent">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><U>EXHIBIT G</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>FORM OF AMENDED AND RESTATED</B><BR>
<B>STOCKHOLDERS AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt; background-color: transparent"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exh_102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>Exhibit 10.2 - Series B Preferred Stock and Warrant Purchase Agreement
- Exhibit B &ndash; Form of Warrants</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR UNDER THE SECURITIES LAWS OF
ANY STATE REPRESENTED THEREBY, AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS
AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE CORPORATION HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION
AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>LIPIMETIX DEVELOPMENT, INC.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>WARRANT TO PURCHASE SERIES B-1 PREFERRED STOCK</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%">Warrant No. B-____</td>
    <TD STYLE="font-size: 10pt; text-align: right; width: 50%">August 25, 2016</td></tr>
</table>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">Void after August 24, 2026.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0">THIS CERTIFIES THAT, for value received, the receipt
and sufficiency of which are hereby acknowledged, ______________________, a _______________ ______________, or its registered assigns
(as the case may be, the &ldquo;<B>Holder</B>&rdquo;), is entitled, subject to the terms and conditions set forth herein, to purchase
from LipimetiX Development, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), up to __________________ (_________)
(the &ldquo;<B>Warrant Number</B>&rdquo;) duly authorized, validly issued, fully-paid and non-assessable shares (the &ldquo;<B>Warrant
Shares</B>&rdquo;) of the Company&rsquo;s Series B-1 Preferred Stock, par value $.00001 per share (the &ldquo;<B>Warrant Stock</B>&rdquo;),
subject to adjustment as provided herein, at a purchase price equal to $10.70 per share (the &ldquo;<B>Exercise Price</B>&rdquo;),
subject to adjustment as provided herein. This Warrant is issued pursuant to that certain Series B Preferred Stock and Warrant
Purchase Agreement, dated as of the date hereof, by and among the Company and the Investors party thereto (the &ldquo;<B>Purchase
Agreement</B>&rdquo;). The term &ldquo;<B>Warrant</B>&rdquo; as used herein shall mean this warrant, and any warrants delivered
in substitution or exchange therefor as provided herein. All capitalized terms used but not otherwise defined herein, including
in Section 8 hereof, shall have the meaning set forth in the Purchase Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0">The following is a statement of the rights of the
Holder and the conditions to which this Warrant is subject, and to which the Company and the Holder hereof, by the acceptance of
this Warrant, agrees:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase"><U>Term of Warrant</U></FONT>.</B> Subject to the terms and conditions set forth
herein, this Warrant shall be exercisable, in whole or in part, during the term commencing on August 25, 2016 and ending on August
24, 2026 (subject to extension as provided below, the &ldquo;<B>Exercise Period</B>&rdquo;); provided, however, that in the event
that the expiration date of this Warrant shall fall on a Saturday, Sunday or United States federally recognized holiday, the expiration
date for this Warrant shall be extended to the first business day following such Saturday, Sunday or recognized holiday.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase"><U>Exercise of Warrant</U></FONT>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Manner of Exercise</U>.</B> This Warrant may be exercised by the Holder, in whole or in part, at any time and from
time to time during the Exercise Period, by (i) the surrender of this Warrant to the Company, with the Notice of Exercise attached
hereto as <U>Annex A</U> duly completed and executed on behalf of the Holder, at the principal office of the Company or such other
office or agency of the Company as it may designate by notice in writing to the Holder (the &ldquo;<B>Principal Office</B>&rdquo;),
and (ii) the delivery of payment to the Company of the Exercise Price for the number of Warrant Shares specified in the Notice
of Exercise in any manner specified in subsection (c) or (d) of this Section 2. Notwithstanding the foregoing, this Warrant shall
automatically be deemed to have been exercised immediately prior to, and conditioned upon, the closing of a Qualified Public Offering
or a Corporate Liquidity Transaction, on a Net Issue Exercise basis as set forth in Section 2(d) below, provided that the initial
public offering price or the Fair Market Value per Warrant Share (after giving effect to such Corporate Liquidity Transaction),
as the case may be, is greater than the Exercise Price.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Issuance of Warrant Shares</U>.</B> The Warrant Shares issuable upon any exercise of this Warrant shall be deemed
to be issued to the Holder as the record holder of such Warrant Shares as of the close of business on the date on which this Warrant
shall have been surrendered and payment made for such Warrant Shares as aforesaid. As promptly as practicable thereafter, but in
any event within ten (10) days, the Company shall deliver to the Holder, at the Company&rsquo;s expense, a stock certificate or
certificates for the Warrant Shares specified in the Notice of Exercise. If this Warrant shall have been exercised only in part,
the Company shall, at the time of delivery of the stock certificate or certificates, also deliver to the Holder, at the Company&rsquo;s
expense, a new Warrant evidencing the right to purchase the remaining number of Warrant Shares, which new Warrant shall in all
other respects be identical to this Warrant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Payment of Exercise Price</U>.</B> Unless the Holder is exercising this Warrant pursuant to a Net Issue Exercise as
set forth in Section 2(d) below, the Exercise Price shall be payable in cash or its equivalent, payable by wire transfer of immediately
available funds to a bank account specified by the Company or by certified or bank cashiers&rsquo; check in lawful money of the
United States of America.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Net Issue Exercise</U>.</B> In lieu of payment of the Exercise Price pursuant to Section 2(c), and exclusively in
connection with a Corporate Liquidity Transaction, this Warrant may be exercised by the Holder by the surrender of this Warrant
to the Company, with a duly executed Notice of Exercise marked to reflect Net Issue Exercise and specifying the number of Warrant
Shares to be purchased, during normal business hours on any business day during the Exercise Period. The Company agrees that such
Warrant Shares shall be deemed to be issued to the Holder as the record Holder of such Warrant Shares as of the close of business
on the date on which this Warrant shall have been surrendered as aforesaid (or the date of the Corporate Liquidity Transaction,
as applicable). Upon such exercise, the Holder shall be entitled to receive shares equal to the value of this Warrant (or the
portion thereof being canceled) by surrender of this Warrant to the Company together with notice of such election in which event
the Company shall issue to Holder a number of Warrant Shares computed as of the date of surrender of this Warrant to the Company
(or the date of the Corporate Liquidity Transaction, as applicable) using the following formula:</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle">
    <TD ROWSPAN="2" STYLE="font-size: 10pt; text-align: right; width: 10%">X =&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-decoration: underline; width: 90%">Y(A-B)</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt">&nbsp; &nbsp;&nbsp;A</td></tr>
</table>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 36pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt">Where X = the number of Warrant Shares to be issued to Holder
under this Section 2(d);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -36pt; margin: 0 0 12pt 72pt">Y =&#9;the number of Warrant Shares
purchasable under this Warrant (as adjusted to the date of such calculation);</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt 36pt">A =&#9;the Fair Market Value of one Warrant Share at the
date of such calculation;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -36pt; margin: 0 0 12pt 72pt">B =&#9;the Exercise Price (as adjusted
to the date of such calculation).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Joinder to Investment Agreements</U>.</B> Upon exercise of this Warrant, in whole or in part, the Holder shall become
a party to each of the Investment Agreements as an &ldquo;Investor&rdquo; thereunder (or any successor term used therein to describe
the Investors (as defined therein as of the date hereof)), and, if requested by the Company, shall execute counterpart signature
pages to such Investment Agreements, in each case if and to the extent the Holder is not already a party thereto in such capacity.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Fractional Shares</U>.</B> No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. In lieu of any fractional share to which the Holder would otherwise be entitled, the Company shall make a cash
payment equal to the product of such fraction multiplied by the Fair Market Value of one Warrant Share as of the date of exercise.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase"><U>Exchange and Replacement</U></FONT>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Manner of Exchange and Replacement</U>.</B> This Warrant is exchangeable, upon surrender of the Warrant by the Holder
to the Company at the Principal Office, for new Warrants of like tenor registered in the Holder&rsquo;s name and representing in
the aggregate the right to purchase the same number of Warrant Shares purchasable hereunder, each of such new Warrants to represent
the right to purchase such number of Warrant Shares as shall be designated by the Holder at the time of surrender.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Issuance of New Warrant</U>.</B> Upon receipt by the Company of (i) evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant and (ii) (A) in the case of loss, theft or destruction, an indemnity agreement
reasonably satisfactory in form and substance to the Company or (B) in the case of mutilation, this Warrant, the Company, at its
expense, shall execute and deliver, in lieu of this Warrant, a new Warrant of like tenor and amount.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase"><U>Rights of Stockholders</U></FONT>.</B> The Holder shall not be entitled to vote
or receive dividends or be deemed the holder of the Warrant Shares or any other securities of the Company that may at any time
be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder,
as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any other
matter submitted to the stockholders of the Company at any meeting thereof, or to give or withhold consent to any corporate action
(whether upon any recapitalization, issuance or reclassification of capital stock, change of par value, or change of stock to no
par value, consolidation, merger, conveyance or otherwise) or to receive notice of meetings, or to receive dividends or subscription
rights or otherwise until the Warrant shall have been exercised as provided herein.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase"><U>ADJUSTMENTs</U>.</FONT></B> The Exercise Price and the Warrant Number shall be
subject to adjustment from time to time as provided in this Section 5.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Reclassification, etc.</U></B> If the Company, at any time while this Warrant, or any portion hereof, remains outstanding
and unexpired by reclassification of securities or otherwise, shall change any of the securities as to which purchase rights under
this Warrant exist into the same or a different number of securities of any other class or classes, this Warrant shall thereafter
represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with
respect to the securities that were subject to the purchase rights under this Warrant immediately prior to such reclassification
or other change and the Exercise Price therefor shall be appropriately adjusted, all subject to further adjustment as provided
in this Section 5.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Split, Subdivision or Combination of Shares.</U></B> If the Company at any time while this Warrant, or any portion
hereof, remains outstanding and unexpired shall split, subdivide or combine the securities as to which purchase rights under this
Warrant exist, into a different number of securities of the same class, then (i) in the case of a split or subdivision, the Exercise
Price for such securities shall be proportionately decreased and the Warrant Number shall be proportionately increased, and (ii)
in the case of a combination, the Exercise Price for such securities shall be proportionately increased and the Warrant Number
shall be proportionately decreased.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Mergers or Consolidations</U>. </B> If at any time there shall be a merger or consolidation of the Company with or
into another corporation, other than a Corporate Liquidity Transaction, provision shall be made so that the Warrant Holder shall
thereafter be entitled to receive upon exercise of this Warrant, during the period specified in this Warrant and upon payment of
the Exercise Price, the number of Equity Securities or other securities or property of the Company or the successor corporation
resulting from such merger or consolidation to which a holder of the Warrant Shares deliverable upon exercise of this Warrant would
have been entitled under the provisions of the agreement in such merger or consolidation if this Warrant had been exercised immediately
before such merger or consolidation occurs. In any such case, appropriate adjustment (as determined in good faith by the Board)
shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Warrant Holder
after the merger or consolidation to the end that the provisions of this Warrant (including adjustment of the Exercise Price then
in effect and the Warrant Number) shall be applicable after that event, as near as reasonably may be, in relation to any shares
or other property deliverable after that event upon exercise of this Warrant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Adjustment to Purchase Price and Warrant Number Upon Certain Series B Issuances</U>.</B> If the Company shall, at
any time or from time to time after the date hereof, issue or sell any shares of Series B-2 Preferred Stock for consideration per
share (the &ldquo;<B>Dilutive Issuance Price</B>&rdquo;) less than the Exercise Price in effect immediately prior to such issuance
or sale (the &ldquo;<B>Dilutive Issuance Price</B>&rdquo;), then immediately upon such issuance or sale the Exercise Price in effect
immediately prior to such issuance or sale shall be reduced (and in no event increased) to the Dilutive Issuance Price and the
Warrant Number shall be proportionately increased to that number determined by dividing the product of the original Warrant Number
and the original Exercise Price by the new Dilutive Issuance Price. In addition, for purposes of clarity, it is agreed that the
Warrant Shares issuable upon conversion hereof shall be entitled to the benefit of any conversion price adjustments applicable
to such Series B-1 Shares under the Restated Certificate, as amended or restated from time to time, as though such Warrant Shares
were outstanding as of the date hereof.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Certificate as to Adjustment</U>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As promptly as reasonably practicable following any adjustment of the Exercise Price, but in any event not later than 20
business days thereafter, the Company shall furnish to the Holder a certificate of an executive officer setting forth in reasonable
detail such adjustment and the facts upon which it is based and certifying the calculation thereof.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As promptly as reasonably practicable following the receipt by the Company of a written request by the Holder, but in any
event not later than ten Business Days thereafter, the Company shall furnish to the Holder a certificate of an executive officer
certifying the Exercise Price then in effect and the number of Warrant Shares or the amount, if any, of other shares of stock,
securities or assets then issuable upon exercise of the Warrant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase"><U>Transfer of Warrant</U></FONT>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Non-Transferability</U>.</B> This Warrant may not be assigned or transferred without the prior written consent of
the Company. In the event that the Company agrees to such transfer, and subject to the further restrictions on transfer set forth
in subsection (b) of this Section 6, this Warrant may be transferred by the Holder by (i) surrender of this Warrant to the Company,
with the Assignment Form attached hereto as <U>Annex B</U> duly completed and executed on behalf of the Holder, at the Principal
Office, and (ii) delivery of funds sufficient to pay any transfer tax arising as a result of such transfer. As promptly as practicable
thereafter, but in any event within ten (10) days, the Company shall execute and deliver, at the Company&rsquo;s expense, a new
Warrant registered in the name of the assignee, and for the number of Warrant Shares, specified in the Assignment Form, which new
Warrant shall in all other respects be identical to this Warrant. If this Warrant shall have been transferred only in part, the
Company shall, at the time of delivery of the new Warrant to the assignee, also deliver to the Holder, at the Company&rsquo;s expense,
a new Warrant evidencing the right to purchase the remaining number of Warrant Shares, which new Warrant shall in all other respects
be identical to this Warrant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Compliance with Securities Laws</U>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Holder of this Warrant, by acceptance hereof, acknowledges that, in addition to the requirements set forth above, the
transfer of this Warrant and the Warrant Shares is subject to the Holder&rsquo;s compliance with the provisions of the Securities
Act and any applicable state securities laws in respect of any such transfer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The certificate or certificates representing any Warrant Shares acquired upon exercise of this Warrant, and any securities
issued in respect of such Warrant Shares upon the conversion thereof or any stock split, stock dividend, recapitalization, merger,
consolidation or similar event, shall be stamped or otherwise imprinted with the following legend (unless such a legend is no longer
required under the Securities Act):</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 36pt">THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR UNDER THE SECURITIES LAWS OF ANY STATE REPRESENTED HEREBY, AND MAY NOT BE OFFERED,
SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE CORPORATION
HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 36pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase"><U>Notices</U>.</FONT></B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Events Requiring Notice to Holder</U>. </B> In the event of (i) any taking by the Company of a record of the holders
of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividends or other
distribution, or any right to subscribe for, purchase or otherwise acquire any Equity Securities or other property; (ii) any capital
reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company, any Corporate Transaction
or any other merger or consolidation of the Company; or (iii) any voluntary or involuntary dissolution, liquidation, winding up
or bankruptcy of the Company (each, a &ldquo;<B>Record Event</B>&rdquo;), then and in each such Record Event, the Company shall
give the Holder a notice specifying (A) the date on which any such record is to be taken for the purpose of such dividend, distribution
or right and a description of such dividend, distribution or right; (B) the date on which any such reorganization, reclassification,
recapitalization, Corporate Transaction, merger, consolidation, dissolution, liquidation, winding up or bankruptcy is expected
to become effective; and (C) the time, if any, that is to be fixed as to when the holders of record of Common Stock, Warrant Stock
or other Equity Securities shall be entitled to exchange their shares of Common Stock, Warrant Stock or other Equity Securities
for cash, securities or other property deliverable upon such reorganization, reclassification, recapitalization, Corporate Transaction,
merger, consolidation, dissolution, liquidation, winding up or bankruptcy. In each such Record Event, the notice required by this
Section 7(a) shall be delivered at least fifteen (15) days prior to the date specified in such notice; provided, however, that
neither the failure to give such notice nor any defect therein shall affect the legality or validity of the proceedings described
in clauses (i) through (iii) hereof.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Manner of Notice</U>.</B> Whenever a notice is required to be given to the Holder pursuant to this Warrant (including,
without limitation, any notice required by Section 8(a) above), such notice shall be delivered to the Holder&rsquo;s address of
record as shown on the books of the Company and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal
delivery to Holder, (ii) when sent, if sent by electronic mail or facsimile during normal business hours of the Holder, and if
not sent during normal business hours, then on the Holder&rsquo;s next business day, (iii) five (5) days after having been sent
by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) business day after deposit with a nationally
recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>DEFINITIONS</U>. </B>The following definitions shall apply for all purposes of this Warrant:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Board</B>&rdquo; shall mean the Board of Directors of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Capstone Entity</B>&rdquo; means Capstone Therapeutics Corp. or any Affiliate of Capstone Therapeutics Corp.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Corporate Liquidity Transaction</B>&rdquo; shall mean any consolidation or merger of the Company with or into
any other corporation or other Person, other than a Capstone Entity (including any merger or consolidation in which a subsidiary
of the Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation
other than a transaction involving a Capstone Entity), other than any such consolidation or merger in which the stockholders of
the Company immediately prior to such consolidation or merger, continue to hold at least a majority of the voting power of the
surviving entity in substantially the same proportions and with substantially the same rights, preference and privileges (or, if
the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation or merger.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B>&ldquo;Equity Securities</B>&rdquo; shall mean (i) any Common Stock or other capital stock of the Company, (ii) any
security convertible, with or without consideration, into any Common Stock or other capital stock of the Company (including any
option, warrant or other right to subscribe for or purchase such a security), (iii) any security carrying any option, warrant or
other right to subscribe for or purchase any Common Stock or other capital stock of the Company, or (iv) any such option, warrant
or other right.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Fair Market Value</B>&rdquo; shall mean (i) if the Warrant Stock or the Common Stock or other Equity Securities
into which the Warrant Stock is convertible is traded on a securities exchange, the average of the closing prices of such securities
on such exchange over the thirty (30) day period ending one day before the exercise date; (ii) if the Warrant Stock or the Common
Stock or other Equity Securities into which the Warrant Stock is convertible is actively traded over-the-counter, the average of
the closing bid or sales prices (whichever is applicable) of such securities over the thirty (30) day period ending one day before
the exercise date; (iii) if the Warrant is being exercised in connection with a Corporate Liquidity Transaction, the consideration
to be paid for the Warrant Stock or the Common Stock or other Equity Securities into which the Warrant Stock is convertible in
connection with such Corporate Transaction (for purposes of clarification, in any case in which the price or value of the Common
Stock or other Equity Securities into which the Warrant Stock is convertible is determined pursuant to any of the foregoing clauses
(i) through (iii), such price or value shall be adjusted, and the Fair Market Value of the Warrant Stock shall be based upon, the
number of shares of Common Stock or such other Equity Securities into which one share of Warrant Stock is then convertible); and
(iv) in all other cases, as determined in good faith by the Board.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Investment Agreements</B>&rdquo; shall mean (i) the Amended and Restated Stockholders Agreement, dated as of August
25, 2016, by and among the Company and the Stockholders (as defined therein), as heretofore or hereafter amended, restated, supplemented
or otherwise modified from time to time; (ii) the Registration Rights Agreement, dated as of August 25, 2016, by and among the
Company and the Investors and Common Holders (as defined therein), as heretofore or hereafter amended, restated, supplemented or
otherwise modified from time to time; and (iii) the Purchase Agreement, as heretofore or hereafter amended, restated, supplemented
or otherwise modified from time to time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Person</B>&rdquo; shall mean any individual, corporation, partnership, trust, limited liability company, association
or other entity.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Qualified Public Offering</B>&rdquo; shall mean any public offering of the Company&rsquo;s securities which would
result in a mandatory conversion of the Series B-1 Shares under the Restated Certificate, as amended or restated from time to time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Securities Act</B>&rdquo; shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase"><U>Miscellaneous</U>.</FONT></B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Governing Law</U>.</B> This Warrant and any controversy arising out of or relating to this Warrant shall be governed
by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof,
and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware, without
regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Prevailing Party&rsquo;s Costs and Expenses</U>.</B> If any action at law or in equity (including arbitration) is
necessary to enforce or interpret the terms of this Warrant, the prevailing party shall be entitled to recover from the non-prevailing
party all costs and expenses, reasonable attorneys&rsquo; fees, incurred in such action, in addition to any other relief to which
such party may be entitled.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Delays or Omissions</U>.</B> Except where a time period is specified, no delay on the part of any party in the exercise
of any right, power, privilege or remedy hereunder shall operate as a waiver thereof, nor shall any exercise or partial exercise
of any such right, power, privilege or remedy preclude any further exercise thereof or the exercise of any other right, power,
privilege or remedy.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Amendment and Waiver</U>.</B> No provision of this Warrant may be amended, modified or waived except upon the written
consent of the party against whom such amendment, modification or waiver is to be enforced. The failure of any party to enforce
any of the provisions of this Warrant shall in no way be construed as a waiver of such provisions and shall not affect the right
of such party thereafter to enforce each and every provision of this Warrant in accordance with its terms.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Binding Effect</U>.</B> This Warrant shall be binding upon and inure to the benefit of all of the parties and, to
the extent permitted by this Warrant, their successors, legal representatives and assigns.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Severability</U>.</B> In the event one or more of the provisions of this Warrant should, for any reason, be held to
be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other
provisions of this Warrant, and this Warrant shall be construed as if such invalid, illegal or unenforceable provision had never
been contained herein.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Construction</U>.</B> Whenever the context requires, the gender of any word used in this Warrant includes the masculine,
feminine or neuter, and the number of any word includes the singular or plural. Unless the context otherwise requires, all references
to articles and sections refer to articles and sections of this Warrant, and all references to schedules are to schedules attached
hereto, each of which is made a part hereof for all purposes.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Headings</U>.</B> The headings and subheadings in this Warrant are included for convenience and identification only
and are in no way intended to describe, interpret, define or limit the scope, extent or intent of this Warrant or any provision
hereof.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>[remainder of page intentionally left blank]</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I></I></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0">IN WITNESS WHEREOF, the Company has executed this
Warrant as of the date first above stated.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 0 216pt"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: middle">
    <TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-size: 10pt"><B>LIPIMETIX DEVELOPMENT, INC.</B></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; width: 50%">&nbsp;</td>
    <td style="font-size: 10pt; width: 50%">By:&nbsp;____________________________</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">Name:</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">Title:</td></tr>
</table>


<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>ANNEX A</B></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">To: LIPIMETIX DEVELOPMENT, INC. (the &ldquo;<B>Company</B>&rdquo;)</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0">1.<FONT STYLE="font-size: 10pt">&nbsp; </FONT>The
undersigned hereby elects to purchase _______________ Warrant Shares pursuant to the terms of the attached Warrant, and tenders
herewith payment of the purchase price for such shares in full in the following manner:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 36pt">___</TD><TD STYLE="text-align: justify">The undersigned elects to exercise the attached Warrant by means of a cash payment, and tenders
herewith payment in full for the purchase price of the shares being purchased, together with all applicable transfer taxes, if
any.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -36pt; margin: 0 54pt 0 108pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 36pt">___</TD><TD STYLE="text-align: justify">The undersigned elects to exercise the attached Warrant by means of the surrender of the right
to purchase a number of Warrant Shares in accordance with the provisions of Section&nbsp;2(d) of the Warrant, and also tenders
herewith a cash payment in the amount of all applicable transfer taxes, if any.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -36pt; margin: 0 0 0 108pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0">2.<FONT STYLE="font-size: 10pt">&nbsp; </FONT>In
exercising this Warrant, the undersigned hereby confirms and acknowledges that the Warrant Shares to be issued upon exercise are
being acquired solely for the account of the undersigned and not as a nominee for any other party, or for investment, and that
the undersigned will not offer, sell or otherwise dispose of any such Warrant Shares except under circumstances that will not result
in a violation of the registration provisions of the Securities Act of 1933, as amended, or any applicable state securities laws.</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 36pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 36pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 36pt"></P>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 50%">HOLDER:&nbsp;_____________________________</td></tr>
<tr style="vertical-align: middle">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td>Date:_______________&nbsp;</td>
    <td>By:&nbsp;__________________________________</td></tr>
<tr style="vertical-align: middle">
    <td>&nbsp;</td>
    <td>Name:</td></tr>
<tr style="vertical-align: middle">
    <td>&nbsp;</td>
    <td>Title:</td></tr>
</table>


<P STYLE="font-size: 10pt; margin: 0 0 0 36pt"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 252pt"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>ANNEX B</B></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0">FOR VALUE RECEIVED, the undersigned registered owner
of this Warrant hereby sells, assigns and transfers unto the Assignee named below all of the rights of the undersigned under the
within Warrant, with respect to the number of Warrant Shares set forth below:</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; text-align: center; width: 33%">&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-align: center; width: 34%">&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-align: center; width: 33%">No of</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; text-decoration: underline; text-align: center">Name of Assignee</td>
    <TD STYLE="font-size: 10pt; text-decoration: underline; text-align: center">Address</td>
    <TD STYLE="font-size: 10pt; text-decoration: underline; text-align: center">Shares&nbsp;</td></tr>
</table>


<P STYLE="font-size: 10pt; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">and does hereby irrevocably constitute and appoint Attorney __________________ to
make such transfer on the books of LIPIMETIX DEVELOPMENT, INC., maintained for the purpose, with full power of substitution in
the premises.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0">The Assignee represents that, by its acceptance hereof,
the Assignee acknowledges that this Warrant and the Warrant Shares to be issued upon exercise hereof are being acquired for investment
and that the Assignee will not offer, sell or otherwise dispose of this Warrant or any Warrant Shares to be issued upon exercise
hereof except under circumstances that will not result in a violation of the registration provisions of the Securities Act of 1933,
as amended, or any applicable state securities laws.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 36pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD STYLE="text-align: left; width: 50%; text-indent: 36pt">Dated: _____________________________</td>
    <TD STYLE="width: 50%">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>HOLDER:&nbsp;_____________________</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>By:&nbsp;__________________________</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>Name:</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>Title:</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>ASSIGNEE:&nbsp;____________________</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>By:&nbsp;__________________________</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>Name:</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>Title:</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</table>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exh_103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Exhibit 10.3 &ndash; Series B Preferred Stock and Warrant Purchase
Agreement - Exhibit C &ndash; Form of Amended and Restated Certificate of Incorporation of LipimetiX Development, Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">AMENDED AND RESTATED</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">CERTIFICATE OF INCORPORATION<BR>
OF<BR>
LIPIMETIX DEVELOPMENT, INC.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">(Pursuant to Sections 242 and 245 of the<BR>
General Corporation Law of the State of Delaware)</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">LipimetiX Development, Inc., a corporation
organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &ldquo;<B>General
Corporation Law</B>&rdquo;),</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>DOES HEREBY CERTIFY:</B></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><B>1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>That the name of this corporation is LipimetiX Development, Inc., and that this corporation was originally incorporated
pursuant to the General Corporation Law on June 23, 2015 under the name LipimetiX Development, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><B>2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>That the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation
of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and
its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor,
which resolution setting forth the proposed amendment and restatement is as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>RESOLVED</B>, that the Certificate of Incorporation
of this corporation be amended and restated in its entirety to read as follows:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>First:
</B></FONT>The name of this corporation is LipimetiX Development, Inc. (the &ldquo;<B>Corporation</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Second:
</B></FONT>The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange
Street, in the City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The
Corporation Trust Company.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Third:
</B></FONT>The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Fourth:
</B></FONT>The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i)<B> </B>3,000,000
shares of Common Stock, $.00001 par value per share (&ldquo;<B>Common Stock</B>&rdquo;),<B> </B>2,920,000 of which shall be designated
Class A-1 Common Stock (&ldquo;<B>Class A-1 Common Stock</B>&rdquo;) and 80,000 of which shall be designated Class A-2 Common Stock
(&ldquo;<B>Class A-2 Common Stock</B>&rdquo;); and (ii) 10,000,000 shares of Preferred Stock, $.00001 par value per share (&ldquo;<B>Preferred
Stock</B>&rdquo;), 5,000,000 of which shall be designated Series A Preferred Stock (&ldquo;<B>Series A Preferred Stock</B>&rdquo;),
350,000 of which shall be designated Series B-1 Preferred Stock (&ldquo;<B>Series B-1 Preferred Stock</B>&rdquo;), and 1,200,000
of which shall be designated Series B-2 Preferred Stock (&ldquo;<B>Series B-2 Preferred Stock</B>&rdquo;). The Series B-1 Preferred
Stock and the Series B-2 Preferred Stock are referred to herein collectively as the &ldquo;<B>Series B Preferred Stock</B>.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">The following is a statement of the designations
and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of
capital stock of the Corporation.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-indent: 36pt">A.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>COMMON STOCK</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General</U>. The Class A-1 Common Stock and Class A-2 Common Stock shall be identical in all respects, except as to dividends
and distributions on liquidation as set forth in Section A.3 below, and shall vote together as one class. The voting, dividend
and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers and preferences of
the holders of the Preferred Stock set forth herein.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voting</U>. The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings
of stockholders (and written actions in lieu of meetings). There shall be no cumulative voting. The number of authorized shares
of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to
any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation)
the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented
by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2)
of the General Corporation Law.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dividends; Distributions upon Liquidation</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">(a)&#9;The holders of Common Stock will be
entitled to receive such dividends as the Board of Directors of the Corporation may declare from time to time from funds legally
available therefor, subject to any preferential dividend rights of the Preferred Stock as described in Section B below. Any dividends
declared or payable with respect to the Common Stock shall be payable pro rata to the holders of the Common Stock based on the
number of shares of Common Stock held by each such holder; <U>provided</U>, <U>however</U>, that all amounts in excess of One Hundred
Thousand Dollars ($100,000) paid to any holder of Class A-2 Common Stock pursuant to Sections 5.8, 5.9 and 5.11 of that certain
Exclusive License Agreement dated August 26, 2011, between The UAB Research Foundation and LipimetiX, LLC, a Delaware limited liability
company, as amended on August 3, 2012 and December 15, 2014, and as amended from time to time (such excess amounts being the &ldquo;<U>Excess
Payments</U>&rdquo;) shall be taken into account for, and shall reduce on a dollar-for-dollar basis, the dividends that would otherwise
be payable to the holders of Class A-2 Common Stock hereunder.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">(b)&#9;In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, after the payment of all preferential amounts
required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for distribution
to its stockholders shall be distributed as set forth in Section B.2.2 below; <U>provided</U>, <U>however</U>, that all Excess
Payments not already offset against dividends otherwise payable to the holders of Class A-2 Common Stock pursuant to Section A.3.(a)
above shall be taken into account for, and shall reduce on a dollar-for-dollar basis, the distributions that would otherwise be
payable to the holders of Class A-2 Common Stock hereunder.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-indent: 36pt">B.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>PREFERRED STOCK</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt">The Preferred Stock shall have the following
rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references
to &ldquo;sections&rdquo; or &ldquo;subsections&rdquo; in this Part B of this Article Fourth refer to sections and subsections
of Part B of this Article Fourth.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt 22.5pt; text-align: justify; text-indent: 49.5pt">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dividends</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 94.5pt">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Series A Preferred Stock</U>. From and after the date of the issuance of any shares of Series A Preferred Stock, the
Corporation shall not declare, pay or set aside any dividends on shares of the Common Stock or the Series B Preferred Stock of
the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining
of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series A Preferred Stock then outstanding
shall have previously received, or simultaneously receive, aggregate dividends on each outstanding share of Series A Preferred
Stock in an amount at least equal to the Series A Original Issue Price (the &ldquo;<B>Dividend Preferential Payment</B>&rdquo;).
The &ldquo;<B>Series A Original Issue Price</B>&rdquo; shall mean $1.00 per share, subject to appropriate adjustment in the event
of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock.
Once the Dividend Preferential Payment has been paid in full, the holders of the Series A Preferred Stock shall not be entitled
to receive any further dividends or liquidating distributions pursuant to Section 2.1 hereof, and the Corporation shall not declare,
pay or set aside any dividends on the shares of Series A Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 94.5pt">1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Series B Preferred Stock</U>. From and after the date of the issuance of any shares of Series B Preferred Stock, dividends
at the rate per annum per share equal to five percent (5%) of the Series B-2 Original Issue Price shall accrue on each share of
Series B Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to the Series B Preferred Stock) (the<B> </B>&ldquo;<B>Accruing Dividends</B>&rdquo;). Accruing
Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; <U>provided</U>,<U> however</U>, that
except as set forth in the following sentence of this <U>Section&nbsp;1</U> and except as set forth in <U>Section 2.1</U>, such
Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under
no obligation to pay such Accruing Dividends. The Corporation shall not declare, pay or set aside any dividends on shares of any
other class or series of capital stock of the Corporation (other than the Series A Preferred Stock or dividends on shares of Common
Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate
of Incorporation) the holders of the Series B Preferred Stock then outstanding shall first receive, or simultaneously receive,
a dividend on each outstanding share of Series B Preferred Stock in an amount at least equal to the greater of: (i) the amount
of the aggregate Accruing Dividends then accrued on such share of Series B Preferred Stock and not previously paid; and (ii) that
dividend per share of Series B Preferred Stock as would equal the product of (1) the dividend payable on each share of Common Stock
and (2) the number of shares of Common Stock issuable upon conversion of a share of Series B Preferred Stock, in each case calculated
on the record date for determination of holders entitled to receive such dividend.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.<FONT STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"><U></U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Preferential Payments to Holders of Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution
or winding up of the Corporation or Deemed Liquidation Event, the holders of shares of Preferred Stock then outstanding shall be
entitled to be paid out of the assets of the Corporation available for distribution to its stockholders before any payment shall
be made to the holders of Common Stock by reason of their ownership thereof, the respective amounts set forth below: (i) the holders
of the Series A Preferred Stock shall be entitled to receive an amount per share equal to the Series A Original Issue Price, less
any dividends paid with respect to such share pursuant to Section B.1. above (the amount payable pursuant to this sentence is hereinafter
referred to as the &ldquo;<B>Series A Liquidation Amoun</B>t&rdquo;); (ii) the holders of the Series B-1 Preferred Stock shall
be entitled to receive an amount per share equal to the Series B-1 Original Issue Price, plus any accrued but unpaid dividends
thereon (the amount payable pursuant to this sentence is hereinafter referred to as the &ldquo;<B>Series B-1 Liquidation Amoun</B>t&rdquo;);
and (iii) the holders of the Series B-2 Preferred Stock shall be entitled to receive an amount per share equal to the Series B-2
Original Issue Price, plus any accrued but unpaid dividends thereon (the amount payable pursuant to this sentence is hereinafter
referred to as the &ldquo;<B>Series B-2 Liquidation Amoun</B>t&rdquo;). The &ldquo;<B>Series B-1 Original Issue Price</B>&rdquo;
shall mean $10.70 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or
other similar recapitalization with respect to the Series B Preferred Stock. The &ldquo;<B>Series B-2 Original Issue Price</B>&rdquo;
shall mean the original purchase price per share of the Series B-2 Preferred Stock as determined by the Board of Directors of the
Corporation, and identified as the Series B-2 Original Issue Price in the minutes or resolutions of the Board of Directors of the
Corporation approving the issuance of such Shares, subject to appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to the Series B Preferred Stock. If upon any such liquidation,
dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution
to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be
entitled under this <U>Subsection&nbsp;2.1</U>, the holders of shares of Preferred Stock shall share ratably in any distribution
of the assets available for distribution to the holders of the Preferred Stock in proportion to the respective amounts which would
otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to
such shares were paid in full.<SUP> </SUP></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 108pt; margin: 0 0 12pt">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Payments to Holders of Common Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up
of the Corporation or Deemed Liquidation Event, after the payment in full of the Series A Liquidation Amount, the Series B-1 Liquidation
Amount and the Series B-2 Liquidation Amount, the remaining assets of the Corporation available for distribution to its stockholders
shall be distributed among the holders of shares of Series B Preferred Stock and Common Stock pro rata based on the number of
shares held by each such holder, treating for this purpose all such securities as if they had been converted to Common Stock pursuant
to the terms of this Amended and Restated Certificate of Incorporation immediately prior to such liquidation, dissolution or winding
up of the Corporation.</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Deemed Liquidation Events</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">2.3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definition</U>. Each of the following events shall be considered a <B>&ldquo;Deemed Liquidation Event</B>&rdquo; unless
the holders of at least fifty percent (50%) of the outstanding shares of Preferred Stock elect otherwise by written notice sent
to the Corporation at least five (5) days prior to the effective date of any such event:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a merger or consolidation in which</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;
the Corporation is a constituent party or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to
such merger or consolidation,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt">except any such merger or consolidation involving the Corporation
or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation
continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such
merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation;
or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such
merger or consolidation, the parent corporation of such surviving or resulting corporation; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the sale or transfer, in a single transaction or series of related transactions, by the Corporation or any subsidiary of
the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole or the sale or
disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all
of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where
such sale or transfer is to a wholly owned subsidiary of the Corporation.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">2.3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effecting a Deemed Liquidation Event</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Subsection 2.3.1(a)(i)</U>
unless the agreement or plan of merger or consolidation for such transaction (the &ldquo;<B>Merger Agreement</B>&rdquo;) provides
that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of
the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event of a Deemed Liquidation Event referred to in <U>Subsection 2.3.1(a)(ii)</U> or <U>2.3.1(b)</U>, if the Corporation
does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90) days after such Deemed Liquidation
Event, then (i) the Corporation shall send a written notice to each holder of Series A Preferred Stock and Series B Preferred Stock
no later than the ninetieth (90<SUP>th</SUP>) day after the Deemed Liquidation Event advising the holders of the Series A Preferred
Stock and Series B Preferred Stock of their right (and the requirements to be met to secure such right) to demand a redemption
of their shares as set forth in this subsection (b). If the holders of a majority of the then outstanding shares of Series A Preferred
Stock so request in a written instrument delivered to the Corporation not later than one hundred five (105) days after such Deemed
Liquidation Event, the Corporation shall use the consideration received by the Corporation from such Deemed Liquidation Event (net
of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of
Directors of the Corporation) (the &ldquo;<B>Deemed Liquidation Net Proceeds</B>&rdquo;), to the extent legally available therefore,
on the one hundred twentieth (120<SUP>th</SUP>) day after the consummation of such Deemed Liquidation Event, to redeem all outstanding
shares of Series A Preferred Stock at a price per share equal to the Series A Liquidation Amount. If the holders of a majority
of the then outstanding shares of Series B Preferred Stock so request in a written instrument delivered to the Corporation not
later than one hundred five (105) days after such Deemed Liquidation Event, the Corporation shall use the Deemed Liquidation Net
Proceeds, to the extent legally available therefore, on the one hundred twentieth (120<SUP>th</SUP>) day after the consummation
of such Deemed Liquidation Event, to redeem all outstanding shares of Series B Preferred Stock at a price per share equal to the
Series B-1 Liquidation Amount or Series B-2 Liquidation Amount, as applicable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0cm; margin: 0 0 12pt">Notwithstanding the foregoing, in the event
of a redemption pursuant to the preceding sentence, if the Deemed Liquidation Net Proceeds are not sufficient to redeem all outstanding
shares of each series of Preferred Stock requesting such redemption, the Corporation shall ratably redeem each such holder&rsquo;s
shares of Preferred Stock to the fullest extent of such Deemed Liquidation Net Proceeds, and shall redeem the remaining shares
as soon as it may lawfully do so under Delaware law governing distributions to stockholders. Prior to the distribution or redemption
provided for in this <U>Subsection 2.3.2(b)</U>, the Corporation shall not expend or dissipate the consideration received for such
Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event.</P>

<P STYLE="font-size: 10pt; margin: 0">For purposes of clarity nothing in this Subsection 2.3.3 shall limit any right of a holder
of Series B Preferred Stock to convert any shares of Series B Preferred Stock pursuant to the provisions of</P>

<P STYLE="font-size: 10pt; margin: 0"><U>Subsection 4</U> hereof.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">2.3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock of the Corporation
upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the
value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring person, firm
or other entity.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">2.3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to <U>Subsection
2.3.1(a)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction
of contingencies (the &ldquo;<B>Additional Consideration</B>&rdquo;), the Merger Agreement shall provide that (a) the portion of
such consideration that is not Additional Consideration (such portion, the &ldquo;<B>Initial Consideration</B>&rdquo;) shall be
allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U> as if
the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b) any Additional
Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated
among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U> after taking into
account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Subsection
2.3.4</U>, consideration placed into escrow or retained as holdback to be available for satisfaction of indemnification or similar
obligations in connection with such Deemed Liquidation Event shall be deemed to be Initial Consideration.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voting</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General</U>. Except as specifically set forth herein (including <U>Subsection 3.2</U> below) or as otherwise required
by applicable law, the shares of the Series A Preferred Stock shall not entitle the holders of such shares to vote on matters brought
to the stockholder for a vote. On any matter presented to the stockholders of the Corporation (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of Series B Preferred Stock shall be entitled to cast the number of votes
equal to the number of whole shares of Common Stock into which the shares of Series B Preferred Stock held by such holder are convertible
as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions
of the Certificate of Incorporation, holders of Series B Preferred Stock shall vote together with the holders of Common Stock as
a single class.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Series A Preferred Stock Protective Provisions</U>. At any time when shares of Series A Preferred Stock are outstanding,
the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following
without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative
vote of the holders of at least a majority of the then outstanding shares of Series A Preferred Stock, given in writing or by vote
at a meeting, consenting or voting (as the case may be) separately as a class:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any Deemed Liquidation Event, or consent
to any of the foregoing;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(b)&#9;amend, alter or repeal any provision
of the Certificate of Incorporation or Bylaws of the Corporation;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(c)&#9;create, or authorize the creation
of, or issue or obligate itself to issue shares of, any additional class or series of capital stock, or increase the authorized
number of shares of Series A Preferred Stock or increase the authorized number of shares of any additional class or series of capital
stock;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(d)&#9;(i) reclassify, alter or amend any
existing security of the Corporation that is <I>pari passu</I> with the Series A Preferred Stock in respect of the distribution
of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if
such reclassification, alteration or amendment would render such other security senior to the Series A Preferred Stock in respect
of any such right, preference or privilege, or (ii) reclassify, alter or amend any existing security of the Corporation that is
junior to the Series A Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of
the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render
such other security senior to or pari passu with the Series A Preferred Stock in respect of any such right, preference or privilege;
or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(e)&#9;increase or decrease the authorized
number of directors constituting the Board of Directors.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Series B Preferred Stock Protective Provisions</U>. At any time when shares of Series B Preferred Stock are outstanding,
the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following
without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative
vote of the holders of at least a majority of the then outstanding shares of Series B Preferred Stock, given in writing or by vote
at a meeting, consenting or voting (as the case may be) separately as a class:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(a)&#9;except for any amendments to the
Certificate of Incorporation made in connection with the sale of additional shares of Series B-2 Preferred Stock pursuant to that
certain Series B Preferred Stock and Warrant Purchase Agreement, dated on or about August 22, 2016, by and among the Corporation
and the Purchasers named therein (the <B>&ldquo;Series B Preferred Stock Purchase Agreement&rdquo;</B>), amend, alter or repeal
any provision of the Certificate of Incorporation or Bylaws of the Corporation in a manner that materially adversely affects the
powers, preferences or rights of the Series B Preferred Stock;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(b)&#9;create, or authorize the creation
of, or issue or obligate itself to issue shares of, any additional class or series of capital stock that ranks senior to the Series
B Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation,
the payment of dividends and rights of redemption, or increase the authorized number of shares of Series B Preferred Stock or increase
the authorized number of shares of any additional class or series of capital stock that ranks senior to the Series B Preferred
Stock; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(c)&#9;(i) reclassify, alter or amend any
existing security of the Corporation that is <I>pari passu</I> with the Series B Preferred Stock in respect of the distribution
of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if
such reclassification, alteration or amendment would render such other security senior to the Series B Preferred Stock in respect
of any such right, preference or privilege, or (ii) reclassify, alter or amend any existing security of the Corporation that is
junior to the Series B Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of
the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render
such other security senior to the Series B Preferred Stock in respect of any such right, preference or privilege; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(d)&#9;a material change in the line of business
in which the Corporation is engaged, as determined in good faith by the Corporation.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Optional Conversion</U>. The holders of the Series B Preferred Stock shall have conversion rights as set forth below
(the &ldquo;<B>Conversion Rights</B>&rdquo;). For purposes of this Section 4, references herein to &ldquo;Common Stock&rdquo; shall
refer to &ldquo;Class A-1 Common Stock&rdquo;. References to the &ldquo;Series B Conversion Price&rdquo; shall refer to the &ldquo;Series
B-1 Conversion Price&rdquo; with respect to the shares of Series B-1 Preferred Stock and to the &ldquo;Series B-2 Conversion Price&rdquo;
with respect to shares of Series B-2 Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Convert</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt 22.5pt; text-align: justify; text-indent: 121.5pt">4.1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conversion Ratio</U>. Each share of Series B-2 Preferred Stock shall be convertible, at the option of the holder thereof,
at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number
of fully paid and non-assessable shares of Common Stock as is determined by dividing the Series B Base Price (as defined below)
by the Series B-2 Conversion Price (as defined below) in effect at the time of conversion. Each share of Series B-1 Preferred Stock
shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional
consideration by the holder thereof, into such number of fully paid and non-assessable shares of Common Stock as is determined
by dividing the Series B Base Price by the Series B-1 Conversion Price (as defined below) in effect at the time of conversion.
The &ldquo;<B>Series B Base Price</B>&rdquo; shall be equal to the initial Series B-2 Original Issue Price, subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series
B Preferred Stock. <B> </B>The &ldquo;<B>Series B-1 Conversion Price</B>&rdquo; shall initially be equal to $10.70. The &ldquo;<B>Series
B-2 Conversion Price</B>&rdquo; shall initially be equal to the initial Series B-2 Original Issue Price. Such initial Series B-1
Conversion Price and Series B-2 Conversion Price shall be subject to adjustment as provided below. In connection therewith, references
to the &ldquo;Series B Conversion Price&rdquo; shall refer to the &ldquo;Series B-1 Conversion Price&rdquo; with respect to the
shares of Series B-1 Preferred Stock, and to the &ldquo;Series B-2 Conversion Price&rdquo; with respect to shares of Series B-2
Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Conversion Rights</U>. In the event of a liquidation, dissolution or winding up of the Corporation or
a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date
fixed for the payment of any such amounts distributable on such event to the holders of Series B Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the Series B Preferred
Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to
such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors
of the Corporation. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of
the total number of shares of Series B Preferred Stock the holder is at the time converting into Common Stock and the aggregate
number of shares of Common Stock issuable upon such conversion.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mechanics of Conversion</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice of Conversion</U>. In order for a holder of Series B Preferred Stock to voluntarily convert shares of Series B
Preferred Stock into shares of Common Stock, such holder shall (a) provide written notice to the Corporation&rsquo;s transfer agent
at the office of the transfer agent for the Series B Preferred Stock (or at the principal office of the Corporation if the Corporation
serves as its own transfer agent) that such holder elects to convert all or any number of such holder&rsquo;s shares of Series
B Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder&rsquo;s shares are
certificated, surrender the certificate or certificates for such shares of Series B Preferred Stock (or, if such registered holder
alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable
to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged
loss, theft or destruction of such certificate), at the office of the transfer agent for the Series B Preferred Stock (or at the
principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&rsquo;s
name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the Corporation,
any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer,
in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in
writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as
its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be
the time of conversion (the &ldquo;<B>Conversion Time</B>&rdquo;), and the shares of Common Stock issuable upon conversion of the
specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after
the Conversion Time (i) issue and deliver to such holder of Series B Preferred Stock, or to his, her or its nominees, a certificate
or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof
and a certificate for the number (if any) of the shares of Series B Preferred Stock represented by the surrendered certificate
that were not converted into Common Stock, (ii) pay in cash such amount as provided in <U>Subsection&nbsp;4.2</U> in lieu of any
fraction of a share of Common Stock otherwise issuable upon such conversion and (iii) pay all declared but unpaid dividends on
the shares of Series B Preferred Stock converted.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reservation of Shares</U>. The Corporation shall at all times when the Series B Preferred Stock shall be outstanding,
reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the
Series B Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to
effect the conversion of all outstanding Series B Preferred Stock; and if at any time the number of authorized but unissued shares
of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Series B Preferred Stock,
the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock
to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain
the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Before taking any action which
would cause an adjustment reducing the Series B Conversion Price below the then par value of the shares of Common Stock issuable
upon conversion of the Series B Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its
counsel, be necessary in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common
Stock at such adjusted Series B Conversion Price.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Conversion</U>. All shares of Series B Preferred Stock which shall have been surrendered for conversion as
herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease
and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange
therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in <U>Subsection&nbsp;4.2</U>.
Any shares of Series B Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series,
and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to
reduce the authorized number of shares of Series B Preferred Stock accordingly.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the Series B Conversion Price shall be made for
any declared but unpaid dividends on the Series B Preferred Stock surrendered for conversion or on the Common Stock delivered upon
conversion.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any
issuance or delivery of shares of Common Stock upon conversion of shares of Series B Preferred Stock pursuant to this <U>Section&nbsp;4</U>.
The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the
issuance and delivery of shares of Common Stock in a name other than that in which the shares of Series B Preferred Stock so converted
were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance
has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax
has been paid.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustments to Series B Conversion Price for Diluting Issues</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions shall apply:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Option</B>&rdquo; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common
Stock or Convertible Securities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Series B Original Issue Date</B>&rdquo; shall mean the date on which the first share of Series B Preferred Stock
was issued.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Convertible Securities</B>&rdquo; shall mean any evidences of indebtedness, shares or other securities directly
or indirectly convertible into or exchangeable for Common Stock, but excluding Options.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Additional Shares of Common Stock</B>&rdquo; shall mean all shares of Common Stock issued (or, pursuant to <U>Subsection&nbsp;4.4.3</U>
below, deemed to be issued) by the Corporation after the Series B Original Issue Date, other than (1) the following shares of Common
Stock and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1) and
(2), collectively, &ldquo;<B>Exempted Securities</B>&rdquo;):</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Series A Preferred Stock;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other
distribution on shares of Common Stock that is covered by <U>Subsection 4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or
any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Corporation;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of Common Stock
actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the
terms of such Option or Convertible Security;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions,
or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the
Board of Directors of the Corporation;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(vi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock, Options or Convertible Securities issued to suppliers or third party service providers in connection
with the provision of goods or services pursuant to transactions approved by the Board of Directors of the Corporation, including
without limitation any investment banking or other financial services;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(vii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock, Options or Convertible Securities issued pursuant to the acquisition of another corporation by the
Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, <U>provided</U>
that such issuances are approved by the Board of Directors of the Corporation;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(viii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
s</FONT>hares of Common Stock, Options or Convertible Securities issued in connection with sponsored research, collaboration, technology
license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors
of the Corporation; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(ix)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Series B Preferred Stock or warrants to purchase shares of Series B Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Adjustment of Series B Conversion Price</U>. No adjustment in the Series B Conversion Price shall be made as the result
of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders
of at least fifty percent (50%) of the then outstanding shares of Series B Preferred Stock agreeing that no such adjustment shall
be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Deemed Issue of Additional Shares of Common Stock</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Corporation at any time or from time to time after the Series B Original Issue Date shall issue any Options or Convertible
Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for
the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the
maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions
to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment
of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the
conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the
time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Series B Conversion
Price pursuant to the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment
pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to
anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase or decrease
in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible
Security or (2) any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or
exchange, then, effective upon such increase or decrease becoming effective, the Series B Conversion Price computed upon the original
issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted
to such Series B Conversion Price as would have obtained had such revised terms been in effect upon the original date of issuance
of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this clause&nbsp;(b) shall have
the effect of increasing the Series B Conversion Price to an amount which exceeds the lower of (i) the Series B Conversion Price
in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security,
or (ii) the Series B Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than
deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between
the original adjustment date and such readjustment date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted
Securities), the issuance of which did not result in an adjustment to the Series B Conversion Price pursuant to the terms of <U>Subsection
4.4.4</U> (either because the consideration per share (determined pursuant to <U>Subsection 4.4.5</U>) of the Additional Shares
of Common Stock subject thereto was equal to or greater than the Series B Conversion Price then in effect, or because such Option
or Convertible Security was issued before the Series B Original Issue Date), are revised after the Series B Original Issue Date
as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security
(but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible
Security) to provide for either (1) any increase in the number of shares of Common Stock issuable upon the exercise, conversion
or exchange of any such Option or Convertible Security or (2) any decrease in the consideration payable to the Corporation upon
such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional
Shares of Common Stock subject thereto (determined in the manner provided in <U>Subsection 4.4.3(a)</U> shall be deemed to have
been issued effective upon such increase or decrease becoming effective.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion
thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Series B Conversion
Price pursuant to the terms of <U>Subsection&nbsp;4.4.4</U>, the Series B Conversion Price shall be readjusted to such Series B
Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible
Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the
time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment
to the Series B Conversion Price provided for in this <U>Subsection&nbsp;4.4.3</U> shall be effected at the time of such issuance
or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments
(and any subsequent adjustments shall be treated as provided in clauses (b) and (c) of this <U>Subsection&nbsp;4.4.3</U>). If the
number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security,
or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at
the time such Option or Convertible Security is issued or amended, any adjustment to the Series B Conversion Price that would result
under the terms of this <U>Subsection&nbsp;4.4.3</U> at the time of such issuance or amendment shall instead be effected at the
time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming
for purposes of calculating such adjustment to the Series A Conversion Price that such issuance or amendment took place at the
time such calculation can first be made.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment of Series B Conversion Price Upon Issuance of Additional Shares of Common Stock</U>. In the event the Corporation
shall at any time after the Series B Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of
Common Stock deemed to be issued pursuant to <U>Subsection&nbsp;4.4.3</U>), without consideration or for a consideration per share
less than the Series B Conversion Price in effect immediately prior to such issue, then the Series B Conversion Price shall be
reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance
with the following formula:</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">CP<SUB>2</SUB> = CP<SUB>1</SUB>* (A + B) &divide; (A + C).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt">For purposes of the foregoing formula, the following definitions
shall apply:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;CP<SUB>2</SUB>&rdquo; shall mean the Series B Conversion Price in effect immediately after such issue of Additional
Shares of Common Stock</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;CP<SUB>1</SUB>&rdquo; shall mean the Series B Conversion Price in effect immediately prior to such issue of Additional
Shares of Common Stock;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;A&rdquo; shall mean the number of shares of Common Stock outstanding immediately prior to such issue of Additional
Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding
immediately prior to such issue or upon conversion or exchange of Convertible Securities (including the Series B Preferred Stock)
outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;B&rdquo; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of
Common Stock had been issued at a price per share equal to CP<SUB>1</SUB> (determined by dividing the aggregate consideration received
by the Corporation in respect of such issue by CP<SUB>1</SUB>); and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;C&rdquo; shall mean the number of such Additional Shares of Common Stock issued in such transaction.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Determination of Consideration</U>. For purposes of this <U>Subsection 4.4</U>, the consideration received by the Corporation
for the issue of any Additional Shares of Common Stock shall be computed as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cash and Property</U>: Such consideration shall:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts
paid or payable for accrued interest;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue,
as determined in good faith by the Board of Directors of the Corporation; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the
Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses
(i) and (ii) above, as determined in good faith by the Board of Directors of the Corporation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 180pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Options and Convertible Securities</U>. The consideration per share received by the Corporation for Additional Shares
of Common Stock deemed to have been issued pursuant to <U>Subsection&nbsp;4.4.3</U>, relating to Options and Convertible Securities,
shall be determined by dividing:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible
Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without
regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the
exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible
Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities,
by</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 216pt; margin: 0 0 12pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision
contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange
of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible
Securities and the conversion or exchange of such Convertible Securities.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common
Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Series
B Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, and such issuance dates occur within a period of no more than
ninety (90) days from the first such issuance to the final such issuance, then, upon the final such issuance, the Series B Conversion
Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and
without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 144pt">4.4.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Special Adjustment of Series B-1 Conversion Price Upon Certain Issuances of Series B-2 Preferred Stock</U>. Notwithstanding
the provisions of Section 4.4.1 hereof, in the event that the Corporation shall, at any time after the Series B Original Issue
Date, issue any shares of Series B-2 Preferred Stock for a consideration per share less than the Series B-1 Conversion Price in
effect immediately prior to such issue (the &ldquo;<B>Dilutive Price</B>&rdquo;), then the Series B-1 Conversion Price shall be
reduced, concurrently with each such issue, to the Dilutive Price.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any time or from time to time after the
Series B Original Issue Date effect a subdivision of the outstanding Common Stock, the Series B Conversion Price in effect immediately
before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion
of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock
outstanding. If the Corporation shall at any time or from time to time after the Series B Original Issue Date combine the outstanding
shares of Common Stock, the Series B Conversion Price in effect immediately before the combination shall be proportionately increased
so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion
to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become
effective at the close of business on the date the subdivision or combination becomes effective.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment for Certain Dividends and Distributions</U>. In the event the Corporation at any time or from time to time
after the Series B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock
entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and
in each such event the Series B Conversion Price in effect immediately before such event shall be decreased as of the time of such
issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying
the Series B Conversion Price then in effect by a fraction:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(1)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the
time of such issuance or the close of business on such record date, and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(2)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to
the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment
of such dividend or distribution.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt">Notwithstanding the foregoing (a) if such record date shall have
been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Series
B Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Series B
Conversion Price shall be adjusted pursuant to this subsection as of the time of actual payment of such dividends or distributions;
and (b) that no such adjustment shall be made if the holders of Series B Preferred Stock simultaneously receive a dividend or other
distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if
all outstanding shares of Series B Preferred Stock had been converted into Common Stock on the date of such event.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time
after the Series B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock
entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares
of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section&nbsp;1</U>
do not apply to such dividend or distribution, then and in each such event the holders of Series B Preferred Stock shall receive,
simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other
property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares
of Series B Preferred Stock had been converted into Common Stock on the date of such event.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Subsection 2.3</U>, if there shall
occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common
Stock (but not the Series B Preferred Stock) is converted into or exchanged for securities, cash or other property (other than
a transaction covered by <U>Subsections 4.4</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization,
reclassification, consolidation or merger, each share of Series B Preferred Stock shall thereafter be convertible in lieu of the
Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which
a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of Series B Preferred
Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled
to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of
Directors of the Corporation) shall be made in the application of the provisions in this <U>Section 4</U> with respect to the rights
and interests thereafter of the holders of the Series B Preferred Stock, to the end that the provisions set forth in this <U>Section
4</U> (including provisions with respect to changes in and other adjustments of the Series B Conversion Price) shall thereafter
be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the
conversion of the Series B Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Series B Conversion
Price pursuant to this <U>Section 4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any
event not later than ten (10) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and
furnish to each holder of Series B Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind
and amount of securities, cash or other property into which the Series B Preferred Stock is convertible) and showing in detail
the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after
the written request at any time of any holder of Series B Preferred Stock (but in any event not later than ten (10) days thereafter),
furnish or cause to be furnished to such holder a certificate setting forth (i) the Series B Conversion Price then in effect, and
(ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received
upon the conversion of Series B Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">4.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice of Record Date</U>. In the event:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time
issuable upon conversion of the Series B Preferred Stock) for the purpose of entitling or enabling them to receive any dividend
or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other
securities, or to receive any other security; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed
Liquidation Event; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt">then, and in each such case, the Corporation will send or cause
to be sent to the holders of the Series B Preferred Stock a notice specifying, as the case may be, (i) the record date for such
dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date
on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed
to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock
or securities at the time issuable upon the conversion of the Series B Preferred Stock) shall be entitled to exchange their shares
of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization,
reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character
of such exchange applicable to the Series B Preferred Stock and the Common Stock. Such notice shall be sent at least fifteen (15)
days prior to the record date or effective date for the event specified in such notice.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mandatory Conversion</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Trigger Events</U>. Upon either (a) the closing of the sale of shares of Common Stock to the public at a price of at
least $30.00 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended, resulting in at least $25,000,000 of proceeds, net of the
underwriting discount and commissions, to the Corporation or (b) the date and time, or the occurrence of an event, specified by
vote or written consent of the holders of at least fifty percent (50%) of the then outstanding shares of Series B Preferred Stock
(the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is
referred to herein as the &ldquo;<B>Mandatory Conversion Time</B>&rdquo;), then (i) all outstanding shares of Series B Preferred
Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant
to <U>Subsection 4.1.1</U>, and (ii) such shares may not be reissued by the Corporation.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">5.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Procedural Requirements</U>. All holders of record of shares of Series B Preferred Stock shall be sent written notice
of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Series B Preferred Stock
pursuant to this <U>Section 5</U>. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time.
Upon receipt of such notice, each holder of shares of Series B Preferred Stock in certificated form shall surrender his, her or
its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or
destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against
any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to
the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion
shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly
executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Series
B Preferred Stock converted pursuant to <U>Subsection 5.1</U>, including the rights, if any, to receive notices and vote (other
than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or
holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender
of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items
provided for in the next sentence of this <U>Subsection 5.2</U>. As soon as practicable after the Mandatory Conversion Time and,
if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Series A Preferred
Stock, the Corporation shall (a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates
for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b)pay cash
as provided in <U>Subsection&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion
and the payment of any declared but unpaid dividends on the shares of Series B Preferred Stock converted. Such converted Series
B Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter
take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares
of Series B Preferred Stock accordingly.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Redemption of Series A Preferred Stock</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">6.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mandatory Retirement</U>. In the event that the holders of the Series A Preferred then outstanding shall at any time
have received aggregate dividends in an amount per share equal to the Series A Original Issue Price, the Preferred Stock may be
redeemed at the election of the Corporation (a &ldquo;<B>Mandatory Redemption</B>&rdquo;) out of funds lawfully available therefor
at a price equal to $.001 per share<B> </B>(the &ldquo;<B>Mandatory Redemption Price</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">6.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Optional Redemption Upon Liquidity Trigger Event</U>. In the event of a Liquidity Trigger Event (as defined below) (other
than a Deemed Liquidation Event, which shall be governed by the provisions of Section 2.3 hereof), the Corporation shall send a
written notice to each holder of Series A Preferred Stock no later than the ninetieth (90th) day after the Liquidity Trigger Event
(the &ldquo;<B>Notice of Trigger Event</B>&rdquo;) advising such holders of their right pursuant to the terms of this Section 4
to require the redemption of such shares of Series A Preferred Stock as set forth herein (a &ldquo;<B>Liquidity Event Redemption</B>&rdquo;).
If the holders of at least fifty percent (50%) of the then outstanding shares of Series A Preferred Stock so request in a written
instrument delivered to the Corporation not later than one hundred twenty (120) days after receipt of the Notice of Trigger Event,
the Corporation shall use the Net Cash Proceeds (as defined below) received by the Corporation as part of such Liquidity Trigger
Event, to the extent permitted by Delaware law governing distributions to stockholders (the &ldquo;<B>Available Redemption Proceeds</B>&rdquo;),
to redeem that number of shares of Series A Preferred Stock equal to the largest whole number (the &ldquo;<B>Redemption Shares</B>&rdquo;)
determined by dividing the Available Redemption Proceeds by the Series A Liquidation Amount, and disregarding any fractional shares.
The redemption price for each of the Redemption Shares to be redeemed pursuant hereto shall be the Series A Liquidation Amount
(the &ldquo;<B>Liquidity Event Redemption Price</B>&rdquo;, and together with the Mandatory Redemption Price, the &ldquo;<B>Redemption
Price</B>&rdquo;). As used herein, the term &ldquo;<B>Liquidity Trigger Event</B>&rdquo; shall mean either of the following (except
to the extent that such events constitute a Deemed Liquidation Event): (i) the sale or issuance of any equity or debt securities
of the Corporation, or any other incurrence of indebtedness by the Corporation, that results in Net Cash Proceeds of at least $5,000,000
(other than the sale of Series B Preferred Stock and warrants pursuant to the Series B Preferred Stock Purchase Agreement); or
(ii) the sale, license, or other disposition of any of the assets or property of the Corporation that results in Net Cash Proceeds
of at least $5,000,000. As used herein, the term &ldquo;<B>Net Cash Proceeds</B>&rdquo; shall mean the aggregate cash proceeds
received by the Corporation as a result of the Liquidity Trigger Event, less the costs and expenses of the Corporation incurred
in connection with such Liquidity Trigger Event.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">6.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Redemption Notice</U>. The Corporation shall send written notice of the Mandatory Redemption or the Liquidity Event Redemption,
as applicable (the &ldquo;<B>Redemption Notice</B>&rdquo;), to each holder of record of Series A Preferred Stock not less than
40 days prior to the date for such redemption (the &ldquo;<B>Redemption Date</B>&rdquo;). Each Redemption Notice shall state:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(a)&#9;the number of shares of Series A Preferred
Stock held by the holder that the Corporation shall redeem on the Redemption Date specified in the Redemption Notice;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(b)&#9;the Redemption Date and the Redemption
Price; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 144pt; margin: 0 0 12pt">(c)&#9;that the holder is to surrender to
the Corporation, in the manner and at the place designated, his, her or its certificate or certificates representing the shares
of Series A Preferred Stock to be redeemed.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">6.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Surrender of Certificates; Payment</U>. On or before the applicable Redemption Date, each holder of shares of Series
A Preferred Stock to be redeemed on such Redemption Date, shall surrender the certificate or certificates representing such shares
(or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and
agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the
Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at
the place designated in the Redemption Notice, and thereupon the Redemption Price for such shares shall be payable to the order
of the person whose name appears on such certificate or certificates as the owner thereof.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">6.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rights Subsequent to Redemption</U>. If the Redemption Notice shall have been duly given, and if on the applicable Redemption
Date the Redemption Price payable upon redemption of the shares of Series A Preferred Stock to be redeemed on such Redemption Date
is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner,
then notwithstanding that the certificates evidencing any of the shares of Series A Preferred Stock so called for redemption shall
not have been surrendered, all rights with respect to such shares shall forthwith after the Redemption Date terminate, except only
the right of the holders to receive the Redemption Price without interest upon surrender of their certificate or certificates therefor.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Redeemed or Otherwise Acquired Shares</U>. Any shares of Series A Preferred Stock that are redeemed or otherwise acquired
by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued,
sold or transferred.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver</U>. Any of the rights, powers, preferences and other terms of the Series A Preferred Stock set forth herein may
be waived on behalf of all holders of Series A Preferred Stock by the affirmative written consent or vote of the holders of at
least fifty percentage (50%) of the shares of Series A Preferred Stock then outstanding. Any of the rights, powers, preferences
and other terms of the Series B Preferred Stock set forth herein may be waived on behalf of all holders of Series B Preferred Stock
by the affirmative written consent or vote of the holders of at least fifty percentage (50%) of the shares of Series B Preferred
Stock then outstanding.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice required or permitted by the provisions of this Article Fourth to be given to a holder of shares
of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or
given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon
such mailing or electronic transmission. Any notice to the Company shall be sent to the person and address set forth in Article
Fifth below, with a copy to Leslie M. Taeger, Senior Vice President &amp; Chief Financial Officer, Capstone Therapeutics Corp.,
1275 W. Washington St., Suite 104, Tempe, AZ 85281, or to such other person or persons and addresses as the Company shall designate
in a notice provided to the holders of the Preferred Stock.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Fifth:
</B></FONT>The name and mailing address of the incorporator is as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 108pt; margin: 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt; width: 20%; padding-left: 20pt">Name:</td>
    <TD STYLE="font-size: 10pt; width: 80%">Dennis I. Goldberg, Ph.D.</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt; padding-left: 20pt">Mailing Address:</td>
    <TD STYLE="font-size: 10pt">5 Commonwealth Rd., Suite 2A</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; padding-left: 20pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt">Natick, Massachusetts 07160</td></tr>
</table>


<P STYLE="font-size: 10pt; text-indent: 108pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 108pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-indent: 108pt; margin: 0 0 0 108pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Sixth:
</B></FONT>Subject to any additional vote required by the Certificate of Incorporation or Bylaws, in furtherance and not in limitation
of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any
or all of the Bylaws of the Corporation.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Seventh:
</B></FONT>Subject to any additional vote required by the Certificate of Incorporation, the number of directors of the Corporation
shall be determined in the manner set forth in the Bylaws of the Corporation.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Eighth:
</B></FONT>Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Ninth:
</B></FONT>Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide.
The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to
time by the Board of Directors or in the Bylaws of the Corporation.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Tenth:
</B></FONT>To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation
or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other
law of the State of Delaware is amended after approval by the stockholders of this Article Tenth to authorize corporate action
further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall
be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">Any repeal or modification of the foregoing
provisions of this Article Tenth by the stockholders of the Corporation shall not adversely affect any right or protection of a
director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect
to any acts or omissions of such director occurring prior to, such repeal or modification.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Eleventh:
</B></FONT>To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and
advancement of expenses to) directors, officers, managers and agents of the Corporation (and any other persons to which General
Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other
persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise
permitted by <U>Section 145</U> of the General Corporation Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">Any amendment, repeal or modification of the
foregoing provisions of this Article Eleventh shall not adversely affect any right or protection of any director, officer or other
agent of the Corporation existing at the time of such amendment, repeal or modification.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-transform: uppercase"><B>Twelfth:
</B></FONT>The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in,
or in being offered an opportunity to participate in, any Excluded Opportunity. An &ldquo;<B>Excluded Opportunity</B>&rdquo; is
any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the
possession of any holder of Series A Preferred Stock or any partner, member, director, stockholder, employee or agent of any such
holder, or any person serving as a director or manager of the Corporation at the request of such Holder, other than someone who
is an employee of the Corporation or any of its subsidiaries (collectively, &ldquo;<B>Covered Persons</B>&rdquo;), unless such
matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of,
a Covered Person expressly and solely in such Covered Person&rsquo;s capacity as a director of the Corporation.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: center; text-indent: 0cm">* * *</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 0cm">IN WITNESS WHEREOF, this Amended and Restated
Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 24th day of August, 2016.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 0cm">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 24pt 234pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD STYLE="width: 50%">&nbsp;</td>
    <TD STYLE="width: 7%">By:</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; width: 43%">/s/ Dennis I. Goldberg</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Dennis I. Goldberg, Ph.D.</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>Title:</td>
    <TD STYLE="border-bottom: Black 0.5pt solid">President</td></tr>
</table>


<P STYLE="font-size: 10pt; margin: 0 0 24pt 234pt"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>[Signature Page to Amended and Restated Certificate of Incorporation]</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>



<P STYLE="font-size: 10pt; margin: 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>exh_104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><B>Exhibit 10.4 -Series B Preferred Stock and Warrant Purchase
Agreement - Exhibit F &ndash; Form of Registration Rights Agreement</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><B>REGISTRATION RIGHTS AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">THIS REGISTRATION RIGHTS AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;),
is made as of the 25th day of August, 2016, by and <FONT STYLE="font-weight: normal">among</FONT> LipimetiX Development, Inc.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and each of the investors listed on <U>Schedule A</U> hereto, each of
which is referred to in this Agreement as an &ldquo;<B>Investor</B>&rdquo;, and each of the stockholders listed on <U>Schedule
B</U> hereto, each of whom is referred to herein as a &ldquo;<B>Common Holder</B>&rdquo; and any <FONT STYLE="font-weight: normal">Additional</FONT>
Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with <U>Section 3.9</U> hereof.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><B><U>RECITALS</U></B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>WHEREAS</B>, the Company and the Investors
are parties to the Series B Preferred Stock and Warrant Purchase Agreement, dated as of the date herewith (the &ldquo;<B>Purchase
Agreement</B>&rdquo;); and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>WHEREAS</B>, in order to induce the Company
to enter into the Purchase Agreement and to induce the Investors to invest funds in the Company pursuant to the Purchase Agreement,
the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to
register shares of Common Stock issuable to the Investors, as set forth in this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"><B>NOW, THEREFORE</B>, the parties hereby
agree as follows:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt">1.<FONT STYLE="font-size: 10pt">&nbsp; </FONT><U>Definitions</U>.
For purposes of this Agreement:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.1<FONT STYLE="font-size: 10pt"> </FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Affiliate</B>&rdquo; means, with respect to any specified Person, any
other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including
without limitation any <FONT STYLE="font-weight: normal">general </FONT>partner, managing member, officer<FONT STYLE="font-weight: normal">
or</FONT> director<FONT STYLE="font-weight: normal"> </FONT>of such Person or any venture capital fund now or hereafter
existing that is controlled by one or more general partners or managing members of, or shares the same management company
with, such Person.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.2<FONT STYLE="font-size: 10pt">
</FONT><FONT STYLE="font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;</FONT><B>Common
Holder Registrable Securities</B><FONT STYLE="font-weight: normal">&rdquo; means (i) the 1,120,000 shares of Common Stock held
by the Common Holders, and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right,
or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of
such shares.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.3<FONT STYLE="font-size: 10pt"> </FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Common Stock</B>&rdquo; means shares of the Company&rsquo;s Class A-1
Common Stock, par value $0.00001 per share and Class A-2 Common Stock, par value $0.00001 per share.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"> </FONT>&ldquo;<B>Damages</B>&rdquo; means any loss, damage, claim or
liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other
federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is
based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement
of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by <FONT STYLE="font-weight: normal">the</FONT> <FONT STYLE="font-weight: normal">indemnifying</FONT><B> </B>party <FONT STYLE="font-weight: normal">(or
any of its agents or Affiliates)</FONT><B> </B>of the Securities Act, the Exchange Act, any state securities law, or any rule
or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.5<FONT STYLE="font-size: 10pt"> </FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Derivative Securities</B>&rdquo; means any securities or rights
convertible into, or exercisable or exchangeable for<FONT STYLE="font-weight: normal"> (in each case, directly or
indirectly)</FONT><B>,</B> Common Stock, including options and warrants.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.6
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"> </FONT>&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt"><FONT STYLE="font-weight: normal">1.7&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"> </FONT>&ldquo;</FONT><B>Excluded Registration</B><FONT STYLE="font-weight: normal">&rdquo;
means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option,
stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form
that does not include substantially the same information as would be required to be included in a registration statement covering
the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.8&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"> </FONT>&ldquo;<B>Form S-3</B>&rdquo; means
such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act
subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents
filed by the Company with the SEC.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.9<FONT STYLE="font-size: 10pt"> </FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>GAAP</B>&rdquo; means generally accepted accounting principles in the United
States.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Holder</B>&rdquo; means any holder of Registrable Securities who is a party to this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal">&ldquo;</FONT><B>Immediate Family Member</B><FONT STYLE="font-weight: normal">&rdquo;
means a child</FONT>, <FONT STYLE="font-weight: normal">stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,</FONT><B> </B>or<B> </B><FONT STYLE="font-weight: normal">sister-in-law,
including, adoptive relationships, of a natural person referred to herein.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Initiating Holders</B>&rdquo; means, collectively, Holders who properly initiate a registration request under
this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt"><FONT STYLE="font-weight: normal">1.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;</FONT><B>IPO</B><FONT STYLE="font-weight: normal">&rdquo; means the Company&rsquo;s first underwritten public offering
of its Common Stock under the Securities Act.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt"><FONT STYLE="font-weight: normal">1.14<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;</FONT><B>Person</B><FONT STYLE="font-weight: normal">&rdquo; means any individual, corporation, partnership, trust,
limited liability company, association </FONT>or<FONT STYLE="font-weight: normal"> </FONT>other<FONT STYLE="font-weight: normal">
entity<FONT STYLE="color: blue">.</FONT></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.15<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Preferred Stock</B>&rdquo; means, collectively, shares of the Company&rsquo;s Series A Preferred Stock and Series
B Preferred Stock<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.16<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Registrable Securities</B>&rdquo; means (i) the Common Stock issuable or issued upon conversion of the<B> </B><FONT STYLE="font-weight: normal">Series
B </FONT>Preferred Stock; (ii) any Common Stock<FONT STYLE="font-weight: normal">, or any Common Stock</FONT><B> </B>issued or
issuable<B> </B><FONT STYLE="font-weight: normal">(directly or indirectly)</FONT> upon conversion <FONT STYLE="font-weight: normal">and/or
exercise </FONT>of<B> </B>any <FONT STYLE="font-weight: normal">other</FONT><B> </B><FONT STYLE="font-weight: normal">securities</FONT><B>
</B>of the Company, acquired by the Investors prior to, on, or after the date hereof; (iii) the Common Holder<FONT STYLE="font-weight: normal">
Registrable Securities;</FONT> and (iv) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant,
right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement
of, the shares referenced in clauses <U>(i)</U> and <U>(ii)</U> above; excluding in all cases, however, any Registrable Securities
sold by a Person in a transaction in which the <FONT STYLE="font-weight: normal">applicable</FONT> rights under <FONT STYLE="font-weight: normal">this
Agreement</FONT> are not assigned <FONT STYLE="font-weight: normal">pursuant to <U>Subsection 3.1</U>, and excluding for purposes
of <U>Section 2</U></FONT><B> </B>any shares for which registration rights have terminated pursuant to <U>Subsection 2.11</U> of
this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.17<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Registrable Securities then outstanding</B>&rdquo; means the number of shares determined by adding the <FONT STYLE="font-weight: normal">number
of shares of outstanding </FONT>Common Stock <FONT STYLE="font-weight: normal">that are Registrable Securities</FONT> and the<FONT STYLE="font-weight: normal">
number of shares of</FONT><B> </B>Common Stock issuable <FONT STYLE="font-weight: normal">(directly or indirectly) </FONT>pursuant
to then exercisable <FONT STYLE="font-weight: normal">and/</FONT>or convertible securities that are Registrable Securities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.18<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>SEC</B>&rdquo; means the Securities and Exchange Commission.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.19<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>SEC Rule 144</B>&rdquo; means Rule 144 promulgated by the SEC under the Securities Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.20<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>SEC Rule 145</B>&rdquo; means Rule 145 promulgated by the SEC under the Securities Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.21<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Securities Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.22<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Selling Expenses</B>&rdquo; means all underwriting discounts, selling commissions, and stock transfer taxes applicable
to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except <FONT STYLE="font-weight: normal">for
the fees and disbursements of the Selling Holder Counsel borne and paid by the Company </FONT>as provided in <U>Subsection </U>
<U>2.6</U><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt 31.5pt">1.23<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Series B Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series B-1 Preferred Stock, par value
$0.00001 per share and Series B-2 Preferred Stock, par value $0.00001 per share.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt">2.<FONT STYLE="font-size: 10pt">&nbsp; </FONT><U>Registration
Rights</U>. The Company covenants and agrees as follows:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.1<FONT STYLE="font-size: 10pt"> </FONT><U>Form
S-3 Demand Registration</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal">If at any time when it is eligible to use a Form S-3 registration statement, the Company
receives a request from Holders of at least fifty percent (50%) of the Registrable Securities then outstanding that the Company
file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated
aggregate offering price, net of Selling Expenses, of at least $15 million, then the Company shall (i) within ten (10) days after
the date such request is given, give a notice thereof (a &ldquo;</FONT><B>Demand Notice</B><FONT STYLE="font-weight: normal">&rdquo;)
to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act
covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject
to the limitations of <U>Subsections 2.1(b)</U> and <U>2.3</U>. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"><FONT STYLE="font-weight: normal">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant
to this <U>Subsection 2.1</U> a certificate signed by the Company&rsquo;s chief executive officer stating that in the good faith
judgment of the Company&rsquo;s Board of Directors it would be materially detrimental to the Company and its stockholders for such
registration statement to either become effective or remain effective for as long as such registration statement otherwise would
be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization,
or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company
has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements
under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing,
and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more
than one hundred twenty (120) days after the request of the Initiating Holders is given; <U>provided</U>, <U>however</U>, that
the Company may not invoke this right more than twice in any twelve (12) month period.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal">The Company shall not be obligated to effect, or to take any action to effect, any registration
pursuant to <U>Subsection </U></FONT><U>2.1(a)</U><FONT STYLE="font-weight: normal"> (i) during the period that is sixty (60) days
before the Company&rsquo;s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180)
days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively employing in good
faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected
one registration pursuant to <U>Subsection </U></FONT><U>2.1(a)</U><FONT STYLE="font-weight: normal"> within the twelve (12) month
period immediately preceding the date of such request.</FONT> A registration shall not be counted as &ldquo;effected&rdquo; for
purposes of this <U>Subsection 2.1(c)</U> until such time as the applicable registration statement has been declared effective
by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses
therefor, <FONT STYLE="font-weight: normal">and forfeit their right to one demand registration statement </FONT>pursuant to <U>Subsection
</U> <U>2.6</U><FONT STYLE="font-weight: normal">, in which case such withdrawn registration statement shall be counted as &ldquo;effected&rdquo;
for purposes of this <U>Subsection </U></FONT><U>2.1(c)</U><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.2<FONT STYLE="font-size: 10pt"> </FONT><U>Company
Registration</U>. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of
such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder
notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company,
the Company shall, subject to the provisions of <U>Subsection 2.3</U>, cause to be registered all of the Registrable Securities
that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw
any registration initiated by it under this <U>Subsection 2.2</U> before the effective date of such registration, whether or not
any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with <U>Subsection 2.6</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.3<FONT STYLE="font-size: 10pt"> </FONT><U>Underwriting
Requirements</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, pursuant to <U>Subsection </U> <U>2.1</U><FONT STYLE="font-weight: normal">,</FONT> the Initiating Holders<B> </B>intend
to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company
as a part of their request made pursuant to <U>Subsection </U> <U>2.1</U><FONT STYLE="font-weight: normal">,</FONT> and the Company
shall include such information in the Demand Notice. The underwriter<FONT STYLE="font-weight: normal">(s)</FONT> will be selected
by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right
of any Holder to include such Holder&rsquo;s Registrable Securities in such registration shall be conditioned upon such Holder&rsquo;s
participation in such underwriting and the inclusion of such Holder&rsquo;s Registrable Securities in the underwriting to the extent
provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company
as provided in <U>Subsection </U> <U>2.4(e)</U>) enter into an underwriting agreement in customary form with the underwriter(s)
selected for such underwriting. Notwithstanding any other provision of this <U>Subsection </U> <U>2.3</U><FONT STYLE="font-weight: normal">,</FONT>
if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation on the number of shares
to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten
pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among <FONT STYLE="font-weight: normal">such</FONT>
Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of
Registrable Securities owned by each Holder<FONT STYLE="font-weight: normal"> or in such other proportion as shall mutually be
agreed to by all such selling Holders</FONT>; <U>provided</U>, <U>however</U>, that the number of Registrable Securities held by
the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from
the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters
may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In connection with any offering involving an underwriting of shares of the Company&rsquo;s capital stock pursuant to <U>Subsection
2.2</U>, the Company shall not be required to include any of the Holders&rsquo; Registrable Securities in such underwriting unless
the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such
quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company.
If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering
exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine
is compatible with the success of the offering, then the Company shall be required to include in the offering only that number
of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine
will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities
requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering
shall be <FONT STYLE="font-weight: normal">allocated</FONT> among the selling Holders <FONT STYLE="font-weight: normal">in proportion
(as nearly as practicable to)</FONT> the number of Registrable Securities <FONT STYLE="font-weight: normal">owned</FONT> by <FONT STYLE="font-weight: normal">each</FONT>
selling <FONT STYLE="font-weight: normal">Holder</FONT> or in such other proportions as shall mutually be agreed to by all such
selling Holders. <FONT STYLE="font-weight: normal">To facilitate the allocation of shares in accordance with the above provisions,
the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.</FONT>
For purposes of the provision in this <U>Subsection 2.3</U> <U>(b)</U> concerning apportionment, for any selling <FONT STYLE="font-weight: normal">Holder</FONT>
that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders,
and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and
retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single &ldquo;selling Holder,&rdquo;
and any pro rata reduction with respect to such &ldquo;selling Holder&rdquo; shall be based upon the aggregate number of Registrable
Securities owned by all Persons included in such &ldquo;selling Holder,&rdquo; as defined in this sentence.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of <U>Subsection </U> <U>2.1</U><FONT STYLE="font-weight: normal">,</FONT> a registration shall not be counted
as &ldquo;effected&rdquo; if, as a result of an exercise of the underwriter&rsquo;s cutback provisions in <U>Subsection 2.3</U>
<U>(a)</U>, fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included
in such registration statement are actually included.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.4<FONT STYLE="font-size: 10pt"> </FONT><U>Obligations
of the Company</U>. Whenever required under this <U>Section 2</U> to effect the registration of any Registrable Securities, the
Company shall, as expeditiously as reasonably possible:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially
reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority
of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; <U>provided</U>,
<U>however</U>, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the
Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities
included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended
to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120)
day period shall be extended for up to sixty (60) days, if necessary, to keep the registration statement effective until all such
Registrable Securities are sold;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in
connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition
of all securities covered by such registration statement;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by
the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of
their Registrable Securities;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under
such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U>
that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such
states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by
the Securities Act;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement,
in usual and customary form, with the underwriter<FONT STYLE="font-weight: normal">(s)</FONT> of such offering;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement
to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which
similar securities issued by the Company are then listed;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide
a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>promptly make available for inspection by the selling Holders, any [managing] underwriter<FONT STYLE="font-weight: normal">(s)</FONT>
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained
by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and
properties of the Company, and cause the Company&rsquo;s officers, directors, employees, and independent accountants to supply
all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent<FONT STYLE="font-weight: normal">,
in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct
appropriate due diligence</FONT> in connection <FONT STYLE="font-weight: normal">therewith</FONT>;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(i)<FONT STYLE="font-size: 10pt"> </FONT>notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(j)<FONT STYLE="font-size: 10pt"> </FONT>after
such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">In addition, the Company shall ensure that,
at all times after any registration statement covering a public offering of securities of the Company under the Securities Act
shall have become effective, its insider trading policy shall provide that the Company&rsquo;s directors may implement a trading
program under Rule 10b5-1 of the Exchange Act.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.5<FONT STYLE="font-size: 10pt"> </FONT><U>Furnish
Information</U>. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this <U>Section
2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information
regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably
required to effect the registration of such Holder&rsquo;s Registrable Securities.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.6<FONT STYLE="font-size: 10pt"> </FONT><U>Expenses
of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications
pursuant to <U>Section 2</U>, including all registration, filing, and qualification fees; printers&rsquo; and accounting fees;
fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders
<FONT STYLE="font-weight: normal">(&ldquo;</FONT><B>Selling Holder Counsel</B><FONT STYLE="font-weight: normal">&rdquo;)</FONT>,
shall be borne and paid by the Company; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to <U>Subsection 2.1</U> if the registration request is subsequently withdrawn
at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders
shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration),
unless the Holders of a majority of the Registrable Securities agree to forfeit their right to the registration pursuant to <U>Subsection
2.1(a)</U>. All Selling Expenses relating to Registrable Securities registered pursuant to this <U>Section 2</U> shall be borne
and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.7<FONT STYLE="font-size: 10pt"> </FONT><U>Delay
of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation
of this <U>Section 2</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.8<FONT STYLE="font-size: 10pt"> </FONT><U>Indemnification</U>.
If any Registrable Securities are included in a registration statement under this <U>Section 2</U>:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members,
officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter
(as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within
the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter,
controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating
or defending any<FONT STYLE="font-weight: normal"> claim or</FONT> proceeding from which Damages may result, as such expenses are
incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this <U>Subsection 2.8</U> <U>(a)</U> shall
not apply to amounts paid in settlement of any such <FONT STYLE="font-weight: normal">claim</FONT> or proceeding if such settlement
is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable
for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity
with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned
Person expressly for use in connection with such registration.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company,
and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the
Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in
the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such
underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon
actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling
Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any<FONT STYLE="font-weight: normal">
claim or</FONT> proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that
the indemnity agreement contained in this <U>Subsection 2.8</U> <U>(b)</U> shall not apply to amounts paid in settlement of any
such <FONT STYLE="font-weight: normal">claim</FONT> or proceeding if such settlement is effected without the consent of the Holder,
which consent shall not be unreasonably withheld; and <U>provided</U> <U>further</U> that in no event shall the aggregate amounts
payable by any Holder by way of indemnity or contribution under <U>Subsections 2.8</U> <U>(b)</U> and <U>2.8(d)</U> exceed the
proceeds from the offering <FONT STYLE="font-weight: normal">received by such Holder </FONT>(net of any Selling Expenses<FONT STYLE="font-weight: normal">
paid by such Holder</FONT>), except in the case of fraud or willful misconduct by such Holder.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Promptly after receipt by an indemnified party under this <U>Subsection </U> <U>2.8</U><B> </B>of notice of the commencement
of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified
party will, if a claim in respect thereof is to be made against any indemnifying party under this <U>Subsection </U> <U>2.8</U><FONT STYLE="font-weight: normal">,</FONT>
give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such
action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice
has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; <U>provided</U>, <U>however</U>,
that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel)
shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation
of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such counsel in such action.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either:
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Subsection
</U> <U>2.8</U> but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction
and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in
such case, notwithstanding the fact that this <U>Subsection </U> <U>2.8</U> provides for indemnification in such case, or (ii)
contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under
this <U>Subsection </U> <U>2.8</U><FONT STYLE="font-weight: normal">,</FONT> then, and in each such case, such parties will contribute
to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others)
in such proportion as is appropriate to reflect the relative fault of each of<FONT STYLE="font-weight: normal"> the</FONT> indemnifying
party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim,
damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying
party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue
statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying
party or by the indemnified party and the parties&rsquo; relative intent, knowledge, access to information, and opportunity to
correct or prevent such statement or omission; <U>provided</U>, <U>however</U>, that, in any such case (x) no Holder will be required
to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder
pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation;
and <U>provided</U> <U>further</U> that in no event shall a Holder&rsquo;s liability pursuant to this <U>Subsection 2.8</U> <U>(d)</U>,
when combined with the amounts paid or payable by such Holder pursuant to <U>Subsection 2.8</U> <U>(b)</U>, exceed the proceeds
from the offering <FONT STYLE="font-weight: normal">received by such Holder </FONT>(net of any Selling Expenses <FONT STYLE="font-weight: normal">paid</FONT>
by such Holder<FONT STYLE="font-weight: normal">)</FONT>, except in the case of willful misconduct or fraud by such Holder.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering,
the obligations of the Company and Holders under this <U>Subsection </U> <U>2.8</U> shall survive the completion of any offering
of Registrable Securities in a registration under this <U>Section 2</U>, and otherwise shall survive the termination of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.9<FONT STYLE="font-size: 10pt"> </FONT><U>Reports
Under Exchange Act</U>. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation
of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant
to a registration on Form S-3, the Company shall:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make and keep <FONT STYLE="font-weight: normal">available adequate current </FONT>public information, as those terms are
understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company
for the IPO;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements);
and</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) <FONT STYLE="font-weight: normal">to
the extent accurate, </FONT>a written statement by the Company that it has complied with the reporting requirements of SEC Rule
144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO),
the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies);
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company;
and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that
permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting
requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>&ldquo;Market Stand-off&rdquo; Agreement</U>. Each Holder hereby agrees that it will not, without the prior written consent
of the managing underwriter, during the period commencing on the date of the final prospectus relating to the <FONT STYLE="font-weight: normal">registration
by the Company of shares of its Common Stock or any other equity securities under</FONT> the<FONT STYLE="font-weight: normal">
Securities Act on a</FONT><B> </B>registration statement <FONT STYLE="font-weight: normal">on Form S-1 or Form S-3,</FONT> <FONT STYLE="font-weight: normal">and
ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days
in the case of the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions
on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but
not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments
thereto), or ninety (90) days in the case of any registration other than the IPO, or such other period as may be requested by the
Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports
and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4)
or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), </FONT>(i) lend; offer; pledge; sell; contract to sell;
sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase;
or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable
or exchangeable <FONT STYLE="font-weight: normal">(directly or indirectly) </FONT>for Common Stock (whether such shares or any
such securities are then owned by the Holder or are thereafter acquired)<B> </B>or (ii) enter into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of <FONT STYLE="font-weight: normal">such
securities</FONT>, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock
or other securities, in cash, or otherwise. The foregoing provisions of this <U>Subsection </U> <U>2.10</U><B> </B>shall not apply
to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only
if all officers and directors are subject to the same restrictions. The underwriters in connection with <FONT STYLE="font-weight: normal">such</FONT>
<FONT STYLE="font-weight: normal">registration</FONT> are intended third-party beneficiaries of this <U>Subsection </U> <U>2.10</U>
and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder
further agrees to execute such agreements as may be reasonably requested by the underwriters in <FONT STYLE="font-weight: normal">connection
with such registration</FONT> that are consistent with this <U>Subsection </U> <U>2.10</U> or that are necessary to give further
effect thereto.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">2.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities
in any registration pursuant to <U>Subsections </U> <U>2.1</U> or <U>2.2</U> shall terminate upon the <FONT STYLE="font-weight: normal">earliest
to occur</FONT> of:</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the closing of a Deemed Liquidation Event, as such term is defined in the Company&rsquo;s Certificate of Incorporation;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt"><FONT STYLE="font-weight: normal">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-weight: normal">such time as Rule 144 or another similar exemption under the Securities Act is
available for the sale of</FONT><B> </B>all of such Holder&rsquo;s <FONT STYLE="font-weight: normal">shares without limitation
during a three-month period without registration; and</FONT></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 108pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal">the third anniversary of the IPO.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 36pt">3.<FONT STYLE="font-size: 10pt">&nbsp; </FONT><U>Miscellaneous</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.1<FONT STYLE="font-size: 10pt"> </FONT><U>Successors
and Assigns</U>. <FONT STYLE="font-weight: normal">The rights under this Agreement</FONT> may <FONT STYLE="font-weight: normal">be</FONT><B>
</B>assigned (<FONT STYLE="font-weight: normal">but only with all related obligations</FONT>) <FONT STYLE="font-weight: normal">by
a Holder to a transferee of</FONT> Registrable Securities <FONT STYLE="font-weight: normal">that (i) is an Affiliate of a Holder;
(ii) is a Holder&rsquo;s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder&rsquo;s
Immediate Family Members; or (iii) after such transfer, holds at least five percent (5%) shares of Registrable Securities (subject
to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); <U>provided</U>, <U>however</U>,
that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of
such transferee and the Registrable Securities</FONT> with respect to <FONT STYLE="font-weight: normal">which such</FONT> rights
<FONT STYLE="font-weight: normal">are being transferred; and (y) such transferee agrees in</FONT> a written instrument <FONT STYLE="font-weight: normal">delivered
</FONT>to the Company to be bound by <FONT STYLE="font-weight: normal">and subject to </FONT>the terms <FONT STYLE="font-weight: normal">and
conditions </FONT>of this <FONT STYLE="font-weight: normal">Agreement, including the provisions of <U>Subsection 2.10</U>. For
the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1)
that is an Affiliate or stockholder of a Holder; (2) who is a Holder&rsquo;s Immediate Family Member; or (3) that is a trust for
the benefit of an individual Holder or such Holder&rsquo;s Immediate Family Member shall be aggregated together and with those
of the transferring Holder; <U>provided</U> <U>further</U> that all transferees who would not qualify individually for assignment
of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action
under this </FONT>Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective
successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or
liabilities under or by reason of this Agreement, except as expressly provided herein.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.2<FONT STYLE="font-size: 10pt"> </FONT><U>Governing
Law</U>. This Agreement shall be governed by the internal law of the State of Delaware.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.3<FONT STYLE="font-size: 10pt"> </FONT><U>Counterparts</U>.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. <FONT STYLE="font-weight: normal">Counterparts may be delivered via facsimile, electronic
mail (including pdf</FONT> or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com<FONT STYLE="font-weight: normal">)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes</FONT>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.4<FONT STYLE="font-size: 10pt"> </FONT><U>Titles
and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.5<FONT STYLE="font-size: 10pt"> </FONT><U>Notices</U>.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic
mail or facsimile during the recipient&rsquo;s normal business hours, and if not sent during normal business hours, then on the
recipient&rsquo;s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid; or (iv) one (1) <FONT STYLE="font-weight: normal">business </FONT>day after<FONT STYLE="font-weight: normal">
the business day of</FONT> deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery,
with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth
on <U>Schedule A</U> or <U>Schedule B</U> (as applicable) hereto, or to <FONT STYLE="font-weight: normal">the principal office
of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to </FONT>such email address,
facsimile number, or address as subsequently modified by written notice given in accordance with this <U>Subsection 3.5</U>.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.6<FONT STYLE="font-size: 10pt"> </FONT><U>Amendments
and Waivers</U>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company
and the holders of a majority of the Registrable Securities then outstanding; <U>provided</U> that <FONT STYLE="font-weight: normal">any
provision hereof may be waived by any waiving party on such party&rsquo;s own behalf, without the consent of any other party</FONT>.
The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not
consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with
this <U>Subsection 3.6</U> shall be binding on all parties hereto, regardless of whether any such party has consented thereto.
No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed
to be or construed as a further or continuing waiver of any such term, condition, or provision.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.7<FONT STYLE="font-size: 10pt"> </FONT><U>Severability</U>.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such
invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to
the maximum extent permitted by law.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.8<FONT STYLE="font-size: 10pt"> </FONT><U>Aggregation
of Stock</U>. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose
of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among
themselves in any manner they deem appropriate.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.9<FONT STYLE="font-size: 10pt"> </FONT><U>Additional
Investors</U>. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company&rsquo;s
Series B Preferred Stock after the date hereof, any purchaser of such shares of Series B Preferred Stock may become a party to
this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be
deemed an &ldquo;Investor&rdquo; for all purposes hereunder. No action or consent by the Investors shall be required for such joinder
to this Agreement by such additional <FONT STYLE="font-weight: normal">Investor</FONT>, so long as such additional <FONT STYLE="font-weight: normal">Investor</FONT>
has agreed in writing to be bound by all of the obligations as an &ldquo;Investor&rdquo; hereunder.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.10<FONT STYLE="font-size: 10pt">&nbsp;</FONT><U>Entire
Agreement</U>. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement <FONT STYLE="font-weight: normal">among</FONT> the parties with respect to the subject matter hereof, and any other
written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.11<FONT STYLE="font-size: 10pt">&nbsp;</FONT><U>Dispute Resolution</U>. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state
courts of Arizona and to the jurisdiction of the United States District Court for the District of Arizona for the purpose of any
suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other
proceeding arising out of or based upon this Agreement except in the state courts of Arizona<I> </I>or the United States District
Court for the District of Arizona, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise,
in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts,
that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient
forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not
be enforced in or by such court.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt"><FONT STYLE="text-transform: uppercase">Waiver of Jury Trial</FONT>:<B>
</B>EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT,
THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO
BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION,
INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON
LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE
SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH
ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL
COUNSEL.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 72pt; margin: 0 0 12pt">The prevailing party shall be entitled to
reasonable attorney&rsquo;s fees, costs, and necessary disbursements in addition to any other relief to which such party may be
entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District
Court for the District of Arizona or any court of the State of Arizona.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt; text-align: justify; text-indent: 72pt">3.12<FONT STYLE="font-size: 10pt">&nbsp; </FONT><U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party under this
Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of
such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default,
or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise
afforded to any party, shall be cumulative and not alternative.</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">[Remainder of Page Intentionally Left Blank]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first written above.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; font-size: 10pt; width: 39%"></TD>
    <TD STYLE="width: 61%"><B><U>THE COMPANY</U>:</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>                        <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; margin: 0 0 12pt 20pt; padding-left: 10pt"><P STYLE="font-size: 10pt; text-align: left; margin: 0 0 12pt 20pt">LIPIMETIX DEVELOPMENT, INC.<BR>
<BR>
By: /s/ Dennis I. Goldberg<BR>
Name: Dennis I. Goldberg, Ph.D.<BR>
Title: President</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0 0 12pt 20pt">Address for Notices:</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0 0 0 20pt">5 Commonwealth Rd., Suite 2A</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0 0 0 20pt">Natick, Massachusetts 01760</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0 0 0 20pt">Attn: Dennis I. Goldberg, Ph.D.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0 0 12pt 20pt">Email: dgoldberg@lipimetix.com</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0 0 12pt 20pt"><U>with a copy to</U>:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt 20pt">Leslie M. Taeger <BR>
Senior Vice President &amp; <BR>
&nbsp; &nbsp;&nbsp;&nbsp;Chief Financial Officer <BR>
Capstone Therapeutics Corp. <BR>
1275 W. Washington St., Suite 104 <BR>
Tempe, AZ 85281</P>
</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: -36pt; margin: 0 0 12pt 180pt"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0 0 12pt 180pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD><B><U>COMMON HOLDERS</U>:</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 61%; padding-left: 10pt">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0 0 12pt 20pt">CAPSTONE THERAPEUTICS CORP.,<BR>
        a Delaware corporation</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">By:<U> &#9;/s/ John M. Holliman, III</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt; text-indent: 0.5in">J.M. Holliman, III</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt 20pt; text-indent: 0.5in">Executive Chairman</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>LX STOCKHOLDERS:</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>/s/ Dennis I. Goldberg&#9;</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">Dennis I. Goldberg, Ph.D.</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>/s/ Phillip M. Friden</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">Phillip M. Friden, Ph.D.</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>/s/ Eric Morrel&#9;</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">Eric Morrel, Ph.D.</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"></P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 180pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 180pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0"><I>[Signature Page to Registration Rights Agreement]</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 180pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 180pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 180pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 180pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 61%; padding-left: 10pt">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">_____________________________</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">G.M. Anantharamaiah</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">_____________________________</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">Palgunachari Mayakonda</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">_____________________________</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt 20pt">Frederick Meyer</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">_____________________________</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt 20pt">Michael Webb</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">_____________________________</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">Jeffrey Elton</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">THE UAB RESEARCH FOUNDATION</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">By: __________________________</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt; text-indent: 0.5in">Kathy L. Nugent</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt; text-indent: 0.5in">Chief Executive Officer</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P></TD></TR></TABLE>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 180pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 12pt 144pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"></P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><I></I></P>



<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 0"><I>[Signature Page to Registration Rights Agreement]</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><B></B></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><B>SCHEDULE A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 18pt"><B>Investors</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><B>SCHEDULE B</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 18pt"><B>Common Holders</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 18pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 18pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 18pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 18pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>exh_105.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt"><B>Exhibit 10.5 -Series B Preferred Stock and Warrant Purchase Agreement - Exhibit
G Form of Amended and Restated Stockholders Agreement among LipimetiX Development, Inc. and The Stockholders Named Herein</B></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">AMENDED AND RESTATED<BR>
STOCKHOLDERS AGREEMENT</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">among</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">LIPIMETIX DEVELOPMENT, INC.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">and</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">THE STOCKHOLDERS NAMED HEREIN</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">Dated as of August 25, 2016</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>LIPIMETIX DEVELOPMENT, INC.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 18pt"><B><U>AMENDED AND RESTATED STOCKHOLDERS AGREEMENT</U></B></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"><FONT STYLE="text-transform: uppercase">ThiS AMENDED AND RESTATED
Stockholders Agreement </FONT>(this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of August 25, 2016 by and among
LipimetiX Development, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), Capstone Therapeutics Corp., a Delaware
corporation (&ldquo;<U>CAPS</U>&rdquo;), each of the stockholders listed on the signature page hereto as the LX Stockholders (collectively,
the &ldquo;<U>LX Stockholders</U>&rdquo;), The UAB Research Foundation (&ldquo;<U>UABRF</U>&rdquo;), each of the holders of Series
B Preferred Stock listed on <U>Schedule 1</U> hereto and any subsequent purchasers of the Series B Preferred Stock who become parties
to this Agreement pursuant to the terms hereof (collectively, the &ldquo;<U>Series B Investors</U>&rdquo;), and any other subsequent
stockholders of the Company who become parties to this Agreement pursuant to the terms hereof (each a &ldquo;<U>Stockholder</U>&rdquo;
and, collectively, the &ldquo;<U>Stockholders</U>&rdquo;). CAPS, the LX Stockholders and UABRF are sometimes referred to herein
collectively as the &ldquo;<U>Original Stockholders</U>.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 11.25pt"><B>WITNESSETH:</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">WHEREAS, the Company and the original Stockholders
are parties to that certain Stockholders Agreement dated as of June 23, 2015 (the &ldquo;<U>Original Stockholders&rsquo; Agreement</U>&rdquo;);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">WHEREAS, Section 11.1 of the Original Stockholders
Agreement permits amendments to the Original Stockholders&rsquo; Agreement only upon written approval of Stockholders holding at
least 75% of the Common Shares held by all of the Stockholders;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">WHEREAS, the original Stockholders signing
below own all of the shares of the Company&rsquo;s Common Stock, par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">WHEREAS, concurrently herewith, the Company
is entering into that certain Series B Preferred Stock and Warrant Purchase Agreement (the &ldquo;<U>Series B Purchase Agreement</U>&rdquo;)
pursuant to which the Company may issue and sell to the Series B Investors an aggregate of up to 1,340,176 shares (the &ldquo;<U>2016
Series B Preferred Shares</U>&rdquo;) of its Series B Preferred Stock, together with Warrants (the &ldquo;<U>Series B Warrants</U>&rdquo;)
to purchase up to an aggregate of 49,062 shares of its Series B Preferred Stock (the &ldquo;<U>Warrant Shares</U>,&rdquo; and together
with the 2016 Series B Preferred Shares, the &ldquo;<U>Series B Preferred Shares</U>&rdquo;);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">WHEREAS, the Series B Preferred Shares are
convertible at any time and from time to time into shares of Class A-1 Common Stock of the Company at the option of the holder
of record thereof, and are subject to mandatory conversion under certain circumstances;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">WHEREAS, the Stockholders and the Company
have agreed that it is in their mutual best interests and in the best interest of the Company to amend and restate the Original
Stockholders Agreement as set forth herein; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">WHEREAS, this Amended and Restated Stockholders
Agreement amends, restates, and supersedes in its entirety the Original Stockholders Agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">NOW, THEREFORE, in consideration of the covenants and agreements
contained herein, the parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><FONT STYLE="text-transform: uppercase"><B>AGREEMENT:</B></FONT></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">In consideration of the foregoing and the mutual promises contained
in this Agreement, the parties agree as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Defined Terms</U>. As used in this Agreement:</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Accounting Services Agreement</U>&rdquo; means that certain
Accounting Services Agreement by and between the Company and CAPS dated as of August 3, 2012, as amended from time to time.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Affiliate</U>&rdquo; means, with respect to any Person,
any other Person directly or indirectly controlling, controlled by or under common control with such Person; provided that no securityholder
of the Company shall be deemed an Affiliate of any other securityholder solely by reason of any investment in the Company. For
the purpose of this definition, the term &ldquo;control&rdquo; (including, with correlative meanings, the terms &ldquo;controlling,&rdquo;
&ldquo;controlled by&rdquo; and &ldquo;under common control with&rdquo;), as used with respect to any Person, shall mean the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through
the ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Allocation Ratio</U>&rdquo; means with respect to any
Stockholder the fraction (a) the numerator of which is the number of outstanding Common Shares owned by such Stockholder (assuming
conversion of all outstanding shares of Series B Preferred Stock) and (b)&nbsp;the denominator of which is the number of then outstanding
shares of Common Shares (assuming conversion of all outstanding shares of Series B Preferred Stock).</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Benu Management Agreement</U>&rdquo; means that certain
Management Agreement by and between the Company and Benu BioPharma, Inc., dated as of August 3, 2012, as amended from time to time.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Board</U>&rdquo; means the board of directors of the
Company.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Business Day</U>&rdquo; means any day except a Saturday,
Sunday or other day on which commercial banks in New York City are authorized by law to close.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Bylaws</U>&rdquo; means the Bylaws of the Company, as
amended from time to time.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Capital Stock</U>&rdquo; means (a) Common Shares (whether
now outstanding or hereafter issued in any context), (b) shares of Series&nbsp;A Preferred Stock (whether now outstanding or hereafter
issued in any context), (c) shares of Series B Preferred Stock (whether now outstanding or hereafter issued in any context), (d)
shares of any Other Stock, or (e) any option, warrant or right to receive any Common Shares, Series&nbsp;A Preferred Stock, Series
B Preferred Stock or Other Stock other than options issued under the Company&rsquo;s stock option plan(s) in effect from time to
time (but any Common Shares, Series A Preferred Stock, Series B Preferred Stock or Other Stock issued upon exercise of such options
shall be Capital Stock).</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 12pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 6pt 0">&ldquo;<U>CAPS Majority Holders</U>&rdquo;&nbsp;means
the holders of a majority of the Common Shares held by CAPS and/or any of its Permitted Transferees.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>CAPS Stockholders</U>&rdquo;&nbsp;means CAPS and each
of its Permitted Transferees holding Common Shares.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Certificate of Incorporation</U>&rdquo; means the Amended
and Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware and in
effect as of the date of this Agreement, as amended from time to time, including amendments made through a certificate of designations
filed with the Secretary of State of the State of Delaware.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Change of Control</U>&rdquo;&nbsp;means: (a) the sale
of all or substantially all of the consolidated assets of the Company and the Company Subsidiaries, if any, to a Third Party Purchaser;
(b) a sale resulting in no less than a majority of the Common Shares being held by a Third Party Purchaser; or (c) a merger, consolidation,
recapitalization or reorganization of the Company with or into a Third Party Purchaser that results in the inability of the Stockholders
to designate or elect a majority of the board of directors (or its equivalent)) of the resulting entity or its parent company.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Class A-1 Common Shares</U>&rdquo; means shares of Class
A-1 Common Stock, par value $0.00001 per share, of the Company and any stock into which such Class A-1 Common Shares may hereafter
be converted or changed.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Class A-2 Common Shares</U>&rdquo; means shares of Class
A-2 Common Stock, par value $0.00001 per share, of the Company and any stock into which such Class A-2 Common Shares may hereafter
be converted or changed.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Common Shares</U>&rdquo; means shares of Class A-1 Common
Shares and Class A-2 Common Shares.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Company Breach Event</U>&rdquo; means either of: (i)
the failure of the Company during any calendar year to operate substantially in accordance with the Budget for such year or to
achieve any of the Milestones for such year; or (ii) the failure of the Company to perform any of its obligations hereunder, including
any of the provisions of Sections 4.4, 4.5, or 4.6 hereof.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Company Competitor</U>&rdquo; means any Person who is
engaged in the commercial development, sale or distribution of pharmaceutical products, or any person who owns, directly or indirectly,
an ownership interest in any such Person (other than a passive ownership of less than one percent (1%) of the outstanding stock
of any entity whose stock is traded on an established stock exchange).</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Company Subsidiary</U>&rdquo;&nbsp;means a Subsidiary
of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Governmental Authority</U>&rdquo; means any federal,
state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political
subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority
(to the extent that the rules, regulations or orders of such organization or authority have the force of law), or any arbitrator,
court or tribunal of competent jurisdiction.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Holder</U>&rdquo; means any Stockholder.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>License Agreement</U>&rdquo; means that certain Exclusive
License Agreement dated August 26, 2011 between UABRF and LipimetiX, LLC (&ldquo;<U>LX</U>&rdquo;), as amended on August 3, 2012
and December 15, 2014 by and among UABRF, LX and the Company with LX assigning its interest therein to the Company in connection
therewith, as further amended from time to time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>LX Majority Holders</U>&rdquo;&nbsp;means
the holders of a majority of the Common Shares held by the LX Stockholders and/or any of their respective Permitted Transferees.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>LX Stockholders</U>&rdquo; has the meaning set forth
in the Preamble to this Agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Majority in Interest of the Stockholders</U>&rdquo;
means one or more Stockholders who own, collectively, Shares of the of the Company representing at least a majority of the Voting
Power (without giving effect to the conversion of any convertible Shares or the exercise of any options, warrants or other rights
to acquire Shares).</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>New Shares</U>&rdquo; means any Capital Stock other
than (a) any Capital Stock issued pursuant to an offering of the securities of the Company pursuant to a registration statement
filed pursuant to the Securities Act of 1933, as amended, (b) Common Shares issuable upon the exercise of options, warrants or
other rights to purchase such shares issued or issuable pursuant to the Company&rsquo;s stock option plan(s) in effect from time
to time, or upon the conversion of shares of Series B Preferred Stock, (c) Common Shares or options, warrants or other rights
to purchase Common Shares that are issued or issuable to directors or employees, or other service providers or contractors (including
without limitation any investment bankers or other financial service providers) of the Company for compensatory purposes and are
approved by the Board, and the Common Shares issuable upon the exercise of any such options, warrants or other rights, (d) Capital
Stock issued to the Company&rsquo;s stockholders in connection with any stock split, stock dividend, reverse stock split, recapitalization,
reclassification or similar event in which new Capital Stock is issued only to the Persons who were stockholders of the Company
immediately prior to such issuance and in which the allocation of such new Capital Stock is based upon the proportionate ownership
of Capital Stock immediately prior to such issuance, (e) Capital Stock issued in connection with a lender financing transaction
approved by the Board, (f) Capital Stock issued as consideration for the acquisition of all or a portion of the business or assets
of a Person or all or a portion of the equity securities of a Person, regardless of the structure of such transaction, provided
such Person is not Affiliated with any Investor immediately prior to such acquisition and such issuance is approved by the Board,
(g) Capital Stock issued in connection with the formation of a joint venture or similar arrangement between the Company and a
Person, provided such Person is not Affiliated with any Stockholder immediately prior to such formation and such issuance is approved
by the Board, and (h) the Series B Preferred Shares and the Warrants.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Other Stock</U>&rdquo; means any class or series of
capital stock of the Company (other than Common Shares, Series&nbsp;A Preferred Stock or Series B Preferred Stock) that may hereafter
be authorized.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Permitted Transfer</U>&rdquo;&nbsp;means a Transfer
of Shares carried out pursuant to Section 3.2 or Section 3.3.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Permitted Transferee</U>&rdquo; means a recipient of
a Permitted Transfer.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Person</U>&rdquo; means an individual, corporation,
limited liability company, partnership, association, trust (revocable or irrevocable) or other entity or organization, including
a government or political subdivision or an agency or instrumentality thereof.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Preferred Shares</U>&rdquo; means any Series A Preferred
Stock, Series B Preferred Stock or Other Stock that is designated as a class or series of preferred stock of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Proportionate Share</U>&rdquo; means with respect to
each Stockholder, the fraction whose numerator is the number of Common Shares owned by such Stockholder at the date with respect
to which such amount is being calculated and the denominator of which is the sum of the number of Common Shares outstanding at
such date, in each case assuming conversion of all outstanding shares of Series B Preferred Stock.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Representative</U>&rdquo;&nbsp;means, with respect to
any Person, any and all directors, officers, managers, employees, consultants, financial advisors, counsel, accountants and other
agents of such Person.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Securities Act</U>&rdquo; means the Securities Act of
1933, as amended.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Series A Preferred Stock</U>&rdquo; means shares of Series
A Preferred Stock, par value $0.0001 per share, of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Series B Majority Holders</U>&rdquo; means the holders
of a majority of the Common Shares held by the Series B Investors assuming conversion of all outstanding shares of Series B Preferred
Stock.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Series B-1 Majority Holders</U>&rdquo; means the holders
of a majority of the Common Shares held by the holders of the Series B-1 Preferred Stock assuming conversion of all outstanding
shares of Series B-1 Preferred Stock.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Series B-2 Majority Holders</U>&rdquo; means the holders
of a majority of the Common Shares held by the holders of the Series B-2 Preferred Stock assuming conversion of all outstanding
shares of Series B-2 Preferred Stock.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Series B Preferred Stock</U>&rdquo; means shares of Series
B-1 Preferred Stock and Series B-2 Preferred Stock.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Series B-1 Preferred Stock</U>&rdquo; means shares of
Series B-1 Preferred Stock, par value $0.0001 per share, of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Series B-2 Preferred Stock</U>&rdquo; means shares of
Series B-2 Preferred Stock, par value $0.0001 per share, of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Shares</U>&rdquo; means the Common
Shares and the Preferred Shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Subsidiary</U>&rdquo;&nbsp;means,
with respect to any Person, any other Person of which a majority of the outstanding shares or other equity interests having the
power to vote for directors or comparable managers or other governing body are owned, directly or indirectly, by the first Person.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Supermajority in Interest of the Stockholders</U>&rdquo;&nbsp;means
one or more Stockholders who own, collectively, at least sixty percent (60%) or more of the Common Shares held by all of the Stockholders
entitled to vote on or consent to the matter under consideration, assuming conversion of all outstanding shares of Series B Preferred
Stock.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Third Party Purchaser</U>&rdquo;&nbsp;means any Person
who, immediately prior to the contemplated transaction, (a) does not directly or indirectly own or have the right to acquire any
outstanding Shares or (b) is not a Permitted Transferee of any Person who directly or indirectly owns or has the right to acquire
any Shares.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Transfer</U>&rdquo;&nbsp;means to, directly or indirectly,
sell, transfer, assign, pledge, encumber, hypothecate or similarly dispose of, either voluntarily or involuntarily, by operation
of law or otherwise, or to enter into any contract, option or other arrangement or understanding with respect to the sale, transfer,
assignment, pledge, encumbrance, hypothecation or similar disposition of, any Shares owned by a Person or any interest (including
a beneficial interest) in any Shares owned by a Person. &ldquo;<U>Transfer</U>&rdquo; when used as a noun shall have a correlative
meaning.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>UABRF Shares</U>&rdquo; means those certain Common Shares
held by UABRF.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">&ldquo;<U>Voting Power</U>&rdquo; means the power to cast votes
in a vote of the stockholders of the Company in accordance with the Certificate of Incorporation and shall refer to the total number
of votes entitled to be cast in any such matter on which the stockholders are entitled to vote as a single class.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cross-Reference of Defined Terms</U>. Each of the following terms is defined in the Section set forth opposite such term:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-indent: 37.85pt; padding-left: 20pt"><B>Term</B></TD>
    <TD STYLE="width: 50%; text-align: left; padding-left: 30pt"><B>Section</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 37.85pt; padding-left: 20pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.6pt; padding-left: 40pt">Agreement</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">Preamble</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.6pt; padding-left: 40pt">Budget</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">6.3</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.6pt; padding-left: 40pt">CAPS</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">Preamble</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.6pt; padding-left: 40pt">Company</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">Preamble</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.6pt; padding-left: 40pt">Confidential Information</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">6.4</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">Consent of Spouse</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">11.17</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">Exercising Buyers</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">5.1(c)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.6pt; padding-left: 40pt">New Share Offeree</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">5.1(a)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">Notice of Proposed Issuance</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">5.1(a)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">Offered New Shares</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">5.1(a)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">Participating Stockholder</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">6.2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 40pt">Proposed Purchaser/Proposed Purchasers</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">5.1(a)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">Stockholder/Stockholders</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">Preamble</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">Twenty Day Period</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">5.1(b)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">UABRF</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">Preamble</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 40pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 20pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Board of Directors</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Board of Directors; Composition; Vacancies</U>. Each Stockholder shall vote (in person, by proxy or by action by written
consent, as applicable) all of such Stockholder&rsquo;s Capital Stock, whether now owned or hereafter acquired or which such Stockholder
may be empowered to vote, from time to time and at all times, in whatever manner shall be necessary to ensure that the number of
directors who comprise the Board shall be seven (7) and the members of the Board shall consist of the following:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the provisions of Section 2.1(e) below, the Board shall be comprised as follows: (i) provided that the LX Stockholders
continue to hold any Shares, three (3) individuals designated in writing by the LX Majority Holders (the &ldquo;<U>LX Directors</U>&rdquo;),
who shall initially be Dennis I. Goldberg, Ph.D., Philip M. Friden, Ph.D. and Eric Morrel, Ph.D.; (ii) provided that the CAPS Stockholders
continue to hold any Shares, two (2) individuals designated in writing by the CAPS Majority Holders (the &ldquo;<U>CAPS Directors</U>&rdquo;),
who shall initially be J.M. Holliman, III and Randy Steer; (iii) provided that the Series B Investors continue to hold any shares
of Series B-1 Preferred Stock, one individual, provided such individual constitutes a Qualified Designee as defined below, designated
in writing by the Series B-1 Majority Holders (the &ldquo;<U>Series B-1 Director</U>&rdquo;), who shall initially be Randall R.
Lunn; and (iv) provided that the Series B Investors continue to hold any shares of Series B-2 Preferred Stock, one individual,
provided such individual constitutes a Qualified Designee as defined below, designated in writing by the Series B- 2 Majority Holders
(the &ldquo;<U>Series B- 2 Director</U>&rdquo;, and together with the Series B-1 Director, the &ldquo;<U>Series B Directors</U>&rdquo;
), who shall initially be ____________. To the extent that any of the clauses in (i) through (iv) shall not be applicable because
the LX Stockholders, CAPS Stockholders or Series B Investors, as applicable, no longer hold any of the applicable shares of the
Company, any members of the Board who would otherwise have been designated in accordance with the terms thereof shall instead be
voted upon by all of the stockholders of the Company entitled to vote thereon in accordance with, and pursuant to, the Certificate
of Incorporation.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that a vacancy is created on the Board at any time due to the death, disability, retirement, resignation or
removal of a LX Director and provided that the LX Majority Holders are still entitled to designate the LX Directors pursuant to
Section 2.1(a) above, then the LX Majority Holders shall have the right to designate an individual to fill such vacancy, provided
that such individual constitutes a Qualified Designee, and the Company and each Stockholder hereby agree to take such actions as
may be required to ensure the election or appointment of such designee to fill such vacancy on the Board. In the event that the
LX Majority Holders shall fail to designate in writing a representative to fill a vacant LX Director position on the Board, and
such failure shall continue for more than fifteen (15) days after notice from any director to the LX Stockholders with respect
to such failure, then the vacant position shall be filled by an individual designated by the LX Directors then in office; <U>provided</U>,
<U>however</U>, that such individual shall be removed from such position if the LX Majority Holders so direct and simultaneously
designate a new LX Director.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that a vacancy is created on the Board at any time due to the death, disability, retirement, resignation or
removal of a CAPS Director and provided that the CAPS Majority Holders are still entitled to designate the CAPS Directors pursuant
to Section 2.1(a) above, then the CAPS Majority Holders shall have the right to designate an individual to fill such vacancy, provided
that such individual constitutes a Qualified Designee, and the Company and each Stockholder hereby agree to take such actions as
may be required to ensure the election or appointment of such designee to fill such vacancy on the Board. In the event that the
CAPS Majority Holders shall fail to designate in writing a representative to fill a vacant CAPS Director position on the Board,
and such failure shall continue for more than fifteen (15) days after notice from any director to the CAPS Stockholders with respect
to such failure, then the vacant position shall be filled by an individual designated by the CAPS Directors then in office; <U>provided</U>,
<U>however</U>, that such individual shall be removed from such position if the CAPS Majority Holders so direct and simultaneously
designate a new CAPS Director.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that a vacancy is created on the Board at any time due to the death, disability, retirement, resignation or
removal of a Series B Director and provided that the Series B-1 Majority Holders or Series B-2 Majority Holders, as appropriate,
are still entitled to designate the applicable Series B Director pursuant to Section 2.1(a) above, then the Series B-1 Majority
Holders or Series B-2 Majority Holders, as applicable, shall have the right to designate an individual to fill such vacancy, provided
that such individual constitutes a Qualified Designee, and the Company and each Stockholder hereby agree to take such actions as
may be required to ensure the election or appointment of such designee to fill such vacancy on the Board. In the event that the
Series B-1 Majority Holders or Series B-2 Majority Holders, as applicable, shall fail to designate in writing a representative
to fill the applicable vacant Series B Director position on the Board, and such failure shall continue for more than fifteen (15)
days after notice from any director to the Series B Investors with respect to such failure, then the vacant position shall be filled
by an individual designated by the other Series B Director then in office; <U>provided</U>, <U>however</U>, that such individual
shall be removed from such position if the applicable Series B Majority Holders so direct and simultaneously designate a new Series
B Director.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As used herein, a &ldquo;<U>Qualified Designee</U>&rdquo; shall mean a designee for election to the Board that satisfies
the following requirements:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>none of the &ldquo;bad actor&rdquo; disqualifying events described in Rule 506(d)(1)(i)-(viii) promulgated under the Securities
Act of 1933, as amended (each, a &ldquo;<U>Disqualification Event</U>&rdquo;) shall be applicable to such designee; and</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Such designee shall not be employed by, provide services to, or otherwise be affiliated with a Directly Competitive Business.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Removal; Resignation</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the provisions of Section 2.2(f) below, a LX Director may be removed or replaced at any time from the Board,
without cause, upon, and only upon, the written request of the LX Majority Holders, provided that the LX Majority Holders are still
entitled to designate the LX Directors pursuant to Section 2.1(a) above.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the provisions of Section 2.2(f) below, a CAPS Director may be removed or replaced at any time from the Board,
without cause, upon, and only upon, the written request of the CAPS Majority Holders, provided that the CAPS Majority Holders are
still entitled to designate the CAPS Directors pursuant to Section 2.1(a) above.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the provisions of Section 2.2(f) below, a Series B Director may be removed or replaced at any time from the Board,
without cause, upon, and only upon, the written request of the Series B Majority Holders, provided that the Series B Majority Holders
are still entitled to designate the Series B Directors pursuant to Section 2.1(a) above.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>A director may resign at any time from the Board by delivering his written resignation to the Board and the Stockholder(s)
appointing such director as provided in Section 2.1. Any such resignation shall be effective upon receipt thereof unless it is
specified to be effective at some other time or upon the occurrence of some other event. The Board&rsquo;s or any Stockholder&rsquo;s
acceptance of a resignation shall not be necessary to make it effective.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Stockholder shall vote (in person, by proxy or by action by written consent, as applicable) all of such Stockholder&rsquo;s
Capital Stock, whether now owned or hereafter acquired or which such Stockholder may be empowered to vote, from time to time and
at all times, in whatever manner shall be necessary to ensure that (a) no director designated pursuant to Section&nbsp;2.1 may
be removed from such office unless such removal is directed or approved in writing by the Stockholders entitled to designate such
director, and (b) any vacancy created by the resignation, removal or death of a director designated pursuant to Section&nbsp;2.1
shall be filled with a director designated by the Stockholders entitled to designate such director.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Anything to the contrary in Section 2.1 or 2.2 notwithstanding, any director may be removed for cause by a Majority in Interest
of the Stockholders, and if so removed, may only be replaced thereafter by the Board or by the stockholders of the Company entitled
to vote thereon in accordance with, and pursuant to, the Certificate of Incorporation. In the event of such removal, such member
of the Board shall thereafter be voted upon by all of the stockholders of the Company entitled to vote thereon in accordance with,
and pursuant to, the Certificate of Incorporation, rather than selected in accordance with the provisions of Section 2.1 (a), and
the number of Directors that the persons who designated the removed Director shall thereafter be entitled to designate shall be
reduced by one. For purposes hereof, cause shall include, without limitation, gross negligence, malfeasance or intentional misconduct
in the performance of such person's duties as a director, a breach of such person's fiduciary duties to the Company, a Bad Actor
Disqualification Event becoming applicable to such person, or such person's conviction of, or the entering of a guilty plea or
plea of no contest with respect to, a felony.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General Restrictions on Transfer</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Stockholder acknowledges and agrees that such Stockholder (or any Permitted Transferee of such Stockholder) shall not
Transfer any Shares except as may be approved by a Majority in Interest of the Stockholders (which consent shall not be unreasonably
withheld), as permitted pursuant to Section 3.2 or Section 3.3, or in accordance with the procedures described in Section 3.4 or
Section 3.5, as applicable. No Transfer other than pursuant to Section 3.4 may be made unless the prospective Transferee has executed
and delivered to the Company a counterpart signature or joinder to this Agreement, agreeing to be bound by the terms hereof, in
a form acceptable to a Majority in Interest of the Stockholders.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding any other provision of this Agreement to the contrary (including Section 3.2 and Section 3.3), each Stockholder
agrees that it will not, directly or indirectly, Transfer any of its Shares, and the Company agrees that it shall not issue any
Shares or otherwise approve the Transfer of any Shares:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except as permitted under the Securities Act and other applicable federal or state securities or blue sky laws, and then,
with respect to a Transfer of Shares, if requested by the Company, only upon delivery to the Company of an opinion of counsel in
form and substance satisfactory to the Company to the effect that such Transfer may be effected without registration under the
Securities Act;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if such Transfer or issuance would cause the Company or any of the Company Subsidiaries, if any, to be required to register
as an investment company under the Investment Company Act of 1940, as amended; or</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if such Transfer or issuance would cause the assets of the Company or any of the Company Subsidiaries to be deemed &ldquo;Plan
Assets&rdquo; as defined under the Employee Retirement Income Security Act of 1974 or its accompanying regulations or result in
any &ldquo;prohibited transaction&rdquo; thereunder involving the Company or any Company Subsidiary, if any.</P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt">A Majority in Interest of the Stockholders may refuse: (i) the Transfer of any Shares
to any Person if such Transfer would have a material adverse effect on the Company as a result of any regulatory or other restrictions
imposed by any Governmental Authority; or (ii) the Transfer of any Shares to any Company Competitor. No Transfer described in (i)
or (ii) of the preceding sentence may be effected without the prior written consent of a Majority in Interest of the Stockholders.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any Transfer or attempted Transfer of any Shares in violation of this Agreement shall be null and void, no such Transfer
shall be recorded on the Company&rsquo;s books and the purported transferee in any such Transfer shall not be treated (and the
purported transferor shall continue be treated) as the owner of such Shares for all purposes of this Agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>CAPS Permitted Transfers</U>. The provisions of Section 3.1(a) (other than the last sentence of such section), Section
3.4 (with respect to the Dragging Stockholders only) and Section 3.5 shall not apply to any of the following Transfers by CAPS
of any of its Shares: (i) a Transfer to an Affiliate of CAPS and (ii) in the event of a liquidation, dissolution or winding up
of CAPS, a Transfer to its shareholders in accordance with its constitutive documents. Notwithstanding the foregoing, each of the
foregoing Transfers of Shares shall be subject to Sections 3.1(b) and 3.1(c), and the last sentence of Section 3.1(a).</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>LX and Series B Investors Permitted Transfers</U>. The provisions of Section 3.1(a) (other than the last sentence of
such section), Section 3.4 (with respect to the Dragging Stockholders only) and Section 3.5 shall not apply to any of the following
Transfers by LX Stockholders or the Series B Investors of any of their Shares: (i) a Transfer to an Affiliate of the transferor,
provided that all Shares held by the transferor are so transferred or a Transfer in connection with the death of an LX Stockholder
or a Series B Investor who is a natural person; and (ii) in the event of a liquidation, dissolution or winding up of a LX Stockholder
or a Series B Investor who is a corporation or limited liability company, a Transfer to such entity&rsquo;s shareholders or members
in accordance with its constitutive documents. Notwithstanding the foregoing, each of the foregoing Transfers of Shares shall be
subject to Sections 3.1(b) and 3.1(c), and the last sentence of Section 3.1(a).</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Drag-along Rights</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Participation</U>. If one or more Stockholders (together with their respective Permitted Transferees) holding no less
than a majority of all the Common Shares (assuming conversion of all outstanding shares of Series B Preferred Stock) (such Stockholders,
the &ldquo;<U>Dragging Stockholders</U>&rdquo;), propose to consummate, in one transaction or a series of related transactions,
a Change of Control (a &ldquo;<U>Drag-along Sale</U>&rdquo;), the Dragging Stockholders shall have the right, after delivering
the Drag-along Notice in accordance with Section 3.4(c) and subject to compliance with Section 3.4(d), to require that each other
Stockholder (each, a &ldquo;<U>Drag-along Stockholder</U>&rdquo;) participate in such sale in the manner set forth in Section
3.4(b).</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale of Shares</U>. Subject to compliance with Section 3.4(d):</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Drag-along Sale is structured as a sale resulting in a majority of the Common Shares being held by a Third Party
Purchaser, then each Drag-along Stockholder shall sell, with respect to each class or series of Shares proposed by the Dragging
Stockholders to be included in the Drag-along Sale, the number of Shares of such class or series equal to the product obtained
by multiplying (A) the number of applicable Shares held by such Drag-along Stockholder by (B) a fraction (x) the numerator of which
is equal to the number of applicable Shares that the Dragging Stockholders proposes to sell in the Drag-along Sale and (y) the
denominator of which is equal to the number of applicable Shares held by the Dragging Stockholders at such time; and</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Drag-along Sale is structured as a sale of all or substantially all of the assets of the Company or as a merger,
consolidation, recapitalization, or reorganization of the Company or other transaction requiring the consent or approval of a Majority
in Interest of the Stockholders or of other Stockholders, then notwithstanding anything to the contrary in this Agreement, each
Drag-along Stockholder shall vote in favor of the transaction and otherwise consent to and raise no objection to such transaction,
and shall take all actions to waive any dissenters&rsquo;, appraisal or other similar rights that it may have in connection with
such transaction.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale Notice</U>. The Dragging Stockholders shall exercise their rights pursuant to this Section 3.4 by delivering a
written notice (the <U>&ldquo;Drag-along Notice</U>&rdquo;) to the Company and each Drag-along Stockholder no more than ten (10)
Business Days after the execution and delivery by all of the parties thereto of the definitive agreement entered into with respect
to the Drag-along Sale and, in any event, no later than twenty (20) Business Days prior to the closing date of such Drag-along
Sale. The Drag-along Notice shall make reference to the Dragging Stockholders&rsquo; rights and obligations hereunder and shall
describe in reasonable detail: (i) the name of the Person to whom such Shares are proposed to be sold; (ii) the proposed date,
time and location of the closing of the sale; (iii) the number of each class or series of Shares to be sold by the Dragging Stockholders,
the proposed amount of consideration for the Drag-along Sale and the other material terms and conditions of the Drag-along Sale,
including a description of any non-cash consideration in sufficient detail to permit the valuation thereof and including, if available,
the purchase price per Share of each applicable class or series; and (iv) a copy of any form of agreement proposed to be executed
in connection therewith.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions of Sale</U>. The obligations of the Drag-along Stockholders in respect of a Drag-along Sale under this Section
3.4 are subject to the satisfaction of the following conditions:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The consideration to be received by each Drag-along Stockholder shall be the same form and amount of consideration to be
received by the Dragging Stockholders per Share of each applicable class or series and the terms and conditions of such sale shall,
except as otherwise provided in Section 3.4(d)(ii), be the same as those upon which the Dragging Stockholders sells its Shares;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Dragging Stockholders or any Drag-along Stockholder is given an option as to the form and amount of consideration
to be received, the same option shall be given to all Drag-along Stockholders; and</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Drag-along Stockholder shall execute the applicable purchase agreement, if applicable, and make or provide the same
representations, warranties, covenants, indemnities and agreements as the Dragging Stockholders make or provide in connection with
the Drag-along Sale; <U>provided</U>, <U>however</U>, that each Drag-along Stockholder shall only be obligated to make individual
representations and warranties with respect to its title to and ownership of the applicable Shares, authorization, execution and
delivery of relevant documents, enforceability of such documents against the Drag-along Stockholder, and other matters relating
to such Drag-along Stockholder, but not with respect to any of the foregoing with respect to any other Stockholders or their Shares;
<U>provided</U>, <U>further</U>, <U>however</U>, that all representations, warranties, covenants and indemnities shall be made
by the Dragging Stockholders and each Drag-along Stockholder severally and not jointly and any indemnification obligation shall
be pro rata based on the consideration received by the Dragging Stockholders and each Drag-along Stockholder, in each case in an
amount not to exceed the aggregate proceeds received by the Dragging Stockholders and each such Drag-along Stockholder in connection
with the Drag-along Sale.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cooperation</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Drag-along Stockholder shall take all actions as may be reasonably necessary to consummate the Drag-along Sale, including,
without limitation, entering into agreements and delivering certificates and instruments, in each case, consistent with the agreements
being entered into and the certificates being delivered by the Dragging Stockholders, but subject to Section 3.4(d)(ii).</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If a Drag-Along Stockholder fails, for any reason, to execute any agreements or other documents, or to take any other action
necessary to satisfy its obligations set forth in this Section 3.4, such Drag-along Stockholder: (A) to the extent applicable,
shall be deemed to have assigned all of its right, title and interest in and to its Shares to the Third party Purchaser and the
Third party Purchaser shall have the right to receive all distributions with respect to such Shares, (B) shall be deemed to have
given the Dragging Stockholders an irrevocable proxy, coupled with an interest, to vote its Shares on all matters submitted on
which such Drag-along Stockholder is entitled to a vote, (C) shall be deemed to have given the Dragging Stockholders an irrevocable
power of attorney solely to execute and deliver in such Drag-along Stockholder&rsquo;s name and stead all documents, agreements
and instruments necessary and appropriate to effectuate the Drag-along Sale, and (D) shall cease to have any rights with respect
to such Shares except to only the right to receive the respective amounts for such Drag-along Stockholder&rsquo;s Shares as computed
pursuant to this Section 3.4 upon the closing of the Drag-along Sale as set forth in this Section 3.4. This remedy is in addition
to any other remedies allowed by law or by this Agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. The fees and expenses of the Dragging Stockholders incurred in connection with a Drag-along Sale and for
the benefit of all Drag-along Stockholders (it being understood that costs incurred by or on behalf of Dragging Stockholders for
their sole benefit will not be considered to be for the benefit of all Drag-along Stockholders), to the extent not paid or reimbursed
by the Company or the Third party Purchaser, shall be shared by the Dragging Stockholder and all the Drag-along Stockholders on
a pro rata basis, based on the consideration received by each such Stockholder; <U>provided</U>, <U>however</U>, that no Drag-along
Stockholder shall be obligated to make any out-of-pocket expenditure prior to the consummation of the Drag-along Sale.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tag-along Rights</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Participation</U>. Subject to the terms and conditions specified in Section 3.1 and Section 3.2, if any Stockholder
(the &ldquo;<U>Selling Stockholder</U>&rdquo;) proposes to Transfer any of its Common Shares to any Person (a &ldquo;<U>Proposed
Transferee</U>&rdquo;), each other Stockholder (each, a &ldquo;<U>Tag-along Stockholder</U>&rdquo;) shall be permitted to participate
in such sale (a &ldquo;<U>Tag-along Sale</U>&rdquo;) on the terms and conditions set forth in this Section 3.5.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Application of Transfer Restrictions</U>. The provisions of this Section 3.5 shall not apply to Transfers in which the
Dragging Stockholders have elected to exercise their drag-along right under Section 3.4.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale Notice</U>. Prior to the consummation of any Transfer of Common Shares qualifying under Section 3.5(a), the Selling
Stockholder shall deliver to the Company and each other Stockholder holding Common Shares of the class or series proposed to be
Transferred a written notice (a &ldquo;<B><U>Sale Notice</U></B>&rdquo;) of the proposed Tag-along Sale. The Sale Notice shall
make reference to the Tag-along Stockholders&rsquo; rights hereunder and shall describe in reasonable detail: (i) the aggregate
number of Common Shares the Proposed Transferee has offered or otherwise agreed to purchase; (ii) the identity of the Proposed
Transferee; (iii) the proposed date, time and location of the closing of the Tag-along Sale; (iv) the purchase price per applicable
Common Share (which shall be payable solely in cash) and the other material terms and conditions of the Transfer; and (v) a copy
of any form of agreement proposed to be executed in connection therewith.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Tag-along Right</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Selling Stockholder and each Tag-along Stockholder timely electing to participate in the Tag-along Sale pursuant to
Section 3.5(d)(ii) shall have the right to Transfer in the Tag-along Sale the number of Common Shares equal to the product of
(A) the aggregate number of Common Shares that the Proposed Transferee proposes or has otherwise agreed to buy as stated in the
Sale Notice and (B) a fraction (x) the numerator of which is equal to the number of Common Shares then held by the applicable
Stockholder, and (y) the denominator of which is equal to the number of Common Shares then held by the Selling Stockholder and
all of the Tag-along Stockholders timely electing to participate in the Tag-along Sale pursuant to Section 3.5(d)(ii) (such amount
with respect to the Common Shares, the &ldquo;<U>Tag-along Portion</U>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Tag-along Stockholder shall exercise its right to participate in a Tag-along Sale by delivering to the Selling Stockholder
a written notice (a &ldquo;<U>Tag-along Notice</U>&rdquo;) stating its election to do so and specifying the number of Common Shares
(up to its Tag-along Portion) to be Transferred by it no later than ten (10) days after receipt of the Sale Notice (the &ldquo;<U>Tag-along
Period</U>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The offer of each Tag-along Stockholder set forth in a Tag-along Notice shall be irrevocable, and, to the extent such offer
is accepted, such Tag-along Stockholder shall be bound and obligated to consummate the Transfer on the terms and conditions set
forth in this Section 3.5.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remaining Portions</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any Tag-along Stockholder declines to exercise its right under Section 3.5(d) or elects to exercise it with respect
to less than its full Tag-Along Portion (the aggregate amount of Common Shares resulting from all such unexercised Tag-Along Portions,
the &ldquo;<U>Remaining Portion</U>&rdquo;), the Selling Stockholder shall promptly deliver a written notice (a &ldquo;<U>Remaining
Portion Notice</U>&rdquo;) to those Tag-along Stockholders who have elected to Transfer their Tag-Along Portion in full (each,
a &ldquo;<U>Fully Participating Tag-along Stockholder</U>&rdquo;). The Selling Stockholder and each Fully Participating Tag-along
Stockholder (with respect to any Remaining Portion) shall be entitled to Transfer, in addition to any applicable Common Shares
already being Transferred, a number of Common Shares, held by it equal to the product of (A) the Remaining Portion and (B) a fraction
(x) the numerator of which is equal to the number of Common Shares then held by the applicable Stockholder, and (y) the denominator
of which is equal to the number of Common Shares then held by the Selling Stockholder and all Fully Participating Tag-along Stockholders.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Fully Participating Tag-along Stockholder shall exercise its right to participate in the Transfer described in Section
3.5(e) by delivering to the Selling Stockholder a written notice (a &ldquo;<U>Remaining Tag-along Notice</U>&rdquo;) stating its
election to do so and specifying the number of Common Shares (up to the amounts it may Transfer pursuant to Section 3.5(e)), to
be Transferred by it no later than five (5) Business Days after receipt of the Remaining Portion Notice.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The offer of each Fully Participating Tag-along Stockholder set forth in a Remaining Tag-along Notice shall be irrevocable,
and, to the extent such offer is accepted, such Stockholder shall be bound and obligated to consummate the Transfer on the terms
and conditions set forth in this Section 3.5.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver</U>. Each Tag-along Stockholder who does not deliver a Tag-along Notice in compliance with Section 3.5(d)(ii)
shall be deemed to have waived all of such Tag-along Stockholder&rsquo;s rights to participate in the Tag-along Sale with respect
to the Common Shares owned by such Tag-along Stockholder, and the Selling Stockholder shall (subject to the rights of any other
participating Tag-along Stockholder and the requirements of Section 3.1) thereafter be free to sell to the Proposed Transferee
the Common Shares identified in the Sale Notice at a per Common Share price that is no greater than the applicable per Common Share
price set forth in the Sale Notice and on other terms and conditions which are not in the aggregate materially more favorable to
the Selling Stockholder than those set forth in the Sale Notice, without any further obligation to the non-accepting Tag-along
Stockholders.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions of Sale</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Stockholder participating in the Tag-along Sale shall receive the same consideration per Common Share after deduction
of such Stockholder&rsquo;s proportionate share of the related expenses in accordance with Section 3.5(i) below.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Tag-along Stockholder shall make or provide the same representations, warranties, covenants, indemnities and agreements
as the Selling Stockholder makes or provides in connection with the Tag-along Sale; <U>provided</U>, <U>however</U>, that each
Tag-along Stockholder shall only be obligated to make individual representations and warranties with respect to its title to and
ownership of the applicable Common Shares, authorization, execution and delivery of relevant documents, enforceability of such
documents against the Tag-along Stockholder, and other matters relating to such Tag-along Stockholder, but not with respect to
any of the foregoing with respect to any other Stockholders or their Common Shares; <U>provided</U>, <U>further</U>, <U>however</U>,
that all representations, warranties, covenants and indemnities shall be made by the Selling Stockholder and each Tag-along Stockholder
severally and not jointly and any indemnification obligation shall be pro rata based on the consideration received by the Selling
Stockholder and each Tag-along Stockholder, in each case in an amount not to exceed the aggregate proceeds received by the Selling
Stockholder and each such Tag-along Stockholder in connection with the Tag-along Sale.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cooperation</U>. Each Tag-along Stockholder shall take all actions as may be reasonably necessary to consummate the Tag-along
Sale, including, without limitation, entering into agreements and delivering certificates and instruments, in each case, consistent
with the agreements being entered into and the certificates being delivered by the Selling Stockholder, but subject to Section
3.5(g)(ii).</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. The fees and expenses of the Selling Stockholder incurred in connection with a Tag-along Sale and for the
benefit of all Tag-along Stockholders (it being understood that costs incurred by or on behalf of a Selling Stockholder for its
sole benefit will not be considered to be for the benefit of all Tag-along Stockholders), to the extent not paid or reimbursed
by the Company or the Proposed Transferee, shall be shared by the Selling Stockholder and all the participating Tag-along Stockholders
on a pro rata basis, based on the consideration received by each such Stockholder; <U>provided</U>, <U>however</U>, that no Tag-along
Stockholder shall be obligated to make any out-of-pocket expenditure prior to the consummation of the Tag-along Sale.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consummation of Sale</U>. The Selling Stockholder shall have thirty (30) days following the expiration of the Tag-along
Period in which to consummate the Tag-along Sale, on terms not more favorable to the Selling Stockholder than those set forth in
the Tag-along Notice (which 30-day period may be extended for a reasonable time not to exceed forty-five (45) days to the extent
reasonably necessary to obtain required approvals or consents from any governmental authority). If at the end of such period the
Selling Stockholder has not completed the Tag-along Sale, the Selling Stockholder may not then effect a Transfer that is subject
to this Section 3.5 without again fully complying with the provisions of this Section 3.5.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfers in Violation of the Tag-along Right</U>. If the Selling Stockholder sells or otherwise Transfers to the Proposed
Transferee any of its Common Shares in breach of this Section 3.5, then each Tag-along Stockholder shall have the right to sell
to the Selling Stockholder, and the Selling Stockholder undertakes to purchase from each Tag-along Stockholder, the number of Common
Shares of each applicable class or series that such Tag-along Stockholder would have had the right to sell to the Proposed Transferee
pursuant to this Section 3.5, for a per Common Share amount and form of consideration and upon the terms and conditions on which
the Proposed Transferee bought such Common Shares from the Selling Stockholder, but without indemnity being granted by any Tag-along
Stockholder to the Selling Stockholder; <U>provided</U>, <U>however</U>, that nothing contained in this Section 3.5(k) shall preclude
any Stockholder from seeking alternative remedies against such Selling Stockholder as a result of its breach of this Section 3.5.
The Selling Stockholder shall also reimburse each Tag-along Stockholder for any and all reasonable and documented out-of-pocket
fees and expenses, including reasonable legal fees and expenses, incurred pursuant to the exercise or the attempted exercise of
the Tag-along Stockholders&rsquo; rights under this Section 3.5(k).</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Special Shareholder Matters</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Protective Provisions</U>. In addition to those actions for which this Agreement specifically requires the consent of
one or more Stockholders, neither the Company, the Board nor the Stockholders shall take any of the following actions on behalf
of the Company without first obtaining the written consent of the Stockholders as provided in this Section 4.1:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Issue Shares or any other Capital Stock or securities in the Company or allow or cause any Company Subsidiary, if any, to
do the same;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Authorize or pay any dividends or other distributions to the Stockholders;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Enter into or amend any sale, license or partnering agreements relating to AEM-28 or any other compound then under development
by the Company including, without limitation, the License Agreement;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Enter into, amend or terminate any related party transaction or agreement, including the Benu Management Agreement or the
Accounting Services Agreement;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Enter into or amend any material contract outside the ordinary course of the Company&rsquo;s business;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as otherwise provided in Section 4.2 below, liquidate or dissolve the Company or any Company Subsidiary;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Merge or consolidate the Company with or into one or more Persons as permitted in the Act;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Sell, lease, exchange, or otherwise dispose of all or any portion of Company&rsquo;s property in a single transaction or
a series of related transactions other than in the ordinary course of the Company&rsquo;s business;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Make an assignment for the benefit of creditors of the Company, file a voluntary petition in bankruptcy, consent to the
appointment of a receiver for the Company or its assets, or engage in any other similar event or act; or</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Amend the Company&rsquo;s Certificate of Incorporation or Bylaws.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">Consent of the Stockholders for purposes of this Section 4.1 shall
mean the following:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The written consent of a Supermajority in Interest of the Stockholders; or</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The affirmative vote of a Majority in Interest of the Stockholders at a duly noticed meeting in accordance with the following
procedure: if a Majority in Interest of the Stockholders wish to consent to some action, such Majority in Interest of the Stockholders
may provide written notice thereof to the Board (the &ldquo;<U>Request Notice</U>&rdquo;), whereupon the Board shall call a meeting
of the Stockholders on a date specified by the Majority in Interest of the Stockholders that is not less than 15 days after the
date of the Request Notice; provided, that if the action of the Company is necessary before 15 days after the date of the Request
Notice due to the requirements of law or contract or to prevent or avoid material harm to the Company, the Stockholders may consent
to such action by the written consent of a Majority in Interest of the Stockholders without regard to the procedures in this paragraph
(ii); or</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The written consent of a Majority in Interest of the Stockholders delivered to the Company and effective no earlier than
the date following the date of the Stockholder meeting specified by the Majority in Interest of the Stockholders in the Request
Notice.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dissolution</U>. The parties agree that the Company shall not be dissolved without the written consent of the holders
of a Super Majority in Interest of the Stockholders. At the request of the holders of a Super Majority in Interest of the Stockholders,
the Company agrees to take all actions required to effect the dissolution of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Special Voting Provision</U>. The parties acknowledge and agree that the Common Shares and the Series B Preferred Stock
are entitled to vote together as a single class. If for any reason, the holders of the Class A-2 Shares become entitled to vote
as a separate class, under applicable corporate law or otherwise, the holders of the Class A-2 Shares agree to vote all of their
Shares in the same manner as voted by a majority of the Class A-1 Shares.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accounting and Tax Services</U>. The Company and CAPS have previously entered into the Accounting Services Agreement.
The Company agrees to maintain such Accounting Services Agreement in full force and effect and not to terminate, amend, modify
or fail to renew such agreement, without the written consent of CAPS. Without limiting the forgoing, the Company agrees that CAPS
shall at all times have full and exclusive authority, unless otherwise agreed by CAPS, to provide, direct and manage all accounting,
treasury, funds management and finance functions for the Company, including without limitation, maintaining the Company&rsquo;s
books and records, managing the Company&rsquo;s funds, including receipts and disbursements, overseeing the preparation of tax
returns, and preparing financial statements. The Company agrees that CAPS shall have full access to all Company records and information
requested by CAPS in connection therewith.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Budget/Milestones</U>. On or before January 15 of each year, the Company shall prepare a written budget and operational
plan (the &ldquo;<U>Budget</U>&rdquo;) for the upcoming calendar year that is acceptable to, and approved by, a majority of the
CAPS Directors, containing operational and other milestones (the &ldquo;<U>Milestones</U>&rdquo;) acceptable to, and approved by,
a majority of the CAPS Directors. The Company shall use best efforts to cause the Company to be operated in accordance with the
Budget and to achieve the Milestones.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covenants</U>. Upon the written request of a Majority in Interest of the Stockholders, the Company agrees to take the
following actions:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>declare dividends on the capital stock of the Company out of funds legally available therefor, in such amounts and with
respect to such classes of stock as the Majority in Interest of the Stockholders shall direct, subject to the preferential rights
of the Preferred Stock as set forth in the Company&rsquo;s Certificate of Incorporation; and</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>offer, sell and issue New Shares (subject to Section 5.1 below) of the Company on such terms and conditions as may be directed
by a Majority in Interest of the Stockholders.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rights to Purchase</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rights to Purchase</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event a Majority in Interest of the Stockholders desires to issue any New Shares, the Company shall first deliver
to each Stockholder (each such Stockholder being referred to in this <U>Section&nbsp;5</U> as a &ldquo;<U>New Share Offeree</U>&rdquo;)
a written notice (the &ldquo;<U>Notice of Proposed Issuance</U>&rdquo;) specifying in reasonable detail the total number of such
New Shares which the Company then desires to issue (the &ldquo;<U>Offered New Shares</U>&rdquo;), the preferences, powers, rights
and privileges of such Offered New Shares, the price per share for the Offered New Shares and the proposed purchaser(s) of such
Offered New Shares (collectively, the &ldquo;<U>Proposed Purchasers</U>&rdquo;; individually, a &ldquo;<U>Proposed Purchaser</U>&rdquo;),
and stating that the New Share Offerees shall have the right to purchase the Offered New Shares in the manner specified in this
<U>Section&nbsp;5.1</U> at the price and in accordance with the terms and conditions specified in such Notice of Proposed Issuance.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During the twenty (20) day period commencing on the date on which the Notice of Proposed Issuance has been delivered to
all of the New Share Offerees (the &ldquo;<U>Twenty Day Period</U>&rdquo;), the New Share Offerees shall have the option to purchase
Offered New Shares at the price and pursuant to the terms specified in the Notice of Proposed Issuance. Each New Share Offeree
electing to purchase Offered New Shares must give written notice of such election to the Company during such Twenty Day Period.
Each New Share Offeree shall have the right to purchase that number of the Offered New Shares as shall be equal to the total number
of the Offered New Shares multiplied by such New Share Offeree&rsquo;s Proportionate Share at the date the Notice of Proposed Issuance
is given. If, at the termination of such Twenty Day Period any New Share Offeree shall not have delivered a notice to the Company
exercising such New Share Offeree&rsquo;s right to purchase Offered New Shares, such New Share Offeree shall be deemed to have
waived all of its rights under this <U>Section 5</U> with respect to the purchase of such Offered New Shares.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If each New Share Offeree does not elect to purchase its full proportionate share of any Offered New Shares pursuant to
<U>Section 5.1(b</U>) during the Twenty Day Period applicable to such Offered New Shares, then the Company shall, within two (2)
Business Days after the expiration of such Twenty Day Period, send written notice to those New Share Offerees who fully exercised
their options within such Twenty Day Period (the &ldquo;<U>Exercising Buyers</U>&rdquo;), indicating the number of remaining Offered
New Shares. Each Exercising Buyer shall have an additional option to purchase all or any part of the balance of such remaining
Offered New Shares. To exercise such option, an Exercising Buyer must deliver notice of such additional exercise to the Company
within five (5) Business Days after receipt of such notice from the Company stating the number of such remaining Offered New Shares
such Exercising Buyer elects to purchase. In the event the Exercising Buyers in the aggregate exercise such option for a total
number of remaining Offered New Shares in excess of the number available, such Offered New Shares will be allocated as follows:
first, each Exercising Buyer who elects to purchase a number of additional Offered New Shares which is less than the number of
additional Offered New Shares multiplied by the Allocation Ratio applicable to such Exercising Buyer, will purchase the amount
of such Offered New Shares such Exercising Buyer has elected to purchase; and second, the remaining Offered New Shares will be
allocated among the Exercising Buyers who have exercised their option pursuant to this <U>Section&nbsp;5.1(c)</U> in proportion
to their respective Allocation Ratios.<B> </B></P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall have the right, until the expiration of one hundred eighty (180) days commencing on the first day immediately
following the expiration of the option period provided in <U>Section 5.1(c)</U> with respect to such Offered New Shares, to issue
the remaining Offered New Shares to the Proposed Purchaser(s) at a price not less than, and on other terms and conditions no more
favorable to the Proposed Purchaser(s) than, the price and other terms and conditions specified in the Notice of Proposed Issuance.
If for any reason the Offered New Shares are not issued within such period and at such price and on such terms and conditions,
the right to issue such Offered New Shares in accordance with the Notice of Proposed Issuance shall expire and the provisions of
this Agreement shall continue to be applicable to the Offered New Shares.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">5.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Price</U>. The purchase price for the Offered New Shares shall, unless otherwise agreed in writing by the parties to
such transaction, be paid in cash or by certified check on the date of the closing.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">5.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing</U>. The closing of the purchase and sale of the Offered New Shares shall occur at the same time and on the same
date but shall not be earlier than thirty (30) days following the last day of the applicable Twenty Day Period. At such closing,
the New Share Offerees or the Proposed Purchaser(s), as the case may be, shall deliver the consideration required by <U>Section&nbsp;5.2</U>
and the Company shall deliver certificates representing the Offered New Shares.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">5.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Obligation to Sell</U>. Except as may be required by Section 4.6(b) hereof, the Company shall not be obligated to
consummate any proposed issuance of New Shares, nor be liable to any Stockholder if the Company has not consummated any proposed
issuance of New Shares pursuant to this <U>Section 5</U> for any reason, regardless of whether it shall have delivered a Notice
of Proposed Issuance or received any notice of exercise in respect of such proposed issuance.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">5.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Alternative Procedures</U>. If the Board determines that the Company requires additional funds from the sale of New Shares
prior to the time such funds would be available if the provisions of this <U>Section 5</U> were complied with in full, the Board
may authorize the Company to accept subscriptions for, and issue, New Shares from some or all of the Stockholders without compliance
in full with the procedures provided in this <U>Section 5</U>; <U>provided</U>, <U>however</U>, that the Company concurrently establishes
an alternative procedure whereby each Investor, as soon as practicable after such issuance, is provided a purchase right with respect
to such New Shares equivalent to, and providing substantially the same overall effect of, the rights provided in this <U>Section
5</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Corporate Information</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">6.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Financial Statements</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall deliver the following to each Stockholder who owns at least two percent (2%) of the outstanding Common
Shares (assuming conversion of all outstanding shares of Series B Preferred Stock):</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Annual Financial Statements</U>. As soon as available, and in any event within one hundred twenty (120) days after the
end of each fiscal year, unaudited consolidated balance sheets of the Company and Company Subsidiaries, if any, as at the end of
each such Fiscal Year and unaudited consolidated statements of income, cash flows and Stockholders&rsquo; equity for such Fiscal
Year, in each case setting forth in comparative form the figures for the previous Fiscal Year, all in reasonable detail and all
prepared in accordance with GAAP, consistently applied (subject to normal year-end audit adjustments and the absence of notes thereto)
The parties agree, however, that for so long as CAPS has no material sources of revenue other than from, or as a result of, the
operations of the Company, delivery of the unaudited consolidated financial statements of CAPS shall be deemed to satisfy the foregoing
requirements.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Quarterly Financial Statements</U>. As soon as available, and in any event within forty-five (45) days after the end
of each quarterly accounting period in each Fiscal Year (other than the last fiscal quarter of the Fiscal Year), unaudited consolidated
balance sheets of the Company and Company Subsidiaries, if any, as at the end of each such fiscal quarter and for the current Fiscal
Year to date and unaudited consolidated statements of income, cash flows and Stockholders&rsquo; equity for such fiscal quarter
and for the current Fiscal Year to date, in each case setting forth in comparative form the figures for the corresponding periods
of the previous fiscal quarter, all in reasonable detail and all prepared in accordance with GAAP, consistently applied (subject
to normal year-end audit adjustments and the absence of notes thereto). The parties agree, however, that for so long as CAPS has
no material sources of revenue other than from, or as a result of, the operations of the Company, delivery of the unaudited consolidated
financial statements of CAPS shall be deemed to satisfy the foregoing requirements.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless earlier terminated, the rights granted pursuant to this <U>Section&nbsp;6.1</U> shall terminate if the Company becomes
subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">6.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Inspection Rights</U>. Upon reasonable notice from a Stockholder, the Company shall, and shall afford each Stockholder
and its Representatives reasonable access during normal business hours to (a) the Company&rsquo;s and the Company Subsidiaries&rsquo;,
if any, properties, offices, plants and other facilities, (b) the corporate, financial and similar records, reports and documents
of the Company and the Company Subsidiaries, if any, including, without limitation, all books and records, minutes of proceedings,
internal management documents, reports of operations, reports of adverse developments, copies of any management letters and communications
with the Company, and to permit each Stockholder and its Representatives to examine such documents and make copies thereof, and
(c) the Company&rsquo;s and the Company Subsidiaries&rsquo;, if any, officers, senior employees and public accountants, and to
afford each Stockholder and its Representatives the opportunity to discuss and advise on the affairs, finances and accounts of
the Company and the Company Subsidiaries, if any, with their officers, senior employees and public accountants (and the Company
hereby authorizes said accountants to discuss with such Stockholder and its Representatives such affairs, finances and accounts).</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">6.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Budget</U>. The Board shall use best efforts to operate the Company in all material respects in accordance with the Budget.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">6.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality and Use of Information</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Stockholder (a &ldquo;<U>Company Person</U>&rdquo;) acknowledges that during the term of this Agreement, it will have
access to and become acquainted with trade secrets, proprietary information and confidential information belonging to the Company,
the Company Subsidiaries, if any, and their Affiliates that are not generally known to the public, including, but not limited to,
information concerning business plans, financial statements and other information provided pursuant to this Agreement, operating
practices and methods, expansion plans, strategic plans, marketing plans, contracts, customer lists or other business documents
which the Company treats as confidential, in any format whatsoever (including oral, written, electronic or any other form or medium)
(collectively, &ldquo;<B><U>Confidential Information</U></B>&rdquo;). In addition, each Company Person acknowledges that: (i) the
Company has invested, and continues to invest, substantial time, expense and specialized knowledge in developing its Confidential
Information; (ii) the Confidential Information provides the Company with a competitive advantage over others in the marketplace;
and (iii) the Company would be irreparably harmed if the Confidential Information were disclosed to competitors or made available
to the public. Without limiting the applicability of any other agreement to which any Company Person is subject, no Company Person
shall, directly or indirectly, whether through such Company Person&rsquo;s agents, employees contractors, affiliates or otherwise,
disclose or use (other than solely for the purposes of such Company Person monitoring and analyzing his investment in the Company
or performing his duties as a director, manager, officer, employee, consultant or other service provider of the Company) at any
time, including, without limitation, use for personal, commercial or proprietary advantage or profit, either during his membership,
association or employment with the Company or thereafter, any Confidential Information of which such Company Person is or becomes
aware. Each Company Person in possession of Confidential Information shall take all appropriate steps to safeguard such information
and to protect it against disclosure, misuse, espionage, loss and theft.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Nothing contained in Section 6.4 shall prevent any Company Person from disclosing Confidential Information: (i) upon the
order of any court or administrative agency; (ii) upon the request or demand of any regulatory agency or authority having jurisdiction
over such Company Person; (iii) to the extent compelled by legal process or required or requested pursuant to subpoena, interrogatories
or other discovery requests; (iv) to the extent necessary in connection with the exercise of any remedy hereunder; (v) to other
directors or other Stockholders; (vi) to a Stockholder&rsquo;s Representatives who, in the reasonable judgment of such Company
Person, needs to know such Confidential Information; or (vii) to any potential Permitted Transferee in connection with a proposed
Transfer of Shares from a Stockholder, as long as such Transferee agrees to be bound by the provisions of this Section 6.4 as if
a Stockholder; <U>provided</U>, <U>however</U>, that in the case of clause (i), (ii) or (iii), such Company Person shall notify
the Company, the other directors, and the other Stockholders of the proposed disclosure as far in advance of such disclosure as
practicable (but in no event make any such disclosure before notifying the Company, the other directors, and the other Stockholders)
and use reasonable efforts to ensure that any Confidential Information so disclosed is accorded confidential treatment satisfactory
to the Company, when and if available.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The restrictions of Section 6.4 shall not apply to Confidential Information that: (i) is or becomes generally available
to the public other than as a result of a disclosure by a Company Person in violation of this Agreement; (ii) is or becomes available
to a Company Person or any of its Representatives on a non-confidential basis prior to its disclosure to the receiving Company
Person and any of its Representatives in compliance with this Agreement; (iii) is or has been independently developed or conceived
by such Company Person without use of Confidential Information; or (iv) becomes available to the receiving Company Person or any
of its Representatives on a non-confidential basis from a source other than the Company, any other Company Person or any of their
respective Representatives; <U>provided</U>, <U>however</U>, that such source is not known by the recipient of the Confidential
Information to be bound by a confidentiality agreement with the disclosing Company Person or any of its Representatives.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Company Person agrees that upon the Transfer of his or her ownership of all of his or her Shares for any reason whatsoever,
such Company Person shall surrender to the Company in good condition any record or records kept by such Company Person containing
Confidential Information. Upon request of a Majority in Interest of the Stockholders, such Company Person shall certify in writing
to the Company that he or she has complied with the foregoing, and that he or she has not retained any Confidential Information
in hard or soft copy, or any other form.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">6.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Business Activities</U>. The parties hereto expressly acknowledge and agree that, subject to all confidentiality
provisions contained in Section 6.4 and subject at all times to this Agreement: (i) UABRF, CAPS and their Affiliates are permitted
to have, and may presently or in the future have, investments or other business relationships, ventures, agreements or arrangements
with entities engaged in the business of the Company, other than through the Company and the Company Subsidiaries (an &ldquo;<B><U>Other
Business</U></B>&rdquo;); <U>provided</U>, <U>however</U>, that no such Other Businesses shall be a Directly Competitive Business
(as defined below), <U>provided</U>, <U>further</U>, that&nbsp;UABRF may engage in an Other Business or have presently or in the
future investments in an Other Business including a Directly Competitive Business as long as&nbsp;UABRF does not directly engage
in partnering with or investing in a business that develops, sells or manufactures the Apo E Mimetic molecules, including AEM-28
and AEM-18 and analogs licensed pursuant to the License Agreement; (ii) none of UABRF, CAPS or their Affiliates will be obligated
to inform the Company or any Stockholder of any business opportunity, relationship or investment (a &ldquo;<B><U>Company Opportunity</U></B>&rdquo;)
or to present any Company Opportunity to the Company, and the Company hereby renounces any interest in a Company Opportunity and
any expectancy that a Company Opportunity will be offered to it; (iii) nothing contained herein shall limit, prohibit or restrict
any Manager appointed by the CAPS Majority Holders from serving on the board of directors or other governing body of any Other
Business; and (iv) the Stockholders will not acquire, be provided with an option or opportunity to acquire, or be entitled to any
interest or participation in any Other Business as a result of the participation therein of any of UABRF, CAPS or their Affiliates.
The parties hereto expressly authorize and consent to the involvement of CAPS and/or its Affiliates in any Other Business subject
to the terms contained in this Section 6.5; <U>provided</U>, <U>however</U>, that any transactions between the Company and/or the
Company Subsidiaries, if any, and an Other Business will be on terms no less favorable to the Company and/or any Company Subsidiaries,
if any, than would be obtainable in a comparable arm&rsquo;s-length transaction. For purposes of this Section 6.5, a &ldquo;<U>Directly
Competitive Business</U>&rdquo; is a business that engages in the development, manufacture or sale of any molecules for the treatment
of hypercholesterolemia, hyperlipidemia, acute coronary syndrome, obesity and diabetes.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Legend on Capital Stock</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">7.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Legend</U>. In addition to any other legend that may be required by law or another agreement between the Company and
a Stockholder, each certificate<B><I> </I></B>representing shares of Capital Stock held by a Stockholder or issued to any subsequent
transferee of such shares shall be endorsed with a legend in substantially the following form:</P>

<P STYLE="margin: 0 36pt 12pt; font-size: 10pt">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED, HYPOTHECATED OR
OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT WITH RESPECT THERETO UNDER SUCH ACT AND SUCH STATE
LAWS OR A WRITTEN OPINION OF COUNSEL OR OTHER EVIDENCE REASONABLY SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION
FOR SUCH SALE, OFFER, TRANSFER, PLEDGE, HYPOTHECATION OR OTHER ASSIGNMENT IS AVAILABLE UNDER SUCH ACT AND SUCH STATE LAWS.</P>

<P STYLE="margin: 0 36pt 12pt; font-size: 10pt">THE VOTING, SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED
BY THIS CERTIFICATE IS SUBJECT TO, AND IN CERTAIN CASES PROHIBITED BY, THE TERMS AND CONDITIONS OF A CERTAIN STOCKHOLDERS AGREEMENT
BY AND AMONG THE STOCKHOLDER, THE COMPANY AND CERTAIN OTHER HOLDERS OF STOCK OF THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED
UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">7.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stop Transfer Order</U>. Each Stockholder agrees that, in order to ensure compliance with the restrictions referred to
herein, the Company may issue appropriate &ldquo;stop transfer&rdquo; instructions to its transfer agent, if any, and that, if
the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exculpation and Indemnification</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">8.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exculpation and Covered Persons</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covered Persons</U>. As used herein, the term &ldquo;<B><U>Covered Person</U></B>&rdquo; shall mean (i) each Stockholder,
(ii) each officer, director, shareholder, partner, member, controlling Affiliate, employee, agent or representative of each Stockholder,
and each of their controlling Affiliates, and (iii) each director, officer, employee, agent, manager, or representative of the
Company.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Standard of Care</U>. No Covered Person shall be liable to the Company or any other Covered Person for any loss, damage
or claim incurred by reason of any action taken or omitted to be taken by such Covered Person in good faith and with the belief
that such action or omission is in, or not opposed to, the best interest of the Company, so long as such action or omission does
not constitute fraud, gross negligence or willful misconduct by such Covered Person.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Good Faith Reliance</U>. A Covered Person shall be fully protected in relying in good faith upon the records of the Company
and upon such information, opinions, reports or statements (including financial statements and information, opinions, reports or
statements as to the value or amount of the assets, liabilities, net income or net losses of the Company or any facts pertinent
to the existence and amount of assets from which dividends or other might properly be paid) of the following Persons or groups:
(i) another director; (ii) one or more Officers or employees of the Company; (iii) any attorney, independent accountant, appraiser
or other expert or professional employed or engaged by or on behalf of the Company; or (iv) any other Person selected in good faith
by or on behalf of the Company, in each case as to matters that such relying Person reasonably believes to be within such other
Person&rsquo;s professional or expert competence.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">8.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Liabilities and Duties of Covered Persons</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. This Agreement is not intended to, and does not, create or impose any fiduciary duty on
any Covered Person. Furthermore, each of the Stockholders and the Company hereby waives any and all fiduciary duties that, absent
such waiver, may be implied by Applicable Law, and in doing so, acknowledges and agrees that the duties and obligation of each
Covered Person to each other and to the Company are only as expressly set forth in this Agreement. The provisions of this Agreement,
to the extent that they restrict the duties and liabilities of a Covered Person otherwise existing at law or in equity, are agreed
by the Stockholders to replace such other duties and liabilities of such Covered Person. To the extent that, at law or in equity,
any Covered Person has duties and liabilities related thereto to the Company or to any other Covered Person, a Covered Person acting
under this Agreement shall not be liable to the Company or to any other Covered Person for such Covered Person&rsquo;s good faith
reliance on the provisions of this Agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duties</U>. Whenever in this Agreement a Covered Person is permitted or required to make a decision (including a decision
that is in such Covered Person&rsquo;s &ldquo;discretion&rdquo; or under a grant of similar authority or latitude), the Covered
Person shall be entitled to consider only such interests and factors as such Covered Person desires, including its own interests,
and shall have no duty or obligation to give any consideration to any interest of or factors affecting the Company or any other
Person. Whenever in this Agreement a Covered Person is permitted or required to make a decision in such Covered Person&rsquo;s
&ldquo;good faith&rdquo; or under another express standard, the Covered Person shall act under such express standard and shall
not be subject to any other or different standard imposed by this Agreement or any other Applicable Law.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">8.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General</U>. To the fullest extent permitted by the Act, as the same now exists or may hereafter be amended, substituted
or replaced (but, in the case of any such amendment, substitution or replacement only to the extent that such amendment, substitution
or replacement permits the Company to provide broader indemnification rights than the Act permitted the Company to provide prior
to such amendment, substitution or replacement), the Company shall indemnify, hold harmless, defend, pay and reimburse any Covered
Person against any and all losses, claims, damages, judgments, fines or liabilities, including reasonable legal fees or other
expenses incurred in investigating or defending against such losses, claims, damages, judgments, fines or liabilities, and any
amounts expended in settlement of any claims (collectively, &ldquo;<U>Losses</U>&rdquo;) to which such Covered Person may become
subject by reason of:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any act or omission or alleged act or omission performed or omitted to be performed on behalf of the Company, any Stockholder
or any direct or indirect Subsidiary of the foregoing in connection with the business of the Company; or</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 72pt">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The fact that such Covered Person is or was acting in connection with the business of the Company as a partner, member,
stockholder, controlling Affiliate, manager, director, officer, employee or agent of the Company, any Stockholder, or any of their
respective controlling Affiliates, or that such Covered Person is or was serving at the request of the Company as a partner, member,
manager, director, officer, employee or agent of any Person including the Company or any Company Subsidiary; <U>provided</U>, <U>however</U>,
that (A) such Covered Person acted in good faith and in a manner believed by such Covered Person to be in, or not opposed to, the
best interests of the Company and, with respect to any criminal proceeding, had no reasonable cause to believe his conduct was
unlawful, and (B) such Covered Person&rsquo;s conduct did not constitute fraud, gross negligence or willful misconduct, in either
case as determined by a final, nonappealable order of a court of competent jurisdiction. In connection with the foregoing, the
termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of <I>nolo contendere</I>
or its equivalent, shall not, of itself, create a presumption that the Covered Person did not act in good faith or, with respect
to any criminal proceeding, had reasonable cause to believe that such Covered Person&rsquo;s conduct was unlawful, or that the
Covered Person&rsquo;s conduct constituted fraud, gross negligence or willful misconduct.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reimbursement</U>. The Company shall promptly reimburse (and/or advance to the extent reasonably required) each Covered
Person for reasonable legal or other expenses (as incurred) of such Covered Person in connection with investigating, preparing
to defend or defending any claim, lawsuit or other proceeding relating to any Losses for which such Covered Person may be indemnified
pursuant to this Section 8.3; <U>provided</U>, <U>however</U>, that if it is finally judicially determined that such Covered Person
is not entitled to the indemnification provided by this Section 8.3, then such Covered Person shall promptly reimburse the Company
for any reimbursed or advanced expenses.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entitlement to Indemnity</U>. The indemnification provided by this Section 8.3 shall not be deemed exclusive of any other
rights to indemnification to which those seeking indemnification may be entitled under any agreement or otherwise. The provisions
of this Section 8.3 shall continue to afford protection to each Covered Person regardless of whether such Covered Person remains
in the position or capacity pursuant to which such Covered Person became entitled to indemnification under this Section 8.3 and
shall inure to the benefit of the executors, administrators, legatees and distributees of such Covered Person.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. To the extent available on commercially reasonable terms, the Company may purchase, at its expense, insurance
to cover Losses covered by the foregoing indemnification provisions and to otherwise cover Losses for any breach or alleged breach
by any Covered Person of such Covered Person&rsquo;s duties in such amount and with such deductibles as the Board may determine;
<U>provided</U>, <U>however</U>, that the failure to obtain such insurance shall not affect the right to indemnification of any
Covered Person under the indemnification provisions contained herein, including the right to be reimbursed or advanced expenses
or otherwise indemnified for Losses hereunder. If any Covered Person recovers any amounts in respect of any Losses from any insurance
coverage, then such Covered Person shall, to the extent that such recovery is duplicative, reimburse the Company for any amounts
previously paid to such Covered Person by the Company in respect of such Losses.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Funding of Indemnification Obligation</U>. Notwithstanding anything contained herein to the contrary, any indemnity by
the Company relating to the matters covered in this Section 8.3 shall be provided out of and to the extent of Company assets only,
and no Stockholder (unless such Stockholder otherwise agrees in writing) shall have personal liability on account thereof.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Savings Clause</U>. If this Section 8.3 or any portion hereof shall be invalidated on any ground by any court of competent
jurisdiction, then the Company shall nevertheless indemnify and hold harmless each Covered Person pursuant to this Section 8.3
to the fullest extent permitted by any applicable portion of this Section 8.3 that shall not have been invalidated and to the fullest
extent permitted by applicable law.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. The provisions of this Section 8.3 shall be a contract between the Company, on the one hand, and each
Covered Person who served in such capacity at any time while this Section 8.3 is in effect, on the other hand, pursuant to which
the Company and each such Covered Person intend to be legally bound. No amendment, modification or repeal of this Section 8.3 that
adversely affects the rights of a Covered Person to indemnification for Losses incurred or relating to a state of facts existing
prior to such amendment, modification or repeal shall apply in such a way as to eliminate or reduce such Covered Person&rsquo;s
entitlement to indemnification for such Losses without the Covered Person&rsquo;s prior written consent.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">8.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. The provisions of Section 8.3 shall survive the dissolution, liquidation, winding up and termination of
the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. This Agreement shall be effective as of the date hereof and shall continue in effect until and shall terminate
upon the earlier to occur of:</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the written agreement of Stockholders whose outstanding shares of Capital Stock are sufficient to amend this Agreement pursuant
to Section 11.1;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company (whether pursuant to a
proceeding under the United States bankruptcy code or any similar law, Federal or state, whether now or hereafter existing), or
the general assignment by the Company of all or substantially all of its property for the benefit of creditors; or</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the merger of the Company into or the consolidation of the Company with one or more corporations not Affiliated with (i)
the Company or (ii) Stockholders then owning a majority of the Voting Power if, as a result of such merger or consolidation, the
Stockholders holding a majority of the Voting Power immediately prior to such merger or consolidation do not own a majority of
the Voting Power (or a majority of the voting power of the surviving entity if the Company is not the surviving entity) immediately
after such merger or consolidation.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Specific Enforcement</U>. Each party acknowledges and agrees that each other party will be irreparably damaged in the
event any of the provisions of this Agreement are not performed by the parties in accordance with their specific terms and conditions
or are otherwise breached. Accordingly, it is agreed that each of the Company and the Stockholders shall be entitled to an injunction
to prevent breaches of this Agreement and to specific enforcement of this Agreement and its provisions, in addition to any other
remedy to which a party may be entitled at law or in equity (without the posting of any bond or other security and without having
to prove actual damages), and if any action shall be brought in equity to enforce any of the provisions of this Agreement, none
of the parties shall raise the defense that there is an adequate remedy at law.</P>

<P STYLE="font-size: 10pt; text-indent: 0cm; margin: 0 0 12pt">11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement may be amended or modified and the observance of any provision hereof may be waived (either generally or
in a particular instance and either retroactively or prospectively) only by a written instrument executed by a Supermajority in
Interest of the Stockholders.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any amendment, modification or waiver effected in accordance herewith shall be binding upon each party and each of their
respective successors and permitted assigns, regardless of whether such Person entered into or approved such amendment, modification
or waiver. The Company shall give written notice of any amendment or modification of this Agreement or any waiver under this Agreement
to any party that did not consent in writing to such amendment, modification or waiver after such amendment, modification or waiver
becomes effective.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Except as otherwise expressly provided herein, and subject to the restrictions on Transfer
set forth herein, the provisions of this Agreement shall inure to the benefit of and be binding upon the respective successors,
permitted assigns, heirs, executors and administrators of the parties.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Third Party Beneficiaries</U>. Except as expressly provided in this Agreement, nothing in this Agreement is intended
to confer upon any Person, other than the parties or their respective successors and permitted assigns, any rights or remedies
under or by reason of this Agreement. Each Person entitled to indemnification under Section 8 shall be entitled to the benefits
thereof and authorized to enforce the terms thereof that are for its benefit, even if such Person is not a party.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All notices and other communications given or made pursuant to this Agreement shall be in writing, shall
be transmitted to the appropriate party by hand delivery, by registered or certified mail, return receipt requested, postage prepaid
or by overnight delivery by an internationally recognized overnight courier and shall be addressed to such party at his, her or
its address shown on the signature page hereto, provided a copy of any notice provided to the Company shall also be provided to
Leslie M. Taeger, Senior Vice President &amp; Chief Financial Officer, Capstone Therapeutics Corp., 1275 W. Washington St., Suite
104, Tempe, AZ 85281. Any party may designate by written notice given to all parties a new address to which any notice, demand
or other communication hereunder shall thereafter be given. Each notice or other communication transmitted in the manner described
in this Section 11.4 shall be deemed to have been given and received for all purposes: (a) upon personal delivery to the party
to be notified, (b) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid,
or (c) two (2) days after deposit with an internationally recognized overnight courier, with written verification of receipt.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Further Assurances</U>. Each party agrees to execute such additional documents or instruments as may be reasonably necessary
or desirable in order to carry out the provisions of this Agreement. Without limiting the foregoing, each Stockholder shall vote
(in person, by proxy or by action by written consent, as applicable) all of such Stockholder&rsquo;s Capital Stock, whether now
owned or hereafter acquired or which such Stockholder may be empowered to vote, from time to time and at all times, in whatever
manner shall be necessary to increase the number of authorized Common Shares from time to time to ensure that there will be sufficient
Common Shares available for conversion of all of the shares of Preferred Stock outstanding at any given time.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. The determination by a court of competent jurisdiction that any provision of this Agreement is invalid
or unenforceable shall in no way affect the validity or enforceability of any other provision of this Agreement, which shall remain
in full force and effect in the same manner and to the same extent as if the invalid or unenforceable provision had not been contained
in this Agreement. If any such invalidity or unenforceability of a provision of this Agreement becomes known or apparent to any
of the parties, the parties shall negotiate promptly and in good faith in an attempt to make appropriate changes and adjustments
to such provisions specifically and this Agreement generally to achieve as closely as possible, consistent with applicable law,
the intent and spirit of such provision specifically and this Agreement generally.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver</U>. No delay or omission in exercising, or failure to exercise, any right, power or remedy accruing to any party
under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or
remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or
an acquiescence therein, or of any similar breach or default thereafter occurring; nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval
of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any
party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically
set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. This Agreement (including the Schedules and Exhibits hereto) contains the entire agreement of the
parties with respect to the subject matter hereof, and supersedes any prior communications, understandings or agreements of the
parties with respect to the subject matter hereof. This Agreement, however, does not supersede any obligations of confidentiality
that may exist among the parties pursuant to any other agreements between or among them.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. All issues and questions concerning the application, construction, validity, interpretation and enforcement
of this Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without giving
effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would
cause the application of laws of any jurisdiction other than those of the State of Delaware.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Arbitration</U>. All claims, disputes and other matters in controversy (a &ldquo;<U>Dispute</U>&rdquo;) regarding any
matter set forth in this Agreement shall be resolved exclusively according to the procedures set forth in this Section 11.10.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If a Dispute arises relating to any matter set forth herein between or among the parties hereto, it is expected that the
parties will attempt in good faith to resolve any such dispute in an amicable and mutually satisfactory manner.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event such efforts are unsuccessful, any party may serve a notice of arbitration (&ldquo;<U>Notice of Arbitration</U>&rdquo;)
on any other party. The Notice of Arbitration shall be dated, and without prejudice to any right under the applicable rules of
arbitration permitting subsequent modifications, shall specify the claims or issues that are to be subjected to arbitration.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>THE PARTIES AGREE THAT IN ORDER TO PROMOTE TO THE FULLEST EXTENT REASONABLY POSSIBLE A MUTUALLY AMICABLE RESOLUTION OF THE
DISPUTE IN A TIMELY, EFFICIENT AND COST-EFFECTIVE MANNER, THEY WILL WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY AND SETTLE
THEIR DISPUTE BY SUBMITTING THE CONTROVERSY TO ARBITRATION TO AN ARBITRATOR OR ARBITRATION PANEL, AS APPLICABLE, SELECTED IN ACCORDANCE
HEREWITH FOR PROCEEDINGS GOVERNED BY THE COMMERCIAL RULES OF THE AMERICAN ARBITRATION ASSOCIATION (A.A.A.) EXCEPT THAT ALL PARTIES
SHALL BE ENTITLED TO ALL DISCOVERY RIGHTS ALLOWED UNDER THE DELAWARE RULES OF CIVIL PROCEDURE.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties shall attempt to select a mutually agreeable arbitrator. If no agreement is reached within ten (10) Business
Days of the Notice of Arbitration, then each party shall select one Person to act as arbitrator, and the two so selected shall,
within fifteen (15) calendar days of their selection, select a third arbitrator. If the arbitrators selected by the parties are
unable or fail to agree upon the third arbitrator within the allotted time, the each party shall replace the Person selected to
act as arbitrator, and the two so replacement arbitrators shall, within fifteen (15) calendar days of their selection, select a
third arbitrator. This process shall be repeated until a three person arbitration panel is selected. All arbitrators shall serve
as neutral, independent and impartial arbitrators. In all cases, it shall be a condition of such appointment that the arbitrator(s)
can conduct all proceedings and render a decision within sixty (60) days after selection of the arbitrator or arbitrator panel,
as applicable.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. &sect;1 <U>et</U> <U>seq</U>., and the judgment
upon the award rendered by the arbitrator may be entered by any court having jurisdiction thereof. Any party may elect to participate
in the arbitration telephonically. Any substantive or procedural rights other than the enforceability of the arbitration agreement
shall be governed by Delaware law, without regards to Delaware&rsquo;s conflict of laws principles.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties further expressly agree that (i) the arbitrator(s) shall only reach his or her decision by applying strict rules
of law to the facts, (ii) the arbitration shall be conducted in the English language, in Maricopa County, Arizona, (iii) the party
in whose favor the arbitration award is rendered shall be entitled to recover costs and expenses of the arbitration including,
but not limited to, attorneys&rsquo; fees and the cost and expense of administration of the arbitration proceedings, and any costs
and attorney&rsquo;s fees incurred in executing on or enforcing the arbitration award or, if the decision is not clearly in favor
of one party or other, such costs and expenses shall be borne as determined by the arbitrator, and (iv) the arbitral award shall
be issued in Maricopa County, Arizona.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as provided in the following sentences, no party shall be entitled to commence or maintain any action in a court
of law upon any matter in dispute until such matter shall have been submitted and determined as provided herein and then only for
the enforcement of such arbitration award. Provided that, notwithstanding this dispute resolution policy, either party may apply
to the United States District Court for the District of Delaware or the Court of Chancery of the State of Delaware, to seek injunctive
relief before or after the pendency of any arbitration proceeding. The institution of any action for injunctive relief shall not
constitute a waiver of the right or obligation of any party to submit any claim seeking relief other than injunctive relief to
arbitration. Judgment upon the award may be entered by the United States District Court for the District of Delaware or the Court
of Chancery of the State of Delaware, or application may be made to any such court for the judicial acceptance of the award and
order of enforcement, as the case may be, if the Arbitrator&rsquo;s award or decision is not complied with within seven (7) Business
Days of the Arbitrator&rsquo;s decision.</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Arbitration shall be the sole and exclusive procedure for resolution of disputes between the parties, including any disputes
that might arise after termination of this Agreement, except as set forth otherwise herein with respect to equitable remedies.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Equitable Remedies</U>. Each party hereto acknowledges that a breach or threatened breach by such party of any of its
obligations under this Agreement would give rise to irreparable harm to the other parties, for which monetary damages would not
be an adequate remedy, and hereby agrees that in the event of a breach or a threatened breach by such party of any such obligations,
each of the other parties hereto shall, in addition to any and all other rights and remedies that may be available to them in respect
of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance and
any other relief that may be available from a court of competent jurisdiction (without any requirement to post bond).</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Attorneys&rsquo; Fees</U>. In the event that any party hereto institutes any legal suit, action or proceeding, including
arbitration, against another party in respect of a matter arising out of or relating to this Agreement, the prevailing party in
the suit, action or proceeding shall be entitled to receive, in addition to all other damages to which it may be entitled, the
costs incurred by such party in conducting the suit, action or proceeding, including reasonable attorneys&rsquo; fees and expenses
and court costs.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies Cumulative</U>. The rights and remedies under this Agreement are cumulative and are in addition to and not in
substitution for any other rights and remedies available at law or in equity or otherwise, except to the extent expressly provided
in this Agreement to the contrary.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.14<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are used for convenience only and are not to
be considered in construing or interpreting this Agreement.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.15<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, all of which will be considered one and
the same agreement and will become effective when one or more counterparts have been signed by each of the parties and delivered
to the other parties, regardless of whether all of the parties have executed the same counterpart. Counterparts may be delivered
via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes.<B> </B></P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.16<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Splits, Stock Dividends, etc</U>. In the event of any issuance of Capital Stock after the date of this Agreement
to the Stockholders (including in connection with any stock split, stock dividend, recapitalization, reorganization, or the like),
such Capital Stock shall become subject to this Agreement and shall be endorsed with the legend set forth in Section 7.1 herein.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.17<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Spousal Consent</U>. If any Stockholder has a spouse on the date on which such Stockholder enters into this Agreement,
such Stockholder&rsquo;s spouse shall execute and deliver to the Company a Consent of Spouse, effective as of such date, unless
waived by the Company. If any Stockholder should marry or remarry subsequent to the date on which such Stockholder enters into
this Agreement, such Stockholder shall within thirty (30) days thereafter obtain his or her new spouse&rsquo;s acknowledgment of
and consent to the provisions of this Agreement by causing such new spouse to execute and deliver to the Company a Consent of Spouse,
unless waived by the Company. Notwithstanding the execution and delivery thereof, no Consent of Spouse shall be deemed to confer
on or convey to a spouse any rights in such Stockholder&rsquo;s Capital Stock or any interest therein.</P>

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36pt; margin: 0 0 12pt">11.18<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Construction</U>. The parties agree that this Agreement is the product of negotiations between sophisticated Persons,
all of whom were represented by counsel, and each of whom had an opportunity to participate in, and did participate in, the drafting
of each provision hereof. Accordingly, ambiguities in this Agreement, if any, shall not be construed strictly or in favor of or
against any party but rather shall be given fair and reasonable construction without regard to the rule of <I>contra proferentem</I>.
As used in this Agreement, the masculine gender shall include the feminine and neuter gender. The words &ldquo;hereof&rdquo;, &ldquo;herein&rdquo;
and &ldquo;hereunder&rdquo; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and
not to any particular provision of this Agreement. Unless otherwise specified or the context otherwise requires, (a) references
made in this Agreement to an Article, Section, Clause, Schedule or an Exhibit are to a Section, Clause, Schedule or an Exhibit
of or to this Agreement, (b) the term &ldquo;or&rdquo; has the inclusive meaning represented by the term &ldquo;and/or&rdquo;.
All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as
if set forth in full herein. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein, shall have
the meaning as defined in this Agreement. Whenever the words &ldquo;include,&rdquo; &ldquo;includes&rdquo; or &ldquo;including&rdquo;
are used in this Agreement, they shall be deemed to be followed by the words &ldquo;without limitation,&rdquo; whether or not they
are in fact followed by those words or words of like import. References to any Person include the successors and permitted assigns
of that Person. References to &ldquo;$&rdquo; or dollar amounts are to lawful currency of the United States of America, unless
otherwise expressly stated.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><I>[signature page follows]</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 12pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0 0 12pt">IN WITNESS WHEREOF, the parties have executed
this Amended and Restated Stockholders Agreement as of the date first above written.</P>

<P STYLE="font-size: 10pt; text-indent: -36pt; margin: 0 0 12pt 180pt"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 180pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD STYLE="width: 46%">&nbsp;</td>
    <TD STYLE="font-weight: bold; width: 54%; padding-left: 10pt"><U>THE COMPANY</U><FONT STYLE="font-size: 10pt; font-style: normal"><B>:</B></FONT></td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="font-weight: bold; padding-left: 30pt">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">LIPIMETIX DEVELOPMENT, INC.</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-decoration: underline; padding-left: 30pt">By: /s/ Dennis I. Goldberg</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">Name: Dennis I. Goldberg, Ph.D.</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">Title: President</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">Address for Notices:</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">5 Commonwealth Rd., Suite 2A</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">Natick, Massachusetts 01760</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">Attn: Dennis I. Goldberg, Ph.D.</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 30pt">Email: dgoldberg@lipimetix.com</td></tr>
</table>


<P STYLE="font-size: 10pt; margin: 0 0 0 180pt"></P>

<P STYLE="font-size: 10pt; margin: 0 0 12pt 144pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt"><B><U>STOCKHOLDERS</U>:</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 54%; padding-left: 10pt">
        <P STYLE="margin: 0 22.95pt 0 20pt; font-size: 10pt"><U>CAPS:</U></P>
        <P STYLE="margin: 0 22.95pt 0 20pt; font-size: 10pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0 0 12pt 20pt">CAPSTONE THERAPEUTICS CORP.,<BR>
        a Delaware corporation</P>
        <P STYLE="font-size: 10pt; margin: 0 0 0 20pt"><U>By: /s/ &#9;J.M. Holliman, III</U></P>
        <P STYLE="font-size: 10pt; margin: 0 0 0 20pt; text-indent: 0.5in">J.M. Holliman, III</P>
        <P STYLE="font-size: 10pt; margin: 0 0 12pt 20pt; text-indent: 0.5in">Executive Chairman</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>LX STOCKHOLDERS:</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>/s/ &#9;Dennis I. Goldberg</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">Dennis I. Goldberg, Ph.D.</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>/s/ Phillip M. Friden</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">Phillip M. Friden, Ph.D.</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>/s/ Eric Morrel</U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">Eric Morrel, Ph.D.</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"><U>_____________________ </U></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt">G.M. Anantharamaiah&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0 0 0 20pt"></P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0 0 0 180pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 180pt"></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 12pt"><I>[Signature Page to Amended and Restated Stockholders Agreement]</I></P>



<P STYLE="font-size: 10pt; margin: 0 0 0 180pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0 0 0 180pt"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 180pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0 0 0 180pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 30pt">__________________________________</TD></TR>
<tr style="vertical-align: middle">
    <TD STYLE="width: 46%">&nbsp;</td>
    <TD STYLE="text-align: justify; width: 54%; padding-left: 30pt">Palgunachari Mayakonda</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: justify; padding-left: 30pt">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 30pt">__________________________________</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 30pt">Frederick Meyer</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 30pt">__________________________________</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 30pt">Michael Webb</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 30pt">__________________________________</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 30pt">Jeffrey Elton</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: justify; padding-left: 30pt">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: justify; padding-left: 30pt">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: justify; padding-left: 30pt">THE UAB RESEARCH FOUNDATION</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: justify; padding-left: 30pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 30pt">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: justify; padding-left: 30pt">By: _______________________________</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left; padding-left: 60pt">Kathy L. Nugent</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD STYLE="padding-left: 60pt">Chief Executive Officer</td></tr>
</table>


<P STYLE="font-size: 10pt; margin: 0 0 0 180pt"></P>

<P STYLE="font-size: 10pt; margin: 0 0 0 180pt">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 72pt; margin: 0 0 12pt 144pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="padding-left: 30pt; width: 54%"><U>SERIES B INVESTORS</U>:</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"><B>&nbsp;</B><BR></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 12pt"><I>[Signature Page to Amended and Restated
Stockholders Agreement]</I></P>

<P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 12pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin-top: 0; text-align: center; margin-bottom: 12pt"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252"><meta name="GENERATOR" content="MSHTML 8.00.7601.18094"></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><strong>Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering</strong></p><p style="text-align: center;"><p> <p align="justify">TEMPE, Ariz., Aug.  25, 2016  (GLOBE NEWSWIRE) -- <strong>Capstone Therapeutics Corp. </strong>(OTCQB:CAPS)<strong> (&#8220;the Company&#8221;) and LipimetiX Development, Inc., </strong>the Company&#8217;s drug development joint venture (&#8220;<strong>JV</strong>&#8221;) announced today that the JV&#8217;s Series B-1 preferred stock offering totaling $1,012,000 closed on August 25, 2016. Individual accredited investors and management participated in the financing.&#160; &#160;Evolution Venture Partners, a NY-based investment bank, has been engaged to advise the JV on corporate finance matters.</p>  <p align="justify">This closing of the Series B-1 preferred stock offering resulted in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV&#8217;s common shares at the election of the holders, and warrants to purchase an additional 33,088 shares of JV Series B-1 preferred stock, at an exercise price of $10.70 per share. The preferred stock issued at closing represents 7.8% of the post-closing common stock of the JV, on an as-converted basis and suggests an approximate $13.7 million post-money valuation. Following this Series B-1 closing, Capstone owns 59.3% of the JV.</p>  <p>Dennis I. Goldberg, President of LipimetiX Development, Inc. stated, &#8220;We appreciate the confidence shown by this investor group in allowing us to advance the development of AEM-28-14.&#160; This molecule has shown profound and rapid reduction of both cholesterol and triglycerides in multiple validated preclinical models.&#160; In addition, the molecule continues to be evaluated under material transfer agreement by pharma, lending credibility to our program and to our efforts to finance further development.&#8221;&#160; &#160;The JV&#8217;s development goals are to conduct Phase 1a, 1b, and 2a human clinical trials with AEM-28-14 (and/or analogs) to show an acceptable safety profile and efficacy signals in indications involving hypercholesterolemia and hypertriglyceridemia.</p>  <p>Raising additional funds in the JV may or may not occur, and additional funds raised, if any, may not be sufficient for the JV to reach its development goals or create shareholder value, and may also contain terms or conditions that could significantly impact the Company&#8217;s investment value or ownership position.</p>  <p><strong>Chimeric Apolipoprotein E Mimetic Peptides</strong></p>  <p>Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body.&#160; Apo E is essential for the normal metabolism of cholesterol and triglycerides.&#160; After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream.&#160; Apo E targets cholesterol and triglyceride-rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood.&#160; Defective metabolism of triglyceride-rich lipoprotein remnants plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to diseases of the coronary, cerebral and peripheral arteries, and to microvascular disease in the kidneys.&#160; This can cause heart attack, stroke, loss of limbs and kidney failure, the most common causes of morbidity and mortality in diabetics.</p>  <p>The University of Alabama at Birmingham (&#8220;UAB&#8221;) scientists patented the first chimeric Apo E mimetic peptide in 1999, reducing the 299 amino acid native Apo E into a 28 amino acid, dual domain peptide that can be delivered therapeutically. &#160;One domain inserts into a lipoprotein surface and the second domain binds to the Apo E receptors in the liver.&#160; In 2010, our JV&#8217;s founding scientist, Dr. Dennis Goldberg, obtained worldwide right to patents for Apo E mimetic peptides from the UAB Research Foundation (&#8220;UABRF&#8221;).&#160; The JV has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and its analogs.</p>  <p>The JV has continued research in to a new generation of chimeric Apo E peptides and has discovered AEM-28-14, resulting in a provisional patent filing in 2015.&#160; AEM-28-14 was found to be more potent (as tested in multiple animal models) than the parent molecule, AEM-28.&#160; Currently the JV intends to concentrate its development efforts on AEM-28-14.</p>  <p>Subject to continued favorable study results and funding availability, the JV may pursue regulatory approval of AEM-28-14 as treatment for Homozygous Familial Hypercholesterolemia and other orphan indications in hypertriglyceridemia.&#160; The JV may, in the future, possibly explore additional indications for its family of Apo E mimetic peptides including Acute Coronary Syndrome, Peripheral Artery Disease and other vascular complications associated with Type 2 Diabetes.</p>  <p><strong>About Capstone Therapeutics</strong></p>  <p>Capstone Therapeutics is a biotechnology company committed to developing novel therapeutic peptides aimed at helping patients with under-served medical conditions.&#160; The Company is focused on development and commercialization of Chimeric Apo E Mimetic Peptides through the LipimetiX Development, Inc. joint venture and currently owns 59.3% of the joint venture.</p>  <p>Capstone&#8217;s corporate headquarters are in Tempe, Arizona.&#160; For more information, please visit the Company's website:&#160; www.capstonethx.com.&#160; For more information on LipimetiX Development, please visit the JV&#8217;s website:&#160; www.lipimetix.com.</p>  <p><em>Statements in this press release or otherwise attributable to Capstone regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.&#160; These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results.&#160; These risks include the factors discussed in our Form 10-K for the fiscal year ended December 31, 2015, and other documents we file with the U.S. Securities and Exchange Commission.</em></p>  <p align="center">Editor&#8217;s Note:&#160; This press release is also available under the Investors section of the Company&#8217;s website at www.capstonethx.com.</p></p><p>FOR FURTHER INFORMATION: &#160;<br>Investor Relations &#160; &#160; &#160; &#160; &#160; &#160; &#160; <br>(602) 286-5250<br>investorinquiries@capstonethx.com &#160; &#160; &#160; </p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
